{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016520", "CSN": null, "TRF": "ORD_1194331_01", "MRN": "47551224", "PhysicianId": "86631", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "889790", "clinicalId": "891195", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1194331_01", "SampleName": "US1153674.01", "Version": "0", "Sample": {"FM_Id": "ORD_1194331_01", "SampleId": "US1153674.01", "BlockId": "S110-67168R", "TRFNumber": "ORD_1194331_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_09_21", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99654", "MRN": "47551224", "FullName": "\u674e\u5b5f\u8339", "FirstName": "Meng_Ju", "LastName": "Li", "SubmittedDiagnosis": "Carcinosarcoma, Uterus, endometrium, hysterectomy", "Gender": "Female", "DOB": "1974_12_12", "OrderingMD": "\u9673\u6021\u4ec1", "OrderingMDId": "86631", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Uterus", "CollDate": "2021_08_18", "ReceivedDate": "2021-09-29 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Endometrial Carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "318", "clinicalTrialCount": "56", "resistiveCount": "0", "sensitizingCount": "16"}, "VariantProperties": {"VariantProperty": [{"geneName": "ABL1", "isVUS": "true", "variantName": "V43fs*4"}, {"geneName": "AKT3", "isVUS": "true", "variantName": "L277R,R241W,V419A,splice site 697_2A>C"}, {"geneName": "ALK", "isVUS": "true", "variantName": "N285Y"}, {"geneName": "APC", "isVUS": "true", "variantName": "L2136I,L23F,L2574I"}, {"geneName": "AR", "isVUS": "true", "variantName": "A871V,D551E,Y364D"}, {"geneName": "ARID1A", "isVUS": "true", "variantName": "G851D"}, {"geneName": "ASXL1", "isVUS": "true", "variantName": "E824D,G1401E,R394H"}, {"geneName": "ATM", "isVUS": "true", "variantName": "E2052K,R493C"}, {"geneName": "ATR", "isVUS": "true", "variantName": "E254D,L108P,R1300C,R635Q,S1701Y"}, {"geneName": "ATRX", "isVUS": "true", "variantName": "D1875Y,K467Q,R701H,T480R"}, {"geneName": "BAP1", "isVUS": "true", "variantName": "D608N"}, {"geneName": "BCOR", "isVUS": "true", "variantName": "E27K,L1334V,V293I"}, {"geneName": "BCORL1", "isVUS": "true", "variantName": "R1226H,S244L,S663Y"}, {"geneName": "BRAF", "isVUS": "true", "variantName": "R389C"}, {"geneName": "BRCA1", "isVUS": "true", "variantName": "D749Y"}, {"geneName": "BRCA2", "isVUS": "true", "variantName": "E1455_E1456>DK,E2020K,L3317R,N1316H,T3414A"}, {"geneName": "BRD4", "isVUS": "true", "variantName": "S499L"}, {"geneName": "BRIP1", "isVUS": "true", "variantName": "L892I,R356Q"}, {"geneName": "BTK", "isVUS": "true", "variantName": "L23I,R13*,R288W,T33I"}, {"geneName": "C11orf30 (EMSY)", "isVUS": "true", "variantName": "E924K,S335N"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "E420D,P567L"}, {"geneName": "CASP8", "isVUS": "true", "variantName": "E311D"}, {"geneName": "CBFB", "isVUS": "true", "variantName": "A99T"}, {"geneName": "CBL", "isVUS": "true", "variantName": "E394G,R462Q"}, {"geneName": "CCND2", "isVUS": "true", "variantName": "K71T"}, {"geneName": "CDK12", "isVUS": "true", "variantName": "K726T"}, {"geneName": "CDK6", "isVUS": "true", "variantName": "R214C"}, {"geneName": "CDK8", "isVUS": "true", "variantName": "N372S,V78I,splice site 1110+1G>T,splice site 205_1G>A"}, {"geneName": "CHEK1", "isVUS": "true", "variantName": "F70L"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "G211E,T872M"}, {"geneName": "CRKL", "isVUS": "true", "variantName": "A208T,F134V"}, {"geneName": "CTCF", "isVUS": "true", "variantName": "K208N"}, {"geneName": "CTNNA1", "isVUS": "true", "variantName": "K867T"}, {"geneName": "CUL3", "isVUS": "true", "variantName": "F224C,F377C"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "K662N,Q469H"}, {"geneName": "DIS3", "isVUS": "true", "variantName": "E117D,R108H"}, {"geneName": "DNMT3A", "isVUS": "true", "variantName": "D702N"}, {"geneName": "DOT1L", "isVUS": "true", "variantName": "S631L"}, {"geneName": "EED", "isVUS": "true", "variantName": "L425F"}, {"geneName": "EP300", "isVUS": "true", "variantName": "E1531G,L68I,M205R"}, {"geneName": "EPHA3", "isVUS": "true", "variantName": "E647*,V626A"}, {"geneName": "EPHB1", "isVUS": "true", "variantName": "E116D,R663W,V234A"}, {"geneName": "ERBB2", "isVUS": "true", "variantName": "R1161Q"}, {"geneName": "ERBB3", "isVUS": "true", "variantName": "H578N"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "A1219T"}, {"geneName": "ERG", "isVUS": "true", "variantName": "F430C"}, {"geneName": "ESR1", "isVUS": "true", "variantName": "D218N"}, {"geneName": "FAM123B", "isVUS": "true", "variantName": "K170Q,S286N"}, {"geneName": "FANCG", "isVUS": "true", "variantName": "V64A,Y268H"}, {"geneName": "FAS", "isVUS": "true", "variantName": "R279C"}, {"geneName": "FGF12", "isVUS": "true", "variantName": "R224M,Y155D"}, {"geneName": "FGF23", "isVUS": "true", "variantName": "A213V"}, {"geneName": "FGF3", "isVUS": "true", "variantName": "R151I,S108L"}, {"geneName": "FGF4", "isVUS": "true", "variantName": "G37D"}, {"geneName": "FGFR4", "isVUS": "true", "variantName": "L113F"}, {"geneName": "FH", "isVUS": "true", "variantName": "P461T"}, {"geneName": "FLT1", "isVUS": "true", "variantName": "F333Y,M945fs*15"}, {"geneName": "FLT3", "isVUS": "true", "variantName": "F710V"}, {"geneName": "GABRA6", "isVUS": "true", "variantName": "L424I,Y233C"}, {"geneName": "GATA6", "isVUS": "true", "variantName": "E460K,N510D"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "A475V,F315C,L132M"}, {"geneName": "GSK3B", "isVUS": "true", "variantName": "A22T,R92I"}, {"geneName": "HGF", "isVUS": "true", "variantName": "L565I,P299H"}, {"geneName": "HSD3B1", "isVUS": "true", "variantName": "L167M"}, {"geneName": "IDH1", "isVUS": "true", "variantName": "R222C"}, {"geneName": "IDH2", "isVUS": "true", "variantName": "D200Y"}, {"geneName": "IGF1R", "isVUS": "true", "variantName": "E83K"}, {"geneName": "IKBKE", "isVUS": "true", "variantName": "E705K"}, {"geneName": "IKZF1", "isVUS": "true", "variantName": "K275N,S105P,S364L"}, {"geneName": "INPP4B", "isVUS": "true", "variantName": "E807D,L277V,L344R"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "D276N,E1199K,P813S,S1174L"}, {"geneName": "JAK1", "isVUS": "true", "variantName": "R93C"}, {"geneName": "JAK2", "isVUS": "true", "variantName": "R803Q"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "E1098*,R893Q,R902W"}, {"geneName": "KDM5C", "isVUS": "true", "variantName": "K101N"}, {"geneName": "KDM6A", "isVUS": "true", "variantName": "R519G"}, {"geneName": "KDR", "isVUS": "true", "variantName": "E685K,G335D,R652I,V1251fs*5"}, {"geneName": "KEAP1", "isVUS": "true", "variantName": "R614Q"}, {"geneName": "KEL", "isVUS": "true", "variantName": "A311T,D497N,E352D,Y714H"}, {"geneName": "KIT", "isVUS": "true", "variantName": "R956W"}, {"geneName": "KLHL6", "isVUS": "true", "variantName": "N200H"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "I3660V,L950I,S941Y,T3574M"}, {"geneName": "LTK", "isVUS": "true", "variantName": "K827T,S830N"}, {"geneName": "MAF", "isVUS": "true", "variantName": "N365K"}, {"geneName": "MAP2K4", "isVUS": "true", "variantName": "R304Q"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "R532Q"}, {"geneName": "MED12", "isVUS": "true", "variantName": "L1300M,R422W,R438C,R470H"}, {"geneName": "MERTK", "isVUS": "true", "variantName": "D579Y,P81S"}, {"geneName": "MET", "isVUS": "true", "variantName": "R1166*"}, {"geneName": "MITF", "isVUS": "true", "variantName": "splice site 760_2A>C"}, {"geneName": "MLH1", "isVUS": "true", "variantName": "D63Y"}, {"geneName": "MLL2", "isVUS": "true", "variantName": "A781T,E1588K,L3776R"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "A780T,E995K,K431T,R1242H"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "F574L,G356D"}, {"geneName": "MTOR", "isVUS": "true", "variantName": "Q2223R"}, {"geneName": "NBN", "isVUS": "true", "variantName": "E474D"}, {"geneName": "NF1", "isVUS": "true", "variantName": "K63N,L2639I,W837L"}, {"geneName": "NF2", "isVUS": "true", "variantName": "R187I,R418C"}, {"geneName": "NKX2_1", "isVUS": "true", "variantName": "D356G"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "A105T,D464N,G2333D"}, {"geneName": "NRAS", "isVUS": "true", "variantName": "Y4C"}, {"geneName": "NSD3 (WHSC1L1)", "isVUS": "true", "variantName": "G748V"}, {"geneName": "NT5C2", "isVUS": "true", "variantName": "K244E,K45N"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "M566T"}, {"geneName": "NTRK2", "isVUS": "true", "variantName": "E70K,R124*"}, {"geneName": "NTRK3", "isVUS": "true", "variantName": "E559G,P725H,R721C"}, {"geneName": "P2RY8", "isVUS": "true", "variantName": "S58L"}, {"geneName": "PALB2", "isVUS": "true", "variantName": "K279N"}, {"geneName": "PARP1", "isVUS": "true", "variantName": "A194V"}, {"geneName": "PARP2", "isVUS": "true", "variantName": "E222Q"}, {"geneName": "PBRM1", "isVUS": "true", "variantName": "R876C"}, {"geneName": "PDCD1 (PD_1)", "isVUS": "true", "variantName": "A50T"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "E556*,M1073V,R346S,splice site 1122_1G>T"}, {"geneName": "PDK1", "isVUS": "true", "variantName": "K73N,R341I"}, {"geneName": "PIK3CA", "isVUS": "true", "variantName": "L285V,R230*,splice site 352+1G>A"}, {"geneName": "PIK3CB", "isVUS": "true", "variantName": "A655V,E225*,N377H,R955*"}, {"geneName": "POLD1", "isVUS": "true", "variantName": "R177C"}, {"geneName": "POLE", "isVUS": "true", "variantName": "L1235I"}, {"geneName": "PPP2R2A", "isVUS": "true", "variantName": "E338A"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "L223I"}, {"geneName": "PTEN", "isVUS": "true", "variantName": "E157D,I5T"}, {"geneName": "PTPN11", "isVUS": "true", "variantName": "K590T"}, {"geneName": "PTPRO", "isVUS": "true", "variantName": "L832R"}, {"geneName": "RAD51", "isVUS": "true", "variantName": "L274I"}, {"geneName": "RAD51B", "isVUS": "true", "variantName": "L321R"}, {"geneName": "RAD51C", "isVUS": "true", "variantName": "S163R"}, {"geneName": "RAD52", "isVUS": "true", "variantName": "R55H"}, {"geneName": "RAF1", "isVUS": "true", "variantName": "E104K"}, {"geneName": "RBM10", "isVUS": "true", "variantName": "E705D"}, {"geneName": "REL", "isVUS": "true", "variantName": "R45Q"}, {"geneName": "RET", "isVUS": "true", "variantName": "R474W"}, {"geneName": "RICTOR", "isVUS": "true", "variantName": "H1453R,K1155T,L612R,L804I,R1110C,R222Q"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "E402D,E908*,I883L,K1533N,N399H,R1212C,R922I,V785M"}, {"geneName": "SETD2", "isVUS": "true", "variantName": "P190L"}, {"geneName": "SF3B1", "isVUS": "true", "variantName": "E809*,R451Q"}, {"geneName": "SGK1", "isVUS": "true", "variantName": "L363I"}, {"geneName": "SMAD2", "isVUS": "true", "variantName": "S276L,S464A"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "R535Q"}, {"geneName": "SPOP", "isVUS": "true", "variantName": "R284C"}, {"geneName": "STAG2", "isVUS": "true", "variantName": "D153N,F1214L"}, {"geneName": "STAT3", "isVUS": "true", "variantName": "T494fs*55"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A418T,E720K,R304W,S363L"}, {"geneName": "TEK", "isVUS": "true", "variantName": "splice site 3063_1G>A"}, {"geneName": "TET2", "isVUS": "true", "variantName": "A241V,Y1935H"}, {"geneName": "TNFAIP3", "isVUS": "true", "variantName": "H289Q"}, {"geneName": "TSC1", "isVUS": "true", "variantName": "K475Q,L930P,R228Q"}, {"geneName": "TSC2", "isVUS": "true", "variantName": "D8Y,K69N"}, {"geneName": "U2AF1", "isVUS": "true", "variantName": "R234C"}, {"geneName": "VEGFA", "isVUS": "true", "variantName": "P363S,S186Y"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ATM", "Include": "true", "Alterations": {"Alteration": {"Name": "R250*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R250*"}}, "Interpretation": "ATM encodes the protein ataxia telangiectasia mutated, which is a serine/threonine protein kinase that plays a key role in the DNA damage response (Shiloh and Ziv, 2013; 23847781). Loss of functional ATM promotes tumorigenesis (Cremona and Behrens, 2014; 23851492). Alterations such as seen here may disrupt ATM function or expression (Jiang et al., 2006; 16603769, Fernandes et al., 2005; 15713674, Scott et al., 2002; 11805335). ATM mutation and homozygous deletion have been observed in 11_12% and up to 1.8% (5/761) samples of endometrial carcinoma, respectively (cBioPortal, COSMIC, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Altered expression of ATM has been reported in 4.5% (1/22) of endometrial hyperplasia samples and in 3.3% (2/61) of endometrioid_type endometrial cancer samples analyzed in one study (Tsuda et al., 2003; 12931023). Hypermethylation of ATM has been reported in 11% of endometrial carcinomas (Suehiro et al., 2008; 18519763). Conflicting findings have been reported regarding the prognostic implications of ATM expression in endometrial carcinomas, with one study reporting a negative correlation between ATM expression and pathological grade (Shan et al., 2015; 25608836) and another a positive correlation between increased ATM expression and unfavorable clinicopathologic features, including increased tumor grade and reduced 5_year recurrence free survival (Mhawech_Fauceglia et al., 2014; 24508840). Loss of functional ATM results in a defective DNA damage response and homologous recombination_mediated DNA repair and may predict sensitivity to PARP inhibitors (Michels et al., 2014; 24037533). Clinical data in prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), gastric cancer (Bang et al., 2015; 26282658), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), papillary renal cell carcinoma (Olson et al., 2016; 27079472), and cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096) indicate that loss or inactivation of ATM may confer sensitivity to PARP inhibitors (Weston et al., 2010; 20739657, Williamson et al., 2010; 20124459, Gilardini et al., 2013; 24252502, Bryant and Helleday, 2006; 16556909, Ihnen et al., 2013; 23729402, Williamson et al., 2012; 22416035, Kubota et al., 2014; 24841718, Huehls et al., 2012; 22833573). In Phase 1 trials of ATR inhibitors, a heavily pretreated patient with colorectal cancer who achieved a CR to berzosertib (O Carrigan et al., 2016; ASCO Abstract 2504) and 4 out of 4 patients with diverse solid tumors who achieved PRs to BAY1895344 (Yap et al., 2020; 32988960) harbored ATM inactivation or protein loss; studies showing reduced cell viability and increased DNA damage in preclinical models of solid tumors (Menezes et al., 2015; 25232030, Vendetti et al., 2015; 26517239, Min et al., 2017; 28138034) and hematologic malignancies (Menezes et al., 2015; 25232030, Kwok et al., 2016; 26563132) also support the increased sensitivity of ATM_deficient cells to ATR inhibitors. Preclinical experiments also indicate that loss of ATM causes dependency on DNA_PKcs in cancer cells; DNA_PKcs inhibitors promoted apoptosis in ATM_deficient cells and were active in a lymphoma mouse model lacking ATM activity (Riabinska et al., 2013; 23761041). One or more of the ATM variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with ataxia_telangiectasia syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. ATM mutation carriers have increased cancer risk, with female carriers displaying a 38% lifetime risk of breast cancer (van Os et al., 2016; 26662178). Biallelic mutations in ATM underlie the rare autosomal_recessive inherited disorder ataxia_telangiectasia (A_T), also referred to as genome instability or DNA damage response syndrome (Rothblum_Oviatt et al., 2016; 27884168). This disease is characterized by genomic instability, sensitivity to DNA_damaging agents, and increased risk of developing cancer (Shiloh and Ziv, 2013; 23847781, Rothblum_Oviatt et al., 2016; 27884168). The prevalence of A_T is estimated at 1:40,000 to 1:100,000 worldwide (Rothblum_Oviatt et al., 2016; 27884168). In the appropriate clinical context, germline testing of ATM is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Talazoparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study reported a PR for a patient with uterine carcinoma and a BRCA2 germline mutation treated with talazoparib plus carboplatin and paclitaxel followed by talazoparib monotherapy (Turk et al., 2018; ASCO Abstract 2548). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD \u2265 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Rucaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of rucaparib for the treatment of endometrial cancers are limited (PubMed, May 2021). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Olaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> A heavily pretreated patient with low_grade endometrioid endometrial adenocarcinoma and germline and somatic BRCA2 mutations experienced ongoing SD for 15 months from single_agent olaparib (Gockley et al., 2018; 29937315). A patient with high_grade serous endometrial cancer harboring a somatic BRIP1 frameshift alteration experienced a CR following olaparib monotherapy (Nakamura et al., 2020; DOI: 10.1200/PO.19.00368). A patient with endometrial adenocarcinoma and PTEN loss experienced clinical benefit for 8 months following olaparib therapy. Although BRCA alterations were not detected, only a subset of common BRCA mutations were assessed, and the authors could not exclude the possibility of other BRCA alterations contributing to the response (Forster et al., 2011; 21468130). Olaparib has been studied primarily for the treatment of ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407); higher response rates have also been observed for patients with platinum_sensitive versus platinum_resistant cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum_sensitive relapsed ovarian cancer, olaparib has demonstrated significantly improved median PFS and median OS compared with placebo in the Phase 3 SOLO_1 study (Moore et al., 2018; 30345884) and in multiple later_phase studies (Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). Phase 3 studies of olaparib for patients with BRCA_mutated metastatic breast (Robson et al., 2017; 28578601) or pancreatic cancer (Golan et al., 2019; 31157963) or for patients with metastatic castration_resistant prostate cancer and BRCA or ATM alterations (de Bono et al., 2020; 32343890) have also reported significantly longer median PFS compared with chemotherapy, placebo, or hormone therapy. Additionally, olaparib has demonstrated clinical activity for patients with other solid tumors harboring BRCA mutations, including leiomyosarcoma (Seligson et al., 2019; 30541756), cholangiocarcinoma (Lin et al., 2019; 31068370), and bladder cancer (Necchi et al., 2018; 29680362) in smaller studies. Olaparib in combination with the AKT inhibitor capivasertib has demonstrated clinical benefit for patients with solid tumors; a Phase 1 trial reported a 45% (25/56) DCR, including 14 PRs and 11 SDs, and 14 of those experiencing clinical benefit had germline BRCA1/2 mutated_solid tumors (Yap et al., 2020; 3253274). In a Phase 2 study of olaparib plus pembrolizumab for patients with advanced solid tumors, those with BRCA1 or BRCA2 mutations and those with homologous recombination deficient tumors reported the highest ORRs of 29% (6/21) and 21% (16/76), respectively. Patients with homologous recombination repair deficient tumors, including and excluding patients with BRCA1/2 mutations, reported lower ORRs of 15% (8/53) and 6.3% (2/32), respectively (Maio et al., 2021; AACR abstract CT178). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Niraparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of niraparib for patients with endometrial cancer, patients experienced an ORR of 4.0% (1/23) and a DCR of 20%, while patients treated with niraparib and dostarlimab experienced an ORR of 14% (3/22) and a DCR of 32% (Madariaga et al., 2021; ASCO Abstract 5574). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04269200", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT04716686", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT02630199", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03188965", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "BRCA2", "Include": "true", "Alterations": {"Alteration": {"Name": "E1879D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E1879D"}}, "Interpretation": "The BRCA2 tumor suppressor gene encodes a protein that regulates the response to DNA damage (Yang et al., 2002; 12228710). Inactivating mutations in BRCA2 can lead to the inability to repair DNA damage and loss of cell cycle checkpoints, which can lead to tumorigenesis (Holloman, 2011; 21731065). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. BRCA2 mutation has been reported in 10% of uterine corpus endometrial and endometrioid carcinoma cases analyzed in the TCGA dataset (Cancer Genome Atlas Research Network., 2013; 23636398). LOH of the wild type BRCA1/2 allele in patients with endometrial carcinoma harboring germline BRCA1/2 mutations has been associated with higher FIGO grade, nonendometrioid histology, and frequent co_occurrence of TP53 mutation (de Jonge et al., 2019; 31492746). Studies have reported that BRCA2 germline mutations do not increase the lifetime risk of endometrial cancer (Levine et al., 2001; 11263938, Segev et al., 2013; 23562522). Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors (Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Tutt et al., 2010; 20609467, Robson et al., 2017; 28578601, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788, Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934, Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755, Domchek et al., 2016; 26723501, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) or ATR inhibitors (Yap et al., 2020; 32988960, Thomas et al., 2018; 29252124, O Carrigan et al., 2016; ASCO Abstract 2504, Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA, Saito et al., 2018; 31299005). Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations (Mateo et al., 2015; 26510020, Swisher et al., 2016; 27908594, Ledermann et al., 2016; 27617661, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) and for patients with platinum_resistant or _refractory disease (Fong et al., 2010; 20406929, Kaufman et al., 2015; 25366685, Sandhu et al., 2013; 23810788, Domchek et al., 2016; 26723501). In a case study, a patient with therapy_induced neuroendocrine prostate cancer and an inactivating BRCA2 rearrangement experienced a CR ongoing for 20 months to the ATR inhibitor berzosertib (Saito et al., 2018; 31299005). Preclinical studies of BRCA1/2 inactivation in T_cell acute lymphoblastic leukemia (T_ALL) (Pouliot et al., 2019; 31721781), ovarian carcinoma (Kim et al., 2017; 27993965), and triple_negative breast cancer (TNBC) (Jin et al., 2018; 29605721) showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA2_deficient cells to ATR inhibitors. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP_inhibitor, olaparib. In a Phase 2 study for patients with PARP_resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA_mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2_mutated solid tumors, 2 patients with BRCA1_mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression (Do et al., 2015; 25964244). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Inactivation of BRCA2 may also predict sensitivity to DNA_damaging drugs such as trabectedin, lurbinectedin, and the platinum chemotherapies cisplatin and carboplatin (Isakoff et al., 2015; 25847936, Dann et al., 2012; 22406760, Evers et al., 2008; 18559613, Soares et al., 2007; 17656556, Miolo et al., 2016; 27561088, Ghouadni et al., 2017; 28467918, Tedesco et al., 2011; ASCO Abstract 1125, Perez et al., 2017; 28626402, Monk et al., 2020; 31924332, Harnicek et al., 2016; 26933761, Cruz et al., 2018; 30240327, Awada et al., 2018; ASCO Abstract 1072, Poveda et al., 2017; 28368437). Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer (Miki et al., 1994; 7545954, Wooster et al., 1995; 8524414), and the lifetime risk of breast and ovarian cancer in BRCA2 mutation carriers has been estimated to be as high as >80% and 23%, respectively (King et al., 2003; 14576434). Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60% (Friedenson, 2005; 16369438). The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10_fold higher prevalence in the Ashkenazi Jewish population (Ford et al., 1994; 7907678, Whittemore et al., 1997; 9042908, Claus et al., 1996; 8635102, Struewing et al., 1997; 9145676, Oddoux et al., 1996; 8841192, King et al., 2003; 14576434, Hall et al., 2009; 19241424). In the appropriate clinical context, germline testing of BRCA2 is recommended.", "Include": "true", "ClinicalTrialNote": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Talazoparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study reported a PR for a patient with uterine carcinoma and a BRCA2 germline mutation treated with talazoparib plus carboplatin and paclitaxel followed by talazoparib monotherapy (Turk et al., 2018; ASCO Abstract 2548). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD \u2265 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Rucaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of rucaparib for the treatment of endometrial cancers are limited (PubMed, May 2021). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Olaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> A heavily pretreated patient with low_grade endometrioid endometrial adenocarcinoma and germline and somatic BRCA2 mutations experienced ongoing SD for 15 months from single_agent olaparib (Gockley et al., 2018; 29937315). A patient with high_grade serous endometrial cancer harboring a somatic BRIP1 frameshift alteration experienced a CR following olaparib monotherapy (Nakamura et al., 2020; DOI: 10.1200/PO.19.00368). A patient with endometrial adenocarcinoma and PTEN loss experienced clinical benefit for 8 months following olaparib therapy. Although BRCA alterations were not detected, only a subset of common BRCA mutations were assessed, and the authors could not exclude the possibility of other BRCA alterations contributing to the response (Forster et al., 2011; 21468130). Olaparib has been studied primarily for the treatment of ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407); higher response rates have also been observed for patients with platinum_sensitive versus platinum_resistant cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum_sensitive relapsed ovarian cancer, olaparib has demonstrated significantly improved median PFS and median OS compared with placebo in the Phase 3 SOLO_1 study (Moore et al., 2018; 30345884) and in multiple later_phase studies (Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). Phase 3 studies of olaparib for patients with BRCA_mutated metastatic breast (Robson et al., 2017; 28578601) or pancreatic cancer (Golan et al., 2019; 31157963) or for patients with metastatic castration_resistant prostate cancer and BRCA or ATM alterations (de Bono et al., 2020; 32343890) have also reported significantly longer median PFS compared with chemotherapy, placebo, or hormone therapy. Additionally, olaparib has demonstrated clinical activity for patients with other solid tumors harboring BRCA mutations, including leiomyosarcoma (Seligson et al., 2019; 30541756), cholangiocarcinoma (Lin et al., 2019; 31068370), and bladder cancer (Necchi et al., 2018; 29680362) in smaller studies. Olaparib in combination with the AKT inhibitor capivasertib has demonstrated clinical benefit for patients with solid tumors; a Phase 1 trial reported a 45% (25/56) DCR, including 14 PRs and 11 SDs, and 14 of those experiencing clinical benefit had germline BRCA1/2 mutated_solid tumors (Yap et al., 2020; 3253274). In a Phase 2 study of olaparib plus pembrolizumab for patients with advanced solid tumors, those with BRCA1 or BRCA2 mutations and those with homologous recombination deficient tumors reported the highest ORRs of 29% (6/21) and 21% (16/76), respectively. Patients with homologous recombination repair deficient tumors, including and excluding patients with BRCA1/2 mutations, reported lower ORRs of 15% (8/53) and 6.3% (2/32), respectively (Maio et al., 2021; AACR abstract CT178). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Niraparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of niraparib for patients with endometrial cancer, patients experienced an ORR of 4.0% (1/23) and a DCR of 20%, while patients treated with niraparib and dostarlimab experienced an ORR of 14% (3/22) and a DCR of 32% (Madariaga et al., 2021; ASCO Abstract 5574). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04269200", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT04716686", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT02630199", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03188965", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CTNNB1", "Include": "true", "Alterations": {"Alteration": {"Name": "K335T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "K335T"}}, "Interpretation": "CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. CTNNB1 mutations have been reported in 7_45% of endometrial carcinomas (ECs) (Cancer Genome Atlas Research Network., 2013; 23636398, Dellinger et al., 2012; 22149432, Saegusa et al., 2001; 11161379, McConechy et al., 2014; 23765252, Huang et al., 2013; 23760948). CTNNB1 mutations are more common in Type 1 EC than Type 2 (Yeramian et al., 2012; 22430211, Machin et al., 2002; 11957146). In addition, one study found that CTNNB1 mutations were identified more frequently in sporadic ECs (31%, 18/58), than in Lynch syndrome (LS)_associated ECs (6.9%, 2/29) (Huang et al., 2013; 23760948). Nuclear beta_catenin protein expression has been observed in 14.7_27.6% (33/224_55/199) of ECs, with a significantly higher incidence in Type 1 tumors (Peir\u00f3 et al., 2013; 22955108, Saegusa et al., 2001; 11161379). Multiple studies have reported that CTNNB1 mutation characterizes an aggressive subset of EC (Kurnit et al., 2017; 28281553, Stelloo et al., 2016; 27006490, Liu et al., 2014; 25214561). One study found that that TP53 or CTNNB1 mutation was an independent marker of poor recurrence_free survival (HR=4.69) for patients with low grade, early stage EC (Kurnit et al., 2017; 28281553). Low membrane expression of beta_catenin has been linked with poor prognosis in EC and ovarian endometrioid carcinomas (Rosen et al., 2010; 19820688, Athanassiadou et al., 2007; 17504383). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a PR rate in 2 out of 4 patients and SD rate of in 1 out of 4 patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Phase 1 and 2 clinical trials of gamma_secretase inhibitor PF_03084014 have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kummar et al., 2015; ASCO Abstract 10563)(Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03008408", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT02159989", "Include": "true"}, {"nctId": "NCT02321501", "Include": "true"}, {"nctId": "NCT03017833", "Include": "true"}, {"nctId": "NCT03430882", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "FANCL", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 904_2A>C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 904_2A>C"}}, "Interpretation": "FANCL encodes a member of the Fanconi anemia nuclear complex, a multiprotein structure also including the products of FANCA, FANCC, FANCF and FANCG. The activity of this complex is essential to prevention of chromosome breakage caused by DNA damage (Pace et al., 2002; 12093742). Germline mutations in FANCL cause Fanconi anemia, a clinically heterogeneous disorder involving various developmental abnormalities as well as predisposition to cancer; underlying these phenotypes are defects in DNA repair (Deakyne and Mazin, 2011; 21568838). Alterations such as seen here may disrupt FANCL function or expression (Alpi et al., 2007; 17938197, Alpi et al., 2008; 19111657, Meetei et al., 2003; 12973351, Machida et al., 2006; 16916645, Hodson et al., 2011; 21775430, Hodson et al., 2013; 24389026, Hodson et al., 2014; 24389026, Seki et al., 2007; 17352736, Ali et al., 2008; 19405097). Germline mutations in FANCL, such as T367fs*13, have been associated with Fanconi anemia, breast cancer, and ovarian cancer and with an increased risk of esophageal cancer and prostate cancer (Fostira et al., 2018; 29335925, Akbari et al., 21279724, Hart et al., 2016; 27084275, Del Valle et al., 2020; 32235514, Chandrasekharappa, et al., 2013; 23613520, Dicks et al., 2017; 28881617). FANCL mutations are most frequently observed in tumors of the prostate (5.9%), liver (4.1%), biliary tract (3.4%), endometrium (3.2%), pancreas (2.7%), large intestine (2.4%), and stomach (2.4%) (COSMIC, May 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of FANCL alterations in solid tumors and hematologic malignancies are limited (PubMed, May 2021). In a prospective study of 255 patients with follicular lymphoma, 2p gain, which includes VRK2, FANCL, and LINC01122, was associated with worse PFS and OS in multivariate analysis (Qu et al., 2019; 30446494). There are no targeted therapies that directly address genomic alterations in FANCL. Clinical evidence in ovarian cancer indicates that FANCL inactivation may confer sensitivity to PARP inhibitors (O Malley et al., 2017; AACR_NCI_EORTC Abstract LB_A12, Dougherty et al., 2014; ASCO Abstract 5536).", "Include": "true", "ClinicalTrialNote": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04269200", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT04716686", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04159155", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "FBXW7", "Include": "true", "Alterations": {"Alteration": {"Name": "R441W", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R441W"}}, "Interpretation": "FBXW7 encodes the F_box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto_oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. FBXW7 mutations have been reported in 14.2% of endometrial carcinomas (COSMIC, Feb 2021) (Tate et al., 2019; 30371878). Studies have variously reported FBXW7 mutation in 18_29% of uterine serous carcinoma, 16% of endometrial cancer, and 2% of endometrioid endometrial cancer cases (Zhao et al., 2013; 23359684, Le et al., 2012; 23104009, Kuhn et al., 2012; 22923510, Spruck et al., 2002; 12183400, Cassia et al., 2003; 14648662). In primary endometrial carcinomas, FBXW7 mutations correlated with lymph node involvement (Garcia_Dios et al., 2013; 23219661). Reduced FBXW7 expression has been associated with poor prognosis in some cancers such as colorectal cancer, gastric cancer, esophageal SCC, cervical SCC, melanoma, and non_small cell lung carcinoma (Tu et al., 2012; 22548670, Iwatsuki et al., 2010; 19739118, Yokobori et al., 2012; 22576686, Yokobori et al., 2009; 19366810, Yokobori et al., 2014; 24165483, Rajagopalan et al., 2004; 14999283, Cheng et al., 2013; 23381582, Xu et al., 2016; 26954701). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Several case studies reported clinical benefit for patients with FBXW7_mutated cancers, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; https://doi.org/10.1016/j.ygyno.2020.05.244). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. FBXW7 inactivation may also result in resistance to anti_tubulin chemotherapies based on results from preclinical studies (Wertz et al., 2011; 21368834).", "Include": "true", "ClinicalTrialNote": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_na\u00efve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_na\u00efve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT02397083", "Include": "true"}, {"nctId": "NCT03008408", "Include": "true"}, {"nctId": "NCT03217669", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT02159989", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "FGFR2", "Include": "true", "Alterations": {"Alteration": {"Name": "N549D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "N549D"}}, "Interpretation": "FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 mutations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Reintjes et al., 2013; 23527311, Dutt et al., 2008; 18552176, Byron et al., 2012; 22383975, Ratisoontorn et al., 2003; 12952211, Mohammadi et al., 2005; 15863029, Ibrahimi et al., 2004; 15282208, Pollock et al., 2007; 17525745, Kapeli and Hurlin, 2011; 21908617, Eathiraij et al., 2011; 21454610, Tanizaki et al., 2015; 26048680, Lorenzi et al., 1997; 9266968, Itoh et al., 1994; 8205545, Chen et al., 2007; 17803937). FGFR2 activating alterations that affect amino acid E565 and mutations such as S252W, P253R, W290C, S372C, Y375C, N549K, and K659E have been reported in patients with Apert, Pfeiffer, Beare_Stevenson, and Crouzon syndromes and syndromic craniosynostosis (Park et al., 1995; 7668257, Wilke et al., 1995; 7719344, Lajeunie et al., 2008; 16418739, Chen et al., 2013; 24411056, Slavotinek et al., 2009; 19610084, Dutt et al., 2008; 18552176, Gozgit et al., 2013; 23468082, Chen et al., 2007; 17803937, Przylepa et al., 1996; 8696350, Kan et al., 2002; 11781872). FGFR2 mutations have been reported in 12.5% of cases in the Uterine Corpus Endometrioid Carcinoma TCGA dataset (Cancer Genome Atlas Research Network., 2013; 23636398). In the scientific literature, mutation of FGFR2 has been identified in 10.3% (48/466) of endometrial carcinoma (EC) tumors in one study, and at similar frequencies in others (Krakstad et al., 2012; 23300780, Dutt et al., 2008; 18552176, Byron et al., 2012; 22383975). FGFR2 expression has been identified in 71.9% (23/32) of EC specimens in one study; however, levels of FGFR2 protein or FGFR2 mRNA have not been consistently demonstrated to be higher in tumor specimens compared to normal endometrial tissues (Gatius et al., 2011; 21725289, Ishikawa et al., 2008; 18292933, Siegfried et al., 1997; 9070494). FGFR2 mutations in endometrioid endometrial tumors have been correlated with decreased disease_free survival in one study (Byron et al., 2012; 22383975). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). Cases of clinical response to selective FGFR inhibitors have been reported for patients with various FGFR2_mutated tumors, including PRs for patients with FGFR2_mutated cholangiocarcinoma treated with AZD4547 (Chae et al., 2018; ASCO Abstract 2503) or erdafitinib (Soria et al., 2017; ASCO Abstract 4074) and a PR for a patient with FGFR2_mutated lung squamous cell carcinoma treated with infigratinib (Slosberg et al., 2018; 29765547). A patient with endometrioid adenocarcinoma and cervical cancer and both an FGFR2 amplification and mutation experienced a PR following treatment with Debio_1347 (Voss et al., 2019; 30745300). Additional clinical responses associated with FGFR2 mutation have been reported for a patient with HNSCC (Liao et al., 2013; 23786770), and in a patient with solitary fibrous tumor treated with pazopanib (Yue et al., 2016; AMP Abstract S06).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04865289", "Include": "true"}, {"nctId": "NCT02450136", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT04042116", "Include": "true"}, {"nctId": "NCT04565275", "Include": "true"}, {"nctId": "NCT02272998", "Include": "true"}, {"nctId": "NCT02856425", "Include": "true"}, {"nctId": "NCT01543763", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "NF1", "Include": "true", "Alterations": {"Alteration": {"Name": "R1362*, R2450*", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "R1362*"}, {"isEquivocal": "false", "name": "R2450*"}]}, "Interpretation": "NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 alterations have been reported in 5_9% of endometrial carcinomas (Myers et al., 2016; 27016228, cBio_Soumerai et al., 2018; 30068706, Cancer Genome Atlas Research Network., 2013; 23636398). Loss of NF1 has been reported in 13% (4/31) of endometrial carcinomas (Murayama_Hosokawa et al., 2010; 20062086). Published data investigating the prognostic implications of NF1 mutation in endometrial carcinomas are limited (PubMed, Feb 2021). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including the approved agents everolimus and temsirolimus, based on limited clinical data (Lim et al., 2016; 26859683, Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)(Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108). A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient MPNST (Malone et al., 2014; 24913553). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.", "Include": "true", "ClinicalTrialNote": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Trametinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Although very little clinical data has been reported on the use of MEK inhibitors in endometrial or uterine cancer, a Phase 1 trial of trametinib in combination with an AKT inhibitor (GSK2141795), reported 3/3 objective responses in uterine/endometrial tumors, with 2 patients achieving stable disease (SD) and 1 partial response (PR) occurring in a patient with mutant KRAS and PTEN loss (Kurzrock et al., 2011; ASCO abstract 3085). In other solid tumor types, a Phase 1 trial of trametinib in 206 patients with solid tumors reported 21 (10%) objective responses (Infante et al., 2012; 22805291). Phase 1 monotherapy trials of RO4987655, another MEK inhibitor, have shown significant response rates in patients with melanoma, including those with BRAF and NRAS mutations, but very low response rates in patients with other solid tumors, including those with KRAS mutations (Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 1b trial of trametinib in combination with gemcitabine in patients with solid tumors showed a complete response in a patient with breast cancer, as well as partial responses in patients with pancreatic or salivary gland cancer (Infante et al., 2013; 23583440). A Phase 1b trial of combination treatment with the MEK inhibitor MEK162 and the PI3K_alpha inhibitor BYL719 reported disease control (partial responses or stable disease) in 47% (21/45) of patients, including partial responses in 2 of 3 patients with KRAS_mutant ovarian cancer and 1 of 3 patients with NRAS_mutant melanoma; a 43% rate of stable disease was observed in patients with KRAS_mutant colorectal cancer, with responses independent of PIK3CA mutation status (Juric et al., 2014; ASCO Abstract 9051). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> A Phase 2 study evaluating selumetinib in patients with recurrent endometrial cancer who had received prior treatment with 1_2 therapies did not reach its primary endpoints of efficacy and 6_month event_free survival, reporting mPFS of 2.3 months and mOS of 8.5 months with 1 CR and 2 PR observed in 52 patients (Coleman et al., 2015; 25887099). Selumetinib has demonstrated efficacy in NF1_associated neurofibroma in Phase 2 studies (Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612) and a Phase 1 study (Dombi et al., 2016; 28029918). Phase 2 studies reported clinical responses in low_grade glioma (Fangusaro et al., 2019; 31151904, Banerjee et al., 2017; 28339824), melanoma (Gupta et al., 2014; 24567366, Robert et al., 2013; 23735514, Kirkwood et al., 2012; 22048237, Banerji et al., 2010; 20179232, Boers_Sonderen et al., 2012; 22293660), and in lung (Lopez_Chavez et al., 2015; 25667274, Hainsworth et al., 2010; 20802351, Middleton et al., 2020; 32669708) and endometrial cancer (Coleman et al., 2015; 25887099). A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed (Allen et al., 2021; ASCO Abstract 10008). Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non_small cell lung cancer (NSCLC), and CRC (Deming et al., 2016; 26666244); 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A (Krishnamurthy et al., 2018; 30042150). Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus (Infante et al., 2017; 28424891), docetaxel or dacarbazine (LoRusso et al., 2017; 28264648), AKT inhibitors (Tolcher et al., 2015; 25516890), or cixutumumab (an anti_IGF_1R antibody)(Wilky et al., 2015; 25268371) reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03989115", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04800822", "Include": "true"}, {"nctId": "NCT02397083", "Include": "true"}, {"nctId": "NCT02070549", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": [{"Name": "R88Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R88Q"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as R88Q observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477). Although alterations such as T1025A seen here have not been fully characterized, they have been associated with sensitivity to targeted therapies or have shown cancer association, which may indicate biological relevance (Tate et al., 2019; 30371878, Rivi\u00e8re et al., 2012; 22729224, Akgumus et al., 2017; 28502730, Slomovitz et al., 2015; 25624430, Al_Rohil et al., 2016; 26479420, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, PIK3CA mutations have been reported in 16_54% of endometrial carcinomas (Garcia_Dios et al., 2013; 23219661, Rudd et al., 2011; 21266528, Kandoth et al., 2013; 23636398). In endometrial cancers, PIK3CA mutations often co_occur with other mutations that activate the PI3K_AKT_mTOR signaling axis, such as PTEN and KRAS alterations (Oda et al., 2005; 16322209, Oda et al., 2008; 18829572). Overexpression of p110_alpha has been reported in 72% of endometrial carcinomas (Akiyama_Abe et al., 2013; 23949151). One study reported PIK3CA exon 9 or 20 mutations in 20% (20/99) of high_grade endometrial carcinomas; these mutations were associated with shorter patient survival within Grade 3 endometrioid carcinoma, but not within endometrial serous carcinoma (McIntyre et al., 2013; 24262879). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). Results from the Phase 2 MATCH trial for patients with PIK3CA_altered solid tumors found that 27% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study of PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_altered tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108). Activating mutations in PIK3CA may confer resistance to HER2_targeted therapies; combined inhibition of HER2 and the PI3K pathway may be required in HER2_positive tumors with PIK3CA mutation (Esteva et al., 2010; 20813970, Baselga et al., 2014; 25332247, Chakrabarty et al., 2010; 20581867, Cizkova et al., 2010; San Antonio Breast Cancer Symposium Abstract P2_09_30, Kataoka et al., 2010; 19633047, Wang et al., 2011; 21676217).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_na\u00efve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_na\u00efve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02688881", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}, {"Name": "T1025A", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "T1025A"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as R88Q observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477). Although alterations such as T1025A seen here have not been fully characterized, they have been associated with sensitivity to targeted therapies or have shown cancer association, which may indicate biological relevance (Tate et al., 2019; 30371878, Rivi\u00e8re et al., 2012; 22729224, Akgumus et al., 2017; 28502730, Slomovitz et al., 2015; 25624430, Al_Rohil et al., 2016; 26479420, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, PIK3CA mutations have been reported in 16_54% of endometrial carcinomas (Garcia_Dios et al., 2013; 23219661, Rudd et al., 2011; 21266528, Kandoth et al., 2013; 23636398). In endometrial cancers, PIK3CA mutations often co_occur with other mutations that activate the PI3K_AKT_mTOR signaling axis, such as PTEN and KRAS alterations (Oda et al., 2005; 16322209, Oda et al., 2008; 18829572). Overexpression of p110_alpha has been reported in 72% of endometrial carcinomas (Akiyama_Abe et al., 2013; 23949151). One study reported PIK3CA exon 9 or 20 mutations in 20% (20/99) of high_grade endometrial carcinomas; these mutations were associated with shorter patient survival within Grade 3 endometrioid carcinoma, but not within endometrial serous carcinoma (McIntyre et al., 2013; 24262879). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). Results from the Phase 2 MATCH trial for patients with PIK3CA_altered solid tumors found that 27% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study of PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_altered tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108). Activating mutations in PIK3CA may confer resistance to HER2_targeted therapies; combined inhibition of HER2 and the PI3K pathway may be required in HER2_positive tumors with PIK3CA mutation (Esteva et al., 2010; 20813970, Baselga et al., 2014; 25332247, Chakrabarty et al., 2010; 20581867, Cizkova et al., 2010; San Antonio Breast Cancer Symposium Abstract P2_09_30, Kataoka et al., 2010; 19633047, Wang et al., 2011; 21676217).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_na\u00efve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_na\u00efve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02688881", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}]}, "ReferenceLinks": null}, {"Name": "PIK3CB", "Include": "true", "Alterations": {"Alteration": {"Name": "R321Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R321Q"}}, "Interpretation": "PIK3CB (PI3K_beta, p110_beta) encodes a member of the class IA phosphoinositide 3_kinases (PIK3CA, PIK3CB, PIK3CD, and PIK3CG), which are essential regulators of cellular proliferation, survival, metabolism, and motility. Dysregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of the tumor suppressor PTEN or activating mutations in PIK3CA (p110_alpha). Contrary to PIK3CA, which is frequently mutated within hot spots causing increased kinase activity, mutation of PIK3CB is quite rare (Phillips et al., 2006; 16380997, Dbouk et al., 2013; 23734178, Pazarentzos et al., 2015; 25982275). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, PIK3CB mutations and amplification have been observed in 5.4% and 2.1% of cases, respectively (Cancer Genome Atlas Research Network., 2013; 23636398). Published data investigating the prognostic implications of PIK3CB alterations in endometrial carcinoma are limited (PubMed, Oct 2020). However, a preclinical study reported that elevated PIK3CB mRNA levels contributed to early endometrial tumorigenesis and increased cellular proliferation of primary tumors (Karlsson et al., 2017; 28002804). Preclinical evidence indicates that PTEN_deficient tumors depend on PI3K_beta (Wee et al., 2008; 18755892, Jia et al., 2008; 18594509, Schmit et al., 2014; 24737887), and inhibitors selective for PI3K_beta, including GSK2636771 and AZD8186, are in clinical trials for PTEN_deficient tumors (Arkenau et al., 2014; ASCO Abstract 2514, Siu et al., 2015; AACR Abstract CT329). PIK3CB activating alterations may further refine the use of PI3K_beta_selective inhibitors (Pazarentzos et al., 2015; 25982275). Two patients with PTEN_deficient prostate tumors and concurrent PIK3CB L1049R mutation or PIK3CB amplification derived significant clinical benefit from treatment with GSK2636771 (de Bono et al., 2015; AACR Abstract CT328). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT03673787", "Include": "true"}, {"nctId": "NCT02397083", "Include": "true"}, {"nctId": "NCT03711058", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3R1", "Include": "true", "Alterations": {"Alteration": {"Name": "E476*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E476*"}}, "Interpretation": "PIK3R1 encodes the p85_alpha regulatory subunit of phosphatidylinositol 3_kinase (PI3K)(Huang et al., 2008; 18418043). Loss of PIK3R1 has been shown to result in increased PI3K signaling (Taniguchi et al., 2010; 20530665, Luo et al., 2006; 16679293, Ueki et al., 2003; 14504291, Mauvais_Jarvis et al., 2002; 11781359), promote tumorigenesis (Taniguchi et al., 2010; 20530665, Thorpe et al., 2017; 28630349, Li et al., 2019; 30755611), and promote hyperplasia in the context of PTEN_deficiency (Luo et al., 2005; 16006513). Alterations such as seen here may disrupt PIK3R1 function or expression (Jaiswal et al., 2009; 19962665, Cheung et al., 2011; 21984976, Ko et al., 2014; 24651434, Quayle et al., 2012; 23166678, Sun et al., 2010; 20713702, Wu et al., 2009; 19915146, Urick et al., 2011; 21478295, Huang et al., 2007; 18079394, Bousquet et al., 2006; 16917505, Oliver et al., 2017; 28143957, Philp et al., 2001; 11606375, Lucas et al., 2014; 25488983, Chen et al., 2018; 29636477, Cheung et al., 2014; 25284480). In the TCGA datasets, PIK3R1 mutation is most frequently observed in endometrial carcinoma (33%)(Cancer Genome Atlas Research Network., 2013; 23636398), glioblastoma (GBM; 11%)(cBio_Brennan et al., 2013; 24120142), uterine carcinosarcoma (11%)(cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210), and lower grade glioma (5%)(Cancer Genome Atlas Research Network., 2015; 26061751). PIK3R1 is often inactivated by in_frame insertions or deletions (indels), and the majority of this class of mutation (80%) was observed in endometrial carcinoma (Ye et al., 2016; 26657142, Cheung et al., 2011; 21984976, Urick et al., 2011; 21478295), although PIK3R1 indels have been reported in other cancer types such as GBM, cervical squamous cell carcinoma, and urothelial bladder carcinoma (Ye et al., 2016; 26657142). On the basis of limited clinical data, reduced PIK3R1 expression has been associated with reduced disease_free survival in prostate cancer (Munkley et al., 2015; 26501081) and metastasis_free survival in breast cancer (Cizkova et al., 2013; 24229379). PIK3R1 expression is not associated with overall survival in neuroendocrine tumors (Qian et al., 2013; 23980085). On the basis of clinical (Matulonis et al., 2015; 25528496, Piha_Paul et al., 2015; ASCO Abstract 2516, Pitz et al., 2015; 25605819, Juric et al., 2016; SABCS Abstract P3_14_01) and preclinical (Thorpe et al., 2017; 28630349, Sun et al., 2010; 20713702) data, PIK3R1 alteration may predict sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors. In patients with PIK3R1 mutation and no other alterations in the PI3K_AKT_mTOR pathway, 2 CRs have been achieved by patients with endometrial cancer treated with the pan_PI3K inhibitor pilaralisib (Matulonis et al., 2015; 25528496), and 1 PR has been achieved by a patient with breast cancer treated with the PI3K_alpha inhibitor alpelisib in combination with ribociclib and letrozole (Juric et al., 2016; SABCS Abstract P3_14_01). Limited clinical and preclinical data suggest that PIK3R1 alterations may also be sensitive to inhibitors of mTOR (Groisberg et al., ASCO 2017; Abstract 2582, Basho et al., 2015; European Cancer Congress Abstract 1871, Basho et al., 2017; 27893038, Myers et al., 2016; 27016228, Day et al., 2019; 30420444, Sun et al., 2010; 20713702, Ou et al., 2014; 25193464) or AKT (Groisberg et al., ASCO 2017; Abstract 2582, Li et al., 2019; 30755611, Quayle et al., 2012; 23166678). One preclinical study reported that PIK3R1 truncation mutations in the 299\u2013370 range confer sensitivity to MEK inhibitors (Cheung et al., 2014; 25284480).", "Include": "true", "ClinicalTrialNote": "On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03711058", "Include": "true"}, {"nctId": "NCT03502733", "Include": "true"}, {"nctId": "NCT03586661", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "R130Q, R173H", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "R130Q"}, {"isEquivocal": "false", "name": "R173H"}]}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454). PTEN mutation has been observed in 55_65% of endometrial cancers and in 70% of primary endometrioid endometrial cancers, whereas PTEN loss has been reported in 5% of endometrial carcinoma cases (Cancer Genome Atlas Research Network., 2013; 23636398, Byron et al., 2008; 18757403, Peterson et al., 2012; 22498935). PTEN mutation or loss has been suggested to play a role in endometrial cancer progression; high PTEN expression has been observed in Grade 1 and 2 tumors but not in Grade 3 tumors (Daniilidou et al., 2013; 23613406, van der Zee et al., 2013; 23288720, Joshi et al., 2012; 22503752, Akiyama_Abe et al., 2013; 23949151). Loss of PTEN protein expression has been correlated with increased survival of patients with Stage 3 or 4 endometrial carcinoma, but not Stage 1 or 2 (Akiyama_Abe et al., 2013; 23949151). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in endometrial cancer have not observed an association between PTEN deficiency and response to the mTOR inhibitors everolimus or temsirolimus (Meyer et al., 2014; 24651628, Oza et al., 2011; 21788564, Mackay et al., 2014; 24166148, Fleming et al., 2014; 24456823, Tsoref et al., 2014; 25173583, Myers et al., 2016; 27016228, Tredan et al., 2013; 23238879, Slomovitz et al., 2010; 20681032). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). In a Phase 1 study of patients treated with PARP and AKT inhibitors olaparib and capivasertib, two patients with PTEN_mutated ovarian cancer and a patient with PTEN_mutated endometrial cancer achieved clinical benefit (CR, PR, or SD >4 months) (Yap et al, 2020; 32532747). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04269200", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04716686", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "RAD51D", "Include": "true", "Alterations": {"Alteration": {"Name": "R253Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R253Q"}}, "Interpretation": "RAD51D, also known as RAD51L3, is involved in homologous recombination_mediated DNA repair and telomere maintenance (Tarsounas et al., 2004; 15109494, Suwaki et al., 2011; 21821141, Sasaki et al., 2004; 15162012, Smiraldo et al., 2005; 15781618). Germline mutations in RAD51D have been associated with hereditary breast and ovarian cancer (Baker et al. 2015; 25445424, Graffeo et al., 2016; 27734215, Osher et al., 2012; 22415235, Peltarri et al., 2012; 22652533, Gutierrez et al., 2014; 24130102, Loveday et al., 2011; 21822267), and RAD51D mutation carriers have an increased lifetime risk of ovarian cancer, estimated to be 10_12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. RAD51D mutation has been observed in 3.1% of endometrioid carcinomas, but not in any samples of other endometrial histologies analyzed in the COSMIC database (Sep 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of RAD51D alteration in endometrial carcinomas are limited (PubMed, Sep 2021). Limited preclinical data (Rivera et al., 2017; 28646019, Loveday et al., 2011; 21822267) and clinical evidence in ovarian cancer (Swisher et al., 2017; 27908594, Kondrashova et al., 2017; 28588062, Chandran et al., 2018; DOI: 10.1200/PO.18.00253, O Malley et al., 2017; AACR_NCI_EORTC Abstract LB_A12) indicate that loss or inactivation of RAD51D may confer sensitivity to PARP inhibitors. Loss of functional RAD51D may also predict sensitivity to DNA_damaging drugs such as mitomycin C and cisplatin (Hinz et al., 2006; 16522646, Wiese et al., 2006; 16717288, Rivera et al., 2017; 28646019, Wickramanayake et al., 2012; 22986143). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Inactivating germline mutations in RAD51D are associated with hereditary breast and ovarian cancer (HBOC) syndrome, an autosomal dominant disorder that predisposes patients to breast and ovarian malignancies (Janatova et al., 2015; 26057125, Stafford et al., 2017; 28591191). The risk of ovarian cancer in RAD51D mutation carriers has been estimated to be 10 to 12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Germline RAD51D mutation has been reported at frequencies of up to 1% in breast and ovarian familial cancer populations without BRCA1/2 mutation (Guti\u00e9rrez_Enr\u00edquez et al., 2014; 24130102, Konstanta, et al., 2018; 30111881, Chen et al., 2018; 30165555). In the appropriate clinical context, germline testing of RAD51D is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04269200", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT04716686", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04159155", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "TSC1", "Include": "true", "Alterations": {"Alteration": {"Name": "Q739*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q739*"}}, "Interpretation": "TSC1 encodes the protein Hamartin, which interacts with Tuberin, the gene product of TSC2, to inhibit and regulate mTOR activity (Tee et al., 2003; 12906785, Inoki et al., 2003; 12869586). Alterations such as seen here may disrupt TSC1 function or expression (Miloloza et al., 2000; 10915759, Hoogeveen_Westerveld et al., 2010; 20547222, Hodges et al., 2001; 11741833). TSC1 mutations have been reported in 5.2% of endometrial carcinomas analyzed in COSMIC (Sep 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of TSC1 alterations in endometrial cancer are limited (PubMed, Oct 2020). Loss or inactivation of TSC1 can activate mTOR signaling (Tee et al., 2003; 12906785, Mallela et al., 2021; 33575875); however, response rates for patients with TSC1_mutated solid tumors treated with MTOR inhibitors such as everolimus and temsirolimus have been low (Adib et al., 2021; 33727259, Nassar et al., 2020; 31653662, Voss et al., 2019; 30327302). In the prospective NCI_MATCH study, the ORR for patients with various TSC1_mutated solid tumors treated with everolimus was 7.7% (1/13); the single response was reported for a patient with urothelial cancer (Adib et al., 2021; 33727259). In TSC1_mutated renal cell carcinoma (RCC), responses to MTOR inhibitors have been described in multiple case series and reports (Ali et al., 2015; 25796537, Lim et al., 2016; 26859683, Kwiatkowski et al., 2016; 26831717, Hamieh et al., 2018; 30256787, Roldan_Romero et al., 2020; 31335987), but retrospective analysis of a broader cohort showed no responses in TSC1_mutated RCC (0/7)(Nassar et al., 2020; 31653662). Retrospective analyses of the RECORD_3, GRANITE_1, and EVOLVE_1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS (Voss et al., 2019; 30327302). Inactivating germline mutations in TSC1 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma (Gomez, 1991; 2039135, van Slegtenhorst et al., 1997; 9242607). TSC1 mutations account for approximately 10 to 30% of reported sporadic cases (Crino et al., 2006; 17005952). Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age (Curatolo et al., 2008; 18722871). In the appropriate clinical context, germline testing of TSC1 is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT02397083", "Include": "true"}, {"nctId": "NCT03008408", "Include": "true"}, {"nctId": "NCT03217669", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "372", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "372"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). A large_scale genomic analysis found that endometrial adenocarcinomas harbored a median TMB of 4.5 Muts/Mb, and 15% of cases had an elevated TMB of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Another study evaluating TMB in endometrial adenocarcinoma reported that 24% of tumors had a mutational burden of greater than 10.4 Muts/Mb (Santin et al., 2016; ASCO Abstract 5591). Increased tumor mutational burden (TMB) in endometrial carcinoma has been correlated with POLE mutation and advanced high_grade endometrioid subtypes (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network, 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559). Ultramutated endometrial tumors (elevated TMB with POLE mutations) have also been associated with improved PFS (Cancer Genome Atlas Research Network, 2013; 23636398). The same study associated lower mutational burden, independent of PD_L1 status, in endometrial carcinomas with poorer prognosis (Cancer Genome Atlas Research Network, 2013; 23636398). For patients with advanced microsatellite_stable endometrial carcinoma not treated with immunotherapy, OS did not significantly differ between patients with TMB_high (\u226510 Muts/Mb) and TMB_low (11.4 vs. 13.5 months, adjusted HR=1.15) in 1 study (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Dostarlimab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Single_agent dostarlimab has been approved to treat patients with mismatch repair deficient (dMMR) endometrial cancer based on results observed in the Phase 1 GARNET study. In the study, dostarlimab elicited an ORR of 42% (30/71; 9 CRs, 21 PRs) for patients with endometrial cancer; median PFS, median OS, and median duration of response (DOR) have not been reached (Oaknin et al., 2020; 33001143). In a Phase 2 study of combination niraparib and dostarlimab for patients with endometrial cancer, patients experienced an ORR of 14% (3/22) and a DCR of 32%, while patients treated with niraparib experienced an ORR of 4.0% (1/23) and a DCR of 20% (Madariaga et al., 2021; ASCO Abstract 5574). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Atezolizumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and urothelial carcinoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, triple_negative breast cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In a Phase 1 study of single_agent atezolizumab, patients with advanced or recurrent uterine cancer achieved an ORR of 13.3% (2/15), a median PFS of 1.4 months, and a median OS of 9.6 months; both objective responses occurred in PD_L1_positive patients (\u2265 5% of immune cells), and one of these patients was also MSI_High (Liu et al., 2019; 31204078). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for the treatment of non_small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515)(Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 25.6% (11/43) of melanomas, 12.5% (7/56) of renal cell carcinomas (RCC) and 16.7% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As single_agent therapy in genomically unselected young patients (<30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 14.5% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell RCC (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab_paclitaxel for patients with previously treated metastatic triple_negative breast cancer (mTNBC) and reported confirmed objective responses for 41.7% (10/24) of patients; no dose_limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) in patients with CRC, 40.9% (9/22) in patients with melanoma, 17.9% (5/28) in patients with NSCLC, and 18.8% (3/16) in patients with other tumors (ovarian cancer, clear_cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose_limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nivolumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma or squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) metastatic colorectal cancer (CRC) that has progressed on fluoropyrimidine, oxaliplatin, and irinotecan. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> A Phase 2 study of cabozantinib combined with nivolumab reported improved median PFS (5.3 vs. 1.9 months) and ORR (25% [9/36] vs. 16.7% [3/18]) compared with nivolumab monotherapy for patients with endometrial cancer; OS was also improved with combination therapy (13.0 vs. 7.9 months), although the data have not matured yet (Lheureux et al., 2020; ASCO Abstract 6010). A retrospective analysis of patients with recurrent and refractory endometrial cancer treated with nivolumab alone or in combination with other agents reported a CR of >20 months for a patient treated with nivolumab and everolimus and an overall clinical benefit rate of 75% (9/12), including 8 SDs of >3 months (Takano et al., 2019; ASCO Abstract e17124). A case study reported 2 PRs to nivolumab for patients with endometrial carcinoma harboring high tumor mutation burden; response was ongoing at 7_9 months (Santin et al., 2016; 27486176). Nivolumab monotherapy has been reported to elicit clinical benefit for patients with multiple types of solid tumors, including melanoma (27\u201331% ORR) (Postow et al., 2015; 25891304, Larkin et al., 2015; 26027431, Robert et al., 2014; 25399552, Topalian et al., 2014; 24590637, Weber et al., 2015; 25795410), non_small cell lung carcinoma (NSCLC; 17\u201320% ORR and 9\u201310 months mOS in unselected patients) (Brahmer et al., 2014; ASCO Abstract 8112, Gettinger et al., 2014; ASCO Abstract 8024, Antonia et al., 2014; ASCO Abstract 8023, Rizvi et al., 2014; ASCO Abstract 8022, Antonia et al., 2014; ASCO Abstract 8113, Brahmer et al., 2015; 26028407, Borghaei et al., 2015; 26412456), urothelial carcinoma (20\u201326% ORR in unselected patients) (Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785), renal cell carcinoma (RCC; 26% ORR) (Amin et al., 2014; ASCO Abstract 5010, McDermott et al., 2016, ASCO Abstract 4507)(Motzer et al., 2014; 25452452, Topalian et al., 2012; 22658127, Brahmer et al., 2010; 20516446, Motzer et al., 2015; 26406148), MSI_High colorectal cancer (CRC; 58% ORR) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO GI Abstract 481), head and neck squamous cell carcinoma (11\u201317% ORR) (Gillison et al., 2016; AACR Abstract CT099, Ferris et al., 2016; ASCO Abstract 6009, Ferris et al. 2019; 31239321), ovarian cancer (6\u201315% ORR) (Brahmer et al., 2012; 22658128, Hamanishi et al., 2015; 26351349, Normann et al., 2019; 31074244), small cell lung cancer (SCLC; 10\u201312% ORR) (Calvo et al., 2015; ECC Abstract 3098, Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), gastroesophageal carcinoma (12\u201318% ORR) (Le et al., 2016; ASCO GI Cancers Abstract 06, Kojima et al., 2016; ASCO GI Cancers Abstract TPS175, Janjigian et al., 2018; 30110194), and cancer of unknown primary (CUP; 10% ORR in unselected, previously treated patients) (Tanizaki et al., 2020; ASCO Abstract 106), as well as with Hodgkin lymphoma (66\u201387% ORR) (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239, Younes et al., 2016; 27451390). Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved further efficacy in melanoma (up to 61% ORR; mOS > 60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (17 months mOS) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19\u201325% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR in unselected patients; 58% ORR in patients with \u22651% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. Combinations of nivolumab with various targeted therapies, such as pazopanib (1a PR in a patient with epithelioid sarcoma) (Paoluzzi et al., 2016; ASCO Abstract 11047), sunitinib (9% ORR in unselected patients with sarcoma) (Broto et al., 2019; ESMO Abstract 1669O), cabozantinib (29% ORR in patients with immunotherapy_refractory urothelial carcinoma) (Nadal et al., 2018; ASCO Abstract 4528), or vemurafenib (1a durable PR in a patient with BRAF V600E_mutated and PD_L1 positive anaplastic thyroid cancer) (Kollipara et al., 2017; 28778959), have also shown evidence of efficacy and continue to undergo clinical investigation. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Avelumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In a Phase 2 trial of avelumab in recurrent endometrial cancer, patients with MMR deficiency or POLE mutation achieved an ORR of 26.7% (4/15) and a median PFS of 4.4 months; for patients with MMR_proficient tumors, the ORR was 6.2% (1/16) and the median PFS was 1.9 months (Konstantinopoulos et al., 2019; 31461377). The JAVELIN Phase 1b study has demonstrated clinical benefit from single_agent avelumab in a variety of solid tumor types, including non_small cell lung carcinoma (NSCLC)(Verschraegen et al., 2016; ASCO Abstract 9036), gastric carcinoma and gastroesophageal junction (GEJ) adenocarcinoma (Chung et al., 2016; ASCO Abstract 4009), urothelial carcinoma (Patel et al., 2016; ESMO Abstract 777PD), mesothelioma (Hassan et al., 2016; ASCO Abstract 8503), ovarian carcinoma (Disis et al., 2016; ASCO Abstract 5533), and breast cancer (Dirix et al., 2016; SABCS Abstract S1_04), and from avelumab combined with axitinib in renal cell carcinoma (Larkin et al., 2016; ESMO Abstract 775PD). Emerging clinical data show a positive trend toward the association of tumor cell PD_L1 expression and improved objective response rate, progression_free survival, or overall survival in NSCLC in the first_line setting and in ovarian and breast cancer (Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1_04, Verschraegen et al., 2016; ASCO Abstract 9036). Limited clinical data indicate activity of avelumab in adrenocortical carcinoma, metastatic castration_resistant prostate cancer, and thymic cancer (Le Tourneau et al., 2016; ASCO Abstract 4516, Fakhrejahani et al., 2017; ASCO GU Abstract 159, Rajan et al., 2016; ASCO Abstract e20106). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Durvalumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The PHAEDRA Phase 2 trial of durvalumab in advanced endometrial cancer reported an ORR of 43% and a DCR of 66% (5 CRs, 10 PRs, 8 SDs in 35 patients) for the MMR_deficient cohort, and an ORR of 3% and a DCR of 29% (1 PR, 9 SDs in 35 patients) for the MMR_proficient cohort using iRECIST criteria (Antill et al., 2019; ASCO Abstract 5501). A Phase 2 study for patients with endometrial carcinoma and carcinosarcoma evaluated durvalumab with or without tremelimumab and reported ORR of 14.8% (4/27 with 1 CR and 3 PRs) versus 11.1% (3/27 with 2 CRs and 1 PR), median PFS of 7.6 weeks versus 8.1 weeks, and median duration of response of 16 weeks versus 8 weeks (Rubinstein et al., 2019; ASCO Abstract 5582). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Pembrolizumab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden_high (TMB_High; \u226510 Muts/Mb), microsatellite instability_high (MSI_High), or mismatch repair deficient (dMMR) solid tumors, or PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), classical Hodgkin lymphoma, cervical cancer, gastric cancer, esophageal cancer, or gastroesophageal junction (GEJ) carcinoma. It is also approved in various treatment settings for patients with melanoma, NSCLC, small cell lung cancer, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, or cutaneous squamous cell carcinoma (CSCC). Combination treatments with pembrolizumab are approved for patients with NSCLC, renal cell carcinoma, endometrial carcinoma that is not MSI_High or dMMR, or triple_negative breast cancer (TNBC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 3 KEYNOTE_775 study, combination pembrolizumab and lenvatinib treatment improved median PFS (mPFS, 7.2 vs. 3.8 months, HR=0.56) and median OS (mOS, 18.3 vs. 11.4 months, HR=0.62) for patients with advanced endometrial cancer and prior platinum chemotherapy, compared with physician\u2019s choice of chemotherapy; benefit was observed in both mismatch repair deficient (dMMR, mPFS HR=0.36, mOS HR=0.37) and proficient (pMMR, mPFS HR=0.60, mOS HR=0.68) subgroups (Makker et al., 2021; SGO Abstract 11512). Similar results for pembrolizumab with lenvatinib were reported in the Phase 1b/2 KEYNOTE_146 study, with a trend toward an improved ORR for patients who were dMMR compared with pMMR (64% vs. 37%) but a similar ORR for patients who were PD_L1 positive (CPS \u22651.0%) compared with PD_L1 negative (36% vs. 40%)(Makker et al., 2020; 32167863). Single_agent pembrolizumab elicited clinical benefit for 26% (3/23 PRs and 3/23 SDs) of patients with advanced PD_L1_positive (CPS \u22651.0%) endometrial cancer included in the Phase 1b KEYNOTE_028 study, with a mPFS of 1.8 months (Ott et al., 2017; 28489510). In the Phase 2 KEYNOTE 158 multi_solid tumor trial, treatment with the PD_1 inhibitor pembrolizumab led to improved ORR for patients with TMB of 10 Muts/Mb or higher compared those with TMB <10 Muts/Mb (28.3% [34/120] vs. 6.5% [41/635])(Marabelle et al., 2020; 32919526). In the KEYNOTE 028/012 pan_solid tumor trials, a similar improvement in ORR was reported for patients with >103 non_synonymous mutations/exome (~ equivalency >8 Muts/Mb as measured by this assay) compared to those with <103 non_synonymous mutations/exome (30.6% [11/36] vs. 6.5% [5/77])(Cristescu et al., 2018; 30309915). A patient with PD_L1_positive, ultramutated endometrial adenocarcinoma harboring POLE mutation experienced a PR to pembrolizumab for more than 14 months (Mehnert et al., 2016; 27159395). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nivolumab + Ipilimumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and pleural mesothelioma. Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) metastatic colorectal cancer (CRC) that has progressed on fluoropyrimidine, oxaliplatin, and irinotecan. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of \u226510 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> A Phase 2 trial treating patients with rare gynecological malignancies with combination nivolumab and ipilimumab reported objective responses in 27% (11/41) of patients, including those with vaginal SCC, ovarian and uterine carcinosarcoma, uterine serous cancer, uterine clear cell carcinoma, and uterine leiomyosarcoma (Klein et al., 2020; ASCO Abstract 6091). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Cemiplimab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD_L1 expression (TPS \u2265 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cemiplimab for the treatment of endometrial cancer are limited (PubMed, May 2021). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression \u226550% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04237649", "Include": "true"}, {"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT04181788", "Include": "true"}, {"nctId": "NCT02829723", "Include": "true"}, {"nctId": "NCT03530397", "Include": "true"}, {"nctId": "NCT02628067", "Include": "true"}, {"nctId": "NCT03192345", "Include": "true"}, {"nctId": "NCT04261439", "Include": "true"}, {"nctId": "NCT03565445", "Include": "true"}, {"nctId": "NCT03799003", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "APC", "Include": "true", "Alterations": {"Alteration": [{"Name": "S2307L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S2307L"}}, "Interpretation": "APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, APC mutations are reported in 12% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). Studies have reported APC mutations at varying frequencies in endometrial carcinoma, from no mutations being detected in 128 samples to 43% (12/28) of analyzed endometrial carcinomas having APC mutations (Pijnenborg et al., 2004; 15361208, Moreno_Bueno et al., 2002; 12439748). APC methylation has been detected at a higher frequency in endometrial adenocarcinomas with microsatellite instability (MSI) (43%, 17/40), than in cases without MSI (16%, 12/74) (Zysman et al., 2002; 12097272, Moreno_Bueno et al., 2002; 12439748). Two studies of endometrial carcinomas have reported the absence of APC protein expression in 8% (2/24) and 71% (30/42) of cases (Pijnenborg et al., 2004; 15361208, Singh et al., 2011; 21813170). A preclinical study using a mouse model demonstrated that loss of APC could induce endometrial cancer (Tanwar et al., 2011; 21363919). The prognostic significance of APC mutations in endometrial cancer remains unclear (PubMed, Jul 2021). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeted to APC defects or WNT upregulation in solid tumors. Preclinical studies have reported that APC inactivation or beta_catenin activation confer synthetic lethality when TRAIL receptors are upregulated and the TRAIL death receptor program is activated (Zhang et al., 2010; 20348907). In addition, the COX_2 inhibitor celecoxib was shown to reduce WNT signaling in cancer cell lines (Lu et al., 2009; 19026633, Tuynman et al., 2008; 18281498). A preclinical study has found that a small_molecule tankyrase inhibitor shows some activity in APC_mutant CRC models (Lau et al., 2013; 23539443). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "R2204*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R2204*"}}, "Interpretation": "APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, APC mutations are reported in 12% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). Studies have reported APC mutations at varying frequencies in endometrial carcinoma, from no mutations being detected in 128 samples to 43% (12/28) of analyzed endometrial carcinomas having APC mutations (Pijnenborg et al., 2004; 15361208, Moreno_Bueno et al., 2002; 12439748). APC methylation has been detected at a higher frequency in endometrial adenocarcinomas with microsatellite instability (MSI) (43%, 17/40), than in cases without MSI (16%, 12/74) (Zysman et al., 2002; 12097272, Moreno_Bueno et al., 2002; 12439748). Two studies of endometrial carcinomas have reported the absence of APC protein expression in 8% (2/24) and 71% (30/42) of cases (Pijnenborg et al., 2004; 15361208, Singh et al., 2011; 21813170). A preclinical study using a mouse model demonstrated that loss of APC could induce endometrial cancer (Tanwar et al., 2011; 21363919). The prognostic significance of APC mutations in endometrial cancer remains unclear (PubMed, Jul 2021). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeted to APC defects or WNT upregulation in solid tumors. Preclinical studies have reported that APC inactivation or beta_catenin activation confer synthetic lethality when TRAIL receptors are upregulated and the TRAIL death receptor program is activated (Zhang et al., 2010; 20348907). In addition, the COX_2 inhibitor celecoxib was shown to reduce WNT signaling in cancer cell lines (Lu et al., 2009; 19026633, Tuynman et al., 2008; 18281498). A preclinical study has found that a small_molecule tankyrase inhibitor shows some activity in APC_mutant CRC models (Lau et al., 2013; 23539443). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "ATRX", "Include": "true", "Alterations": {"Alteration": {"Name": "R907*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R907*"}}, "Interpretation": "ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and W\u00f6hrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CARD11", "Include": "true", "Alterations": {"Alteration": {"Name": "R271W", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R271W"}}, "Interpretation": "CARD11 (also known as CARMA1) is a scaffold protein critical for B_ and T_cell receptor_mediated NF_kappaB (NF_kB) activation (Weil et al., 2004; 15134788, Paul et al., 2013; 23474202, Juilland et al., 2016; 27135977). Activating CARD11 mutations, often occurring within the CARD (aa 18_110) or coiled_coil (aa 130_499) domains, can facilitate constitutive NF_kB signaling, proliferation, and cell survival in lymphomas (Juilland et al., 2016; 27135977, Bognar et al., 2016; 26776161, Chan et al., 2013; 23149938, Brohl et al., 2014; 25352053, Jeelall et al., 2012; 23027925, Lenz et al., 2008; 18323416, Lamason et al., 2010; 20799731, Dong et al., 2011; 21266526, Compagno et al., 2009; 19412164, da Silva Almeida et al., 2015; 26551667, Vallois et al., 2016; 27369867). Preclinical evidence suggests that activating CARD11 mutations may reduce sensitivity to ibrutinib, lenalidomide, and sotrastaurin in lymphoma (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570, Naylor et al., 2011; 21324920). Some germline CARD11 mutations have been found to underlie B_cell expansion with NF_kB and T_cell anergy (BENTA), a disorder characterized by congenital B_cell lymphocytosis (Snow et al., 2012; 23129749, Brohl et al., 2015; 25352053, Juilland et al., 2016; 27135977). CARD11 alterations have been most frequently reported in B_cell lymphomas, including diffuse large B_cell lymphoma (DLBCL; 11_23%)(Bu et al., 2012; 22397314, Lenz et al., 2008; 18323416, Morin et al., 2013; 23699601), follicular lymphoma (21_25%)(Morin et al., 2011; 21796119), primary central nervous system lymphoma (16_30%)(Montesinos_Rongen et al., 2010; 20544211, Braggio et al., 2015; 25991819), splenic marginal zone lymphoma (7_9%)(Rossi et al., 2012; 22891273; Yan et al., 2012; 22102703), and mantle cell lymphoma (6%)(Wu et al., 2016; 27224912). CARD11 mutations have also been detected in T_cell lymphomas, specifically in angioimmunoblastic T_cell lymphomas (AITLs), peripheral T_cell lymphomas (PTCLs), and cases of Sezary syndrome (Vallois et al., 2016; 27369867, Wang et al., 2015; 26551670, da Silva Almeida et al., 2015; 26551667). Copy number gains and consequent CARD11 overexpression have been reported in 71% (12/17) of patients with aggressive AITL and in 41% (30/73) of patients with PTCL (Oshiro et al., 2006; 16484591, Fujiwara et al., 2008; 18633432). Increased CARD11 expression has also been observed in T_ALL (Ma et al., 2014; 25384343). CARD11 amplification in DLBCL and increased CARD11 protein expression in AITL or PTCL is associated with reduced overall survival (Bu et al., 2012; 22397314, Fujiwara et al., 2008; 18633432). Although CARD11 mutations have been detected in a variety of solid tumors (cBio_Krauthammer et al., 2012; 22842228, cBio_Hodis et al., 2012; 22817889, cBio_Witkiewicz et al., 2015; 25855536, Cancer Genome Atlas Research Network., 2014; 25079317, Cancer Genome Atlas Research Network., 2014; 25079552, Cancer Genome Atlas Research Network., 2014; 24476821), the prognostic implications of CARD11 alterations in non_hematological malignancies are unclear. Although there are no therapies targeting CARD11 alterations, a number of drugs that block NF_kB activation are under investigation (Thome et al., 2010; 20685844, Lim et al., 2012; 22435566, Milhollen et al., 2010; 20525923). Preclinical evidence from models of mantle cell lymphoma suggests that tumors with CARD11 mutations may exhibit reduced sensitivity to inhibitors of BCR/NF_kB signaling including ibrutinib and lenalidomide (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570). CARD11 mutations have also been correlated with reduced sensitivity to sotrastaurin (protein kinase C inhibitor) in preclinical models of DLBCL (Naylor et al., 2011; 21324920).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CREBBP", "Include": "true", "Alterations": {"Alteration": {"Name": "E50*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E50*"}}, "Interpretation": "CREBBP encodes a ubiquitously expressed transcriptional coregulatory protein that interacts with multiple transcription factors and can couple control of gene expression to chromatin remodeling via its histone acetyltransferase activity. Inherited microdeletions and truncating point mutations in CREBBP are reported to be causal in approximately 20% of cases of Rubinstein_Taybi syndrome (Pertij et al., 2000; 10699051). The chromosomal rearrangement t(8;16)(p11;p13) is characteristic of the M4/M5 subtype of acute myeloid leukemia (AML) and results in a chimeric gene fusing MYST3/MOZ (a gene essential for the development of the hematopoietic system and maintenance of hematopoietic stem cells) to CREBBP (Borrow et al., 1996; 8782817). CREBBP_BCORL1 fusion has been reported in patients with ossifying fibromyxoid tumors (Kao et al., 2017; 27537276, Hofvander et al., 2020; 31932680). CREBBP mutations have been observed at high frequency in follicular lymphoma (FL, 39%) and diffuse large B_cell lymphoma (DLBCL, 17%), and at lower frequency in acute lymphoblastic leukemia (ALL, 6%), and tumors of the urinary tract (15%), skin (11%), endometrium (9%), liver (9%), and stomach (9%) (COSMIC, 2021)(Tate et al., 2019; 30371878). These mutations include missense substitutions clustered in the CREBBP histone acetyltransferase domain and truncating mutations throughout the gene sequence, suggesting a role for CREBBP inactivation in these diseases. CREBBP mutations have been reported to occur in the transition from prostate acinar carcinoma to squamous cell carcinoma (SCC) (Grasso et al., 2015; 25735316), which may indicate significance for CREBBP in SCC. In two cases of relapsed pediatric B_cell ALL, CREBBP mutation conferred resistance to glucocorticoid therapy (Ma et al., 2015; 25790293). Reports have found CREBBP mutation in 62_68% of patients with FL (Green et al., 2015; 25713363, Loeffler et al., 2015; 25027518), which was associated with immune evasion (Green et al., 2015; 25713363). AML with MYST3/CREBBP fusion was reported to occur in 60_80% of cases 9_72 months after adjuvant chemotherapy for breast cancer and was associated with a poor prognosis (Gervais et al., 2008; 18528428, Haferlach et al., 2009; 19194466). There are no targeted therapies available to address genomic alterations in CREBBP. The use of histone deacetylase (HDAC) inhibitors are being investigated in clinical trials that are recruiting patients with either lymphoma or urothelial carcinoma harboring CREBBP alterations. However, it has been reported that there is no correlation between CREBBP mutation status and response to HDAC inhibitors in DLBCL (Mensah et al., 2015; 25671298).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CTCF", "Include": "true", "Alterations": {"Alteration": {"Name": "R129*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R129*"}}, "Interpretation": "CTCF encodes an 11_zinc_finger protein that is implicated in a number of regulatory roles, including gene activation and repression, imprinting, insulation, methylation, and X chromosome inactivation (Phillips and Corces, 2009; 19563753). CTCF plays a role in transcriptional regulation of a number of key cancer_associated genes, including the oncogene MYC (Gombert and Krumm, 2009; 19568426) and tumor suppressor TP53 (Soto_Reyes and Recillas_Targa, 2010; 20101205), via maintenance of local DNA methylation status. The decreased expression levels of CTCF and/or BORIS, another 11_zinc_finger transcriptional regulator, were reported to be closely associated with global DNA methylation variability and decreased overall survival in epithelial ovarian cancer (Woloszynska_Read et al., 2011; 21296871, Kemp et al., 2014; 24794443). Somatic mutations in CTCF are infrequently reported in most cancers, but have been observed more commonly (24%) in uterine corpus endometrial carcinoma (cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210); nearly half of the observed mutations were truncating, suggesting a tumor suppressor role for CTCF in this disease. In addition, CTCF has been found to act as a tumor suppressor in breast cancer cell line studies (M\u00e9ndez_Catal\u00e1 et al., 2013; 23908591, Tiffen et al., 2013; 23553099). There are no targeted therapies available to address genomic alterations in CTCF.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CTNNA1", "Include": "true", "Alterations": {"Alteration": {"Name": "R451*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R451*"}}, "Interpretation": "CTNNA1 encodes alpha_catenin, a member of the cadherin family that functions in cell adhesion. Alpha_catenin acts as a tumor suppressor, through mechanisms that can vary by tissue (Kobielak and Fuchs, 2004; 15366705, Bajpai et al., 2009; 19458087). Alpha_catenin is one of three catenin proteins that are in complex with E_cadherin to help mediate cell_cell adhesion in epithelial tumor suppression (Kobielak and Fuchs, 2004; 15366705, Bajpai et al., 2009; 19458087); loss of cell adhesion may contribute to cancer cell invasiveness and formation of metastases. In epidermal cells, alpha_catenin acts as a tumor suppressor by inducing YAP1 phosphorylation and cytoplasmic localization (Silvis et al., 2011; 21610251, Piao et al., 2014; 24509793). Alpha_catenin also acts as a tumor suppressor by interacting with IKBalpha to influence the NF_KB pathway in E_cadherin_negative basal_like breast cancer cells (Piao et al., 2014; 24509793). Loss of alpha_catenin expression is also hypothesized to alter the balance between the cytoplasmic (cell adhesion) and nuclear (cell proliferation) functions of beta_catenin, further contributing to oncogenesis (Inge et al., 2008; 18566211). CTNNA1 mutations have been observed with highest incidence in endometrial carcinoma (6.8%)(Cancer Genome Atlas Research Network., 2018; 29625048), cutaneous melanoma (6.4%)(Van Allen., 2014; 24265153), colorectal adenocarcinoma (4.4%)(Cancer Genome Atlas Research Network., 2018; 29625048), and stomach adenocarcinoma (4.0%) TCGA datasets (cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). CTNNA1 mutations have been observed in patients with hereditary diffuse gastric carcinoma without CDH1 mutations (Hansford et al., 2015; 26182300, Majewski et al., 2013; 23208944). Reduced CTNNA1 expression in patients with breast cancer has been correlated with a poor clinical outcome and breast cancer brain metastasis (Ding et al., 2010; 20393555, Piao et al., 2014; 24509793). Deletion and hypermethylation of CTNNA1 has been observed in up to 22% (18/83) of myelodysplastic syndrome (MDS) cases and associated with poor clinicopathological features (Qian et al., 2014; 25153418, Ye et al., 2009; 19826047, Liu et al., 2007; 17159988, Ye et al., 2009; 19826047) and a trend for inferior survival (Qian et al., 2014; 25153418). Loss of CTNNA1 expression via 5q deletion or hypermethylation has been reported as a frequent event in acute myeloid leukemia and associated with shorter relapse_free survival in one study (Liu et al., 2007; 17159988, Chen et al., 2014; 24685333, Li et al., 2016; 27129146). There are no available targeted therapies to address genomic alterations in CTNNA1.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CUL3", "Include": "true", "Alterations": {"Alteration": {"Name": "L602*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "L602*"}}, "Interpretation": "CUL3 encodes the RING ubiquitin ligase cullin 3, which has been shown to form complexes regulating diverse cellular processes, including development and stress responses. Mutations affecting CUL3_KEAP1 complex formation and regulation of the stress_regulated transcription factor NRF2 have been found in 4/5 cases of sporadic papillary renal cell carcinoma (Ooi et al., 2013; 23365135). Mutations affecting the CUL3_KEAP1 complex have also been reported in lung cancer, and linked to increased NF_kB signaling through upregulation of IkkB protein expression (Genschik et al., 2013; 23912815). Decreased CUL3 expression has been linked to an aggressive phenotype in bladder cancer models (Grau et al., 2013; 23308193) and to formation of hepatocellular carcinomas through regulation of cyclin E expression (Kossatz et al., 2013; 20978349). There are no therapies available to directly address genomic alterations in CUL3.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ESR1", "Include": "true", "Alterations": {"Alteration": {"Name": "R256Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R256Q"}}, "Interpretation": "ESR1 encodes estrogen receptor alpha (ER_alpha), one of the major estrogen receptor isoforms in humans. Along with co_activator proteins, the ER complex promotes transcription of genes involved in cell cycle progression and survival (Pearce and Jordan, 2004; 15094156). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. ESR1 mutation has been reported in 2.5_7.1% of endometrial carcinomas analyzed (COSMIC, cBioPortal, Nov 2020)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Lower levels of ER_alpha protein and/or ESR1 mRNA expression have been associated with a reduced survival in endometrial carcinoma (Wik et al., 2013; 23319822, Rahman et al., 2013; 24023309). Therapies that directly target ER_alpha, such as selective ER modulators (SERMs) and the selective ER degrader (SERD) fulvestrant, as well as aromatase inhibitors (AIs) that inhibit estrogen production, are approved to treat ER_positive (ER+) and/or hormone receptor_positive (HR+) breast cancer (NCCN Guidelines v6.2020). AI treatment has also been reported to provide clinical benefit in a subset of HR+ gynecologic malignancies (Straubhar et al., 2017; 28560298, Thangavelu et al., 2013; 24076063, Gershenson et al., 2017; 28221866, Eshfani et al., 2014; 24925537, Ramirez et al., 2008; 18457865). Combinations of fulvestrant and CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib, have also demonstrated efficacy for patients with ESR1_mutated breast cancer (Tolaney et al., 2019; Abstract 4458, Neven et al., 2018; SABCS Abstract PD2_05, Turner et al., 2016; ASCO Abstract 512, Turner et al., 2018; 30345905, Martin et al., 2019; SABCS Abstract GS2_07). Clinical data suggest that ESR1 mutations may confer sensitivity to the first_generation SERD fulvestrant in breast cancer (Fribbens et al., 2016; 27269946, Spoerke et al., 2016; 27174596). A retrospective analysis of ESR1 mutations in gynecologic malignancies reported clinical benefit for patients with ESR1 mutations and fulvestrant treatment as a monotherapy or in combination, including 1 patient with peritoneal serous carcinoma and an ESR1 Y537N mutation who experienced prolonged clinical benefit (48+ months) from fulvestrant monotherapy (Galliard et al., 2019; 30987772). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Extensive clinical evidence indicates that ESR1 mutations arise primarily during treatment with AIs, especially relative to other ER_targeting therapies, and ESR1 ligand_independent activating alterations may predict lack of benefit from subsequent AI treatment in breast carcinoma (Turner et al., 2016; ASCO Abstract 512, Schiavon et al., 2015; 26560360, Fribbens et al., 2016; 27269946, Chandarlapaty et al., 2016; 27532364). In gynecologic malignancies, activating ESR1 Y537S and D538G mutations have been reported to confer resistance to AI treatment, particularly for patients who have already received AI treatment (Galliard et al., 2019; 30987772, Stover et al., 2018; 30828692, Morel et al., 2019; DOI: 10.1200/PO.18.00398 JCO Precision Oncology).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FAM123B", "Include": "true", "Alterations": {"Alteration": {"Name": "E387*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E387*"}}, "Interpretation": "FAM123B, also known as AMER1, encodes the protein WTX, which binds to beta_catenin, enhancing its proteasomal degradation and thereby exerting a repressive effect on WNT pathway signaling (Major et al., 2007; 17510365). Germline mutation or deletion of FAM123B causes osteopathia striata with cranial sclerosis (Jenkins et al., 2009; 19079258, Perdu et al., 2010; 20209645). Somatic mutation of FAM123B is rare in most cancers (COSMIC, 2021)(Tate et al., 2019; 30371878), but is observed at rates ranging from 5_30% in Wilms tumor (Perotti et al., 2008; 18391980, Ruteshouser et al., 2008; 18311776, Rivera et al., 2007; 17204608). No association between FAM123B alteration and clinical features or outcomes of Wilms tumor has been documented. There are no targeted therapies available to address genomic alterations in FAM123B.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KEL", "Include": "true", "Alterations": {"Alteration": {"Name": "E494*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E494*"}}, "Interpretation": "KEL encodes a transmembrane glycoprotein with similarities to zinc_dependent metalloproteases; this glycoprotein is highly polymorphic and forms the Kell blood group antigen (Claperon et al., 2005; 15769748). KEL mutations have been reported in tumors of the skin, lung, endometrium, stomach, large intestine, soft tissue, and liver at rates of 1.9_8.4%; up to 1.2% of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia_small lymphocytic lymphoma (CLL/SLL) samples (COSMIC, 2021)(Tate et al., 2019; 30371878). However, the mechanism by which KEL mutations contribute to tumor formation is not known. There are no therapies available to target genomic alterations in KEL.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KLHL6", "Include": "true", "Alterations": {"Alteration": {"Name": "D104N", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "D104N"}}, "Interpretation": "KLHL6 encodes a protein that exhibits homology to the Drosophila Kelch gene and is hypothesized to play a role in germinal center B_cell differentiation (Gupta_Rossi et al., 2003; 12617994). Whole genome sequencing identified somatic alteration of KLHL6 in a small number of chronic lymphocytic leukemias (Puente et al., 2011; 21642962), whereas an exome_sequencing effort identified similar alterations in a follicular lymphoma case (Weigert et al., 2012; 22585168). KLHL6 lies in a segment of chromosome 3q that has been observed to exhibit significant amplification in both squamous cell lung (Cancer Genome Atlas Research Network, 2012; 22960745) and ovarian (Cancer Genome Atlas Research Network, 2012; 21720365) carcinoma. No targeted therapies are available to address genomic alterations in KLHL6.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MAP3K1", "Include": "true", "Alterations": {"Alteration": {"Name": "G914*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G914*"}}, "Interpretation": "MAP3K1 encodes a multifunctional protein kinase and E3 ubiquitin ligase involved in several signal transduction pathways central to cancer cell biology (Xia et al., 1998; 9808624). Different MAP3K1 protein isoforms have been suggested to exert both pro_ and anti_apoptotic influences (Lu et al., 2002; 12049732, Schlesinger et al., 2002; 11782455). Germline polymorphism in MAP3K1 has been hypothesized to associate with risk for at least some subtypes of breast carcinoma (Garcia_Closas et al., 2008; 18437204), but the extent of effect is small and experimental results have been inconsistently replicated (Slattery et al., 2011; 21475998). Somatic alterations of MAP3K1, including missense mutations, truncating alterations, and loss of heterozygosity, have been observed most frequently in breast and uterine carcinomas (cBioPortal, COSMIC, 2021)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies available to address genomic alterations in MAP3K1.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MLL2", "Include": "true", "Alterations": {"Alteration": {"Name": "R5214C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R5214C"}}, "Interpretation": "MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (COSMIC, 2021)(Tate et al., 2019; 30371878), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MSH6", "Include": "true", "Alterations": {"Alteration": {"Name": "E641*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E641*"}}, "Interpretation": "MSH6 encodes MutS homolog 6 protein, a member of the mismatch repair (MMR) gene family. Defective MMR occurring as a result of mutation(s) in the MMR family (MLH1, MSH2, MSH6, or PMS2) can result in microsatellite instability (MSI), common in colon, endometrium, and stomach cancers (You et al., 2010; 21081928). Alterations such as seen here may disrupt MSH6 function or expression (Li et al., 2013; 23622243, Wu et al., 2011; 21720545, Edelbrock et al., 2013; 23391514, Berends et al., 2002; 11709755, Warren et al., 2007; 17531815, Geng et al., 2012; 22277660). MSH6 mutations have been reported in 17% of endometrioid carcinomas (Cancer Genome Atlas Research Network., 2013; 23636398). Multiple studies have cited an increased risk (16_44%) of endometrial cancer for female carriers of germline MSH6 mutations (Bonadona et al., 2011; 21642682, Baglietto et al., 2010; 20028993, Lu and Daniels, 2013; 23765559). Endometrial tumors harboring MMR protein alterations have been associated with worse overall and progression_free survival (Shih et al., 2011; 21742371). Numerous studies in various cancer types have shown that MSH6 loss or inactivation is associated with MSI and increased mutation burden (Cancer Genome Atlas Network., 2012; 22810696, You et al., 2010; 21081928, Joly et al., 2015; 25504677, Pritchard et al., 2014; 25255306, Rosty et al., 2014; 25117503, McConechy et al., 2015; 25636458). Clinical studies have shown that MSI is associated with patient responses to anti_programmed death 1 (PD_1) immune checkpoint inhibitors pembrolizumab (Le et al., 2015; ASCO Abstract LBA100)(Le et al., 2015; 26028255) and nivolumab (Lipson et al., 2013; 23169436). Higher mutation burden was also reported to be associated with response to pembrolizumab (Rizvi et al., 2015; 25765070). Furthermore, MSI status correlates with higher PD_1 and PD_L1 expression (Gatalica et al., 2014; 25392179), potential biomarkers of response to PD_1 targeted immunotherapies. Therefore, inactivation of MSH6 may confer sensitivity to anti_PD_1 immune checkpoint inhibitors. One or more of the MSH6 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary cancer_predisposing syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in MSH6 are associated with both \"typical\" and \"atypical\" forms of autosomal dominant Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC), which accounts for 1_7% of all colorectal cancers (Silva et al., 2009; 19466295). Approximately 10% of all Lynch syndrome_associated mutations have been attributed to alterations in MSH6 (Peltomaki, 2005; 16083711). Carriers of mutations in MSH6 have a 60_80% risk of colorectal cancer (Kastrinos and Syngal, 2007; 17920897). Lynch syndrome has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Biallelic germline mutation of MSH6 has been shown to account for 20% of cases of the very rare syndrome Constitutional Mismatch Repair Deficiency (CMMRD), which is characterized by a 95% incidence rate of childhood onset lymphoma, leukemia and brain tumors, followed by early_onset colorectal cancer (reviewed in Wimmer et al., 2008; 18709565, Wimmer et al., 2014; 24737826, Scott et al., 2007; 17259933, Ripperger et al., 2010; 20015892, Baris et al., 2016; 26544533). Given the association between MSH6 and these inherited syndromes, in the appropriate clinical context, germline testing of MSH6 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS has been reported in 73_89% of endometrial cancers (Cancer Genome Research Atlas., 2013; 23636398, Black et al., 2006; 16549821, Mackay et al., 2010; 20304627, Kanopiene et al., 2014; 25458958, Hampel et al., 2006; 16885385, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452, Church et al., 2013; 23528559). Data regarding the role of MSI status on prognosis and survival in endometrial cancer are conflicting, with most studies finding no relationship between MSI_H endometrial cancers and survival (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958), and one study predicting improved disease_free and disease_specific survival (Black et al., 2006; 16549821). However, these studies often evaluated endometrial cancers of all FIGO stages together. Studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "POLE", "Include": "true", "Alterations": {"Alteration": {"Name": "V411L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V411L"}}, "Interpretation": "POLE encodes the catalytic subunit A of DNA polymerase epsilon, which plays roles in DNA replication and repair (Popanda and Thielmann., 1992; 1730053). Deleterious mutations in POLE, mainly located within the exonuclease domain (amino acids 268\u2013471) and reported at hotspot residues F104, D275, P286, S297, N363, D368, V411, L424, P436, R446, A456, Y458, S459, and S461, are predicted to disrupt the proofreading function of the enzyme, resulting in a high mutation rate and contributing to the development of \"ultramutated,\" microsatellite_stable cancers (Palles et al., 2013; 23263490, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Valle et al., 2014; 24501277, Church et al., 2013; 23528559, Cancer Genome Atlas Network, 2012; 22810696, Cancer Genome Atlas Research Network, 2013; 23636398, Rayner et al., 2016; 26822575, Spier et al., 2015; 25529843, Shinbrot et al., 2014; 25228659, Bouffet et al., 2016; 27001570, Schlien et al., 2015; 25642631, Rohlin et al., 2014; 24788313, Abdus Sattar et al., 1996; 8987997, Murphy et al., 2006; 16699561). POLE alterations have been reported in 6_15% of endometrial carcinomas (COSMIC, Feb 2021)(Tate et al., 2019; 30371878, Billingsley et al., 2016; 26937754, Church et al., 2013; 23528559, McConechy et al., 2016; 26763250). In the context of endometrial carcinoma, POLE mutations are associated with high tumor grade (Church et al., 2013; 23528559) and correlate with better prognosis, with the most favorable prognosis seen for high_grade tumors (NCCN Uterine Neoplasms Guidelines, v2.2021)(Billingsley et al., 2016; 26937754, Church et al., 2014; 25505230, McConechy et al., 2016; 26763250, Meng et al., 2014; 24844595, Murali et al., 2014; 24872110, Cancer Genome Atlas Research Network et al., 2013; 23636398). There are no targeted therapies that directly address POLE mutations. However, increased mutation load, such as may occur in \"ultramutated\" cancers harboring deleterious mutations in POLE, has been reported to be associated with response to the anti_programmed death 1 (PD_1) immune checkpoint inhibitors pembrolizumab (Mehnert et al., 2016; 27159395, Rizvi et al., 2015; 25765070) and nivolumab (Bouffet et al., 2016; 27001570, Schlien et al., 2015; 25642631). In particular, a patient with non_small cell lung cancer harboring a deleterious POLE mutation achieved durable clinical benefit on pembrolizumab (Rizvi et al., 2015; 25765070); two patients with POLE_mutated endometrial cancer responded to pembrolizumab (Mehnert et al., 2016; 27159395) or nivolumab (Santin et al., 2016; 27486176); two patients with POLE_mutated, TMB_high, MSS colorectal cancer responded to pembrolizumab (Gong et al., 2017; 28188185, Silberman et al., 2019; DOI: 10.1200/PO.18.00214); and two patients with biallelic mismatch repair deficiency (bMMRD)_associated glioblastoma harboring POLE mutations experienced clinically and radiologically significant responses to nivolumab (Bouffet et al., 2016; 27001570). Furthermore, POLE_mutated endometrial cancers have been shown to have higher predicted neoantigen load, increased numbers of tumor_infiltrated lymphocytes (TILs), and higher expression of PD_1 and PD_L1 in the TILs (Howitt et al., 2015; 26181000), which are potential biomarkers of response to anti_PD_1 immunotherapies. Germline mutations in POLE underlie polymerase proofreading_associated polyposis (PPAP), a highly penetrant, autosomal_dominant disorder characterized by the development of adenomatous polyps and an increased risk of intestinal, colorectal, and endometrial cancers (Palles et al., 2013; 23263490, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Valle et al., 2014; 24501277, Church et al., 2014; 24509466, Spier et al., 2015; 25529843). PPAP underlies 0.1% to 0.4% of familial cancers (Mur et al., 2020; 32792570). The lifetime risk of colorectal cancer for a POLE mutation carrier is estimated to be 21% to 28% (Buchanan et al., 2018; 29120461). In the appropriate clinical context, germline testing of POLE is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SETD2", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 5278_1G>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 5278_1G>T"}}, "Interpretation": "SETD2 encodes a histone lysine_36 methyltransferase (Sun et al., 2005; 16118227) that preferentially interacts with the expanded N_terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease (Faber et al., 1998; 9700202). SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non_tumor tissue, suggesting a potential tumor suppressor role (Al Sarakbi et al., 2009; 19698110). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma (Varela et al., 2011; 21248752). SETD2 has been associated with favorable prognosis in gastric cancer (Chen et al., 2018; 29522714). SETD2 has also been associated with poor prognosis in RCC and MDS (Chen et al., 2020; 32202636, Liu et al.,; 2015; 26559293), while data in other tumor types is limited (PubMed, Jun 2021). There are no targeted therapies available to address genomic alterations in SETD2.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SPEN", "Include": "true", "Alterations": {"Alteration": {"Name": "A2727V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "A2727V"}}, "Interpretation": "SPEN (also known as MINT or SHARP) encodes a transcriptional regulator that interacts with HDAC1 and the SMRT/NcoR corepressors (Shi et al., 2001; 11331609, Ariyoshi and Schwabe, 2003; 12897056). SPEN represses the transcriptional activity of the NOTCH signaling pathway (Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742). Activation of NOTCH signaling results in binding of the transcription factor RBPJ to the NOTCH intracellular domain and consequent activation of the NOTCH transcriptional program (Kopan and Ilagan., 2009; 19379690). SPEN binding to RBPJ has been shown to repress NOTCH_mediated transcription (Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742). SPEN alterations that result in loss of the RBPJ_interaction domain (aa 2804_2816)(Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742) or the SPOC domain (aa 3498_3664)(Ariyoshi and Schwabe, 2003; 12897056) are predicted to disrupt binding of SPEN to RBPJ or corepressors and are likely to be inactivating. SPEN truncating mutations have been reported in adenoid cystic carcinoma (ACC) (21%) (Stephens et al., 2013; 23778141) and splenic marginal zone lymphoma (SMZL) (5%) (Rossi et al., 2012; 22891273); NOTCH pathway gene mutations were frequent in both ACC and SMZL and observed in approximately 30% of cases (Stephens et al., 2013; 23778141, Rossi et al., 2012; 22891273). There are no targeted therapies available to address SPEN inactivating mutations. Although gamma_secretase inhibitors are in clinical development to target NOTCH activation, it is not known if these therapies would be beneficial in the context of SPEN mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "STAG2", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 463_1G>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 463_1G>T"}}, "Interpretation": "STAG2 encodes a subunit of the cohesin complex, which maintains sister chromatid cohesion. The cohesin complex includes four subunits: SMC1A, SMC3, RAD21, and either STAG1 or STAG2 (Solomon et al., 2014; 24856830). Cohesin is also involved in transcriptional regulation, DNA replication and DNA repair (Solomon et al., 2014; 24856830). STAG2 mutations, which are mostly truncating, or loss of STAG2 protein expression have been reported in multiple cancer types (Kandoth et al., 2013; 24132290, Solomon et al., 2014; 24856830). STAG2 deletion has been shown to promote tumorigenesis in preclinical studies (Evers et al., 2014; 24484537), and STAG2 inactivation has been proposed to promote tumorigenesis via a mechanism that involves increased aneuploidy (Guo et al., 2013; 24121792, Solomon et al., 2013; 24121789, Solomon et al., 2011; 21852505) or altered transcriptional regulation (Thota et al., 2014; 25006131, Balb\u00e1s_Mart\u00ednez et al., 2013; 24121791, Kon et al., 2013; 23955599, Taylor et al., 2014; 24270882). STAG2 mutations have been observed most frequently in urothelial bladder carcinoma (16_35%) (Solomon et al., 2013; 24121789, Balb\u00e1s_Mart\u00ednez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882, Cancer Genome Atlas Research Network., 2014; 24476821), Ewing sarcoma (13_22%) (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205), upper urinary tract urothelial carcinoma (11%) (Hoang et al., 2013; 23926200), myeloid malignancies (6%) (Thota et al., 2014; 25006131, Kon et al., 2013; 23955599), and glioblastoma (6%) (Solomon et al., 2011; 21852505). STAG2 truncation mutations are associated with loss of protein expression (Solomon et al., 2013; 24121789, Balb\u00e1s_Mart\u00ednez et al., 2013; 24121791, Taylor et al., 2014; 24270882, Brohl et al., 2014; 25010205). In patients with Ewing sarcoma, STAG2 and TP53 mutations often co_occur and are associated with decreased overall survival, although mutation of either STAG2 or TP53 alone was not demonstrated to affect survival (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205). STAG2 mutation in patients with myelodysplastic syndrome is associated with decreased overall survival and has also been associated with increased response to treatment with azacitidine or decitabine in patients with myeloid malignancies (Thota et al., 2014; 25006131). The data on the prognostic significance of STAG2 mutation or loss of STAG2 protein expression in the context of urothelial bladder carcinoma are conflicting (Solomon et al., 2013; 24121789, Balb\u00e1s_Mart\u00ednez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882). In patients with pancreatic ductal adenocarcinoma, loss of STAG2 staining was significantly associated with decreased overall survival, but was also associated with survival benefit from adjuvant chemotherapy (Evers et al., 2014; 24484537). An inactivating STAG2 mutation was identified in a patient with melanoma that acquired resistance to vemurafenib and preclinical evidence suggests that loss of STAG2 expression decreases the sensitivity of BRAF V600E_positive melanoma cells to vemurafenib, dabrafenib, and trametinib (Shen et al., 2016; 27500726). There are no therapies that directly target STAG2. However, in preclinical studies, STAG2 inactivation by mutation or knockdown resulted in increased sensitivity to PARP inhibitors (Bailey et al., 2014; 24356817) or oxaliplatin (Evers et al., 2014; 24484537).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TNFAIP3", "Include": "true", "Alterations": {"Alteration": {"Name": "R87*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R87*"}}, "Interpretation": "TNFAIP3 encodes tumor necrosis factor alpha_induced protein 3, also known as A20, a regulator of NF_kB signaling and apoptosis (Harhaj and Dixit, 2011; 21119682) that has both ubiquitin ligase and deubiquitinase activities (Wertz et al., 2004; 15258597, Wertz et al., 2015; 26649818) and whose loss or inactivation may be tumorigenic (Honma et al., 2009; 19608751). TNFAIP3 is frequently deleted or mutated in lymphoma, where it functions as a tumor suppressor (Honma et al., 2009; 19608751), but its expression and function are context dependent in solid tumors (Wang et al., 2016; 26909601, Couch et al., 2016; 27072986, Wang et al., 2015; 26485275, Harhaj and Dixit, 2011; 21119682, Salim et al., 2013; 23929716), leukemia (Saitoh et al., 2016; 26437781, Johansson et al., 2016; 26199174, Chen et al., 2015; 26159495), and multiple myeloma (Broyl et al., 2010; 20574050, Troppan et al., 2015; 25856582). TNFAIP3 mutations that disrupt the A20p37 chain (amino acids 371\u2013790), which mediates ubiquitin ligase activity and interaction with the cIAP1/TRAF2 complex (Wertz et al., 2004; 15258597, Yamaguchi et al., 2013; 24008839), are predicted to be inactivating. In T_cells, cleavage of A20 codon R439 by MALT1 has been shown to upregulate NFkB signaling; R439A has been shown to block MALT1_mediated NF_kB activation (Coornaert et al., 2008; 18223652); however, the function of R439 mutations outside of the context of T_cell lymphoma has not been reported. In the COSMIC dataset, TNFAIP3 mutations have been reported in 3.5% of prostate, 3.1% of endometrial, 2.8% of skin, 2.7% of gastric, and 2.4% of large intestine cancers (Jan 2021)(Tate et al., 2019; 30371878). Overexpression of TNFAIP3 has been associated with aggressive high_grade ER_/PR_negative breast tumors (Vendrell et al., 2007; 17297453), resistance to TNF_alpha and TRAIL_induced apoptosis in glioblastoma (Hjelmeland et al., 2010; 20186265, Bellail et al., 2012; 22585859) and to chemotherapy in acute lymphoblastic leukemia (Chen et al., 2015; 26159495), and poor prognosis in adrenocortical carcinoma (Hantel et al., 2016; 26768118). Loss of heterozygosity in the genomic region including TNFAIP3 has been found in 16.8% (25/149) of colorectal adenocarcinomas, and significantly decreased TNFAIP3 mRNA expression has been observed in colorectal cancer (CRC) tumors compared with adjacent non_neoplastic mucosa (Ungerb\u00e4ck et al., 2012; 22843550). Reduced A20 expression has been suggested as a marker of poor prognosis in CRC (Bavi et al., 2011; 22704353). There are no therapies that address the loss of TNFAIP3. A20 has multiple functions and is subject to a wide range of genomic lesions, thereby making it challenging to develop a unified therapeutic approach. Potential avenues targeting dysregulation of ubiquitination pathways include anti_CD20 therapies, such as rituximab, and proteasome inhibitors, such as bortezomib (Hymowitz and Wertz, 2010; 20383180). RNAi_mediated downregulation of TNFAIP3 has been reported to sensitize multiple myeloma cells to bortezomib (Zhu et al., 2011; 21289309).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "F113V, T211A", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "F113V"}, {"isEquivocal": "false", "name": "T211A"}]}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 29% of endometrial carcinomas analyzed in COSMIC, including 60% of serous carcinomas, 36% of clear cell carcinomas, and 23% of endometrioid carcinomas (Feb 2021)(Tate et al., 2019; 30371878). In one large study, high (pathologic) expression of p53 was found in 24% of endometrial carcinoma samples and was associated with non_endometrioid histology, high grade (Grade 3 vs. Grade 1_2), and advanced FIGO stage, as well as with lymph node metastasis and poor disease_specific survival, but was not an independent factor for poor prognosis in multivariate analysis (Trovik et al., 2013; 23932335). In other studies, p53 alterations (defined as TP53 mutation or p53 nuclear expression) have been found to be associated with poor prognosis in patients with endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "XPO1", "Include": "true", "Alterations": {"Alteration": {"Name": "R749Q", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R749Q"}}, "Interpretation": "XPO1 encodes exportin_1, also known as CRM1, a nuclear pore protein that controls nuclear export and localization of multiple cell cycle_ and proliferation_associated proteins (K\u0131rl\u0131 et al., 2015; 26673895). Exportin_1 may also be required for efficient centrosome maintenance by BRCA1 (Brodie and Henderson, 2012; 22262852). XPO1 residue E571 is a mutational hotspot in chronic lymphocytic leukemia (CLL) and other tumor types (Puente et al., 2011; 21642962, Luthra et al., 2014; 24142997, Jeromin et al., 2014; 24113472, Vollbrecht et al., 2015; 26053404, Herling et al., 2016; 27226433, Jardin et al., 2016; 27312795), although mutations at this site have not been functionally characterized. XPO1 D624G has been reported in the context of esophageal squamous cell carcinoma (ESCC) and has been suggested to lead to gain of function (Lin et al., 2014; 24686850). XPO1 mutations have been reported at highest frequency in chronic lymphocytic leukemia (2_15%) and endometrial tumors (3_5%) and at lower incidences in other tumor types (COSMIC, 2021) (Puente et al., 2011; 21642962, Cancer Genome Atlas Research Network., 2013; 23636398, Vollbrecht et al., 2015; 26053404, Gui\u00e8ze et al., 2015; 26316624, Herling et al., 2016; 27226433, Tate et al., 2019; 30371878). One study reported XPO1 mutation at high frequency in cases of Hodgkin lymphoma (26%, 5/19) and primary mediastinal B_cell lymphoma (24%, 28/117) (Jardin et al., 2016; 27312795). In CLL, XPO1 correlates with unmutated IGHV status, presence of NOTCH1 mutations, increased white blood cell count, and decreased progression_free survival after certain chemoimmunotherapy regimens (Puente et al., 2011; 21642962, Jeromin et al., 2014; 24113472, Vollbrecht et al., 2015; 26053404, Herling et al., 2016; 27226433). Increased levels of nuclear exportin_1 have been reported to correlate with clinical stage in human cholangiocarcinoma samples, and reduced exportin_1 expression suppressed tumor growth in a xenograft model of the disease (Luo et al., 2016; 27279267). XPO1 activation may predict sensitivity to XPO1 inhibitors (Neggers et al., 2015; 25579209), such as the selective inhibitors of nuclear export (SINEs) (Ranganathan et al., 2012; 22677130) KPT_330 (Etchin et al., 2013; 23373539) and KPT_8602 (Hing et al., 2016; 27323910, Etchin et al., 2016; 27211268), which are in clinical trials in solid tumors and hematological cancers. In a Phase 1 trial of KPT_330 for unselected advanced solid tumors, one of 157 evaluable patients achieved a complete response, six achieved partial responses (4%), and 67 (43%) achieved stable disease (SD), which was durable for \u22654 months for 27 patients (17%) (Abdul Razak et al., 2016; 26926685). A patient with accelerated_phase chronic myelogenous leukemia (CML) refractory to available tyrosine kinase inhibitors demonstrated short_term anti_leukemic activity from KPT_330 (Walker et al., 2013; 23970380). Inhibitors of XPO1 have shown efficacy in mouse models and cultured cells of CML, T_cell acute lymphoblastic leukemia, acute myeloid leukemia, mantle cell lymphoma, multiple myeloma, and CLL (Etchin et al., 2016; 27211268, Etchin et al., 2016; 26202935, Ranganathan et al., 2016; 27358488, Walker et al., 2013; 23970380, Etchin et al., 2013; 23373539, Zhang et al., 2013; 22986101, Schmidt et al., 2013; 23752175, Lapalombella et al., 2012; 23034282), as well as in GIST, a subset of sarcomas (Nakayama et al., 2016; 26918731), and ESCCs (Lin et al., 2014; 24686850).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ZNF217", "Include": "true", "Alterations": {"Alteration": {"Name": "D326N", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "D326N"}}, "Interpretation": "ZNF217 encodes a candidate oncogene that has likely roles in histone modification and transcriptional repression (Huang et al., 2005; 16203743, Banck et al., 2009; 19242095). ZNF217 amplification has been correlated with protein overexpression in breast carcinoma tumors and cell lines (Collins et al., 1998; 9671742). The role of ZNF217 in promoting tumorigenesis was established in preclinical studies demonstrating that expression of ZNF217 results in the immortalization of both human mammary epithelial cells and ovarian surface epithelial cells in culture (Nonet et al., 2001; 11245413, Li et al., 2007; 17266044). Amplification and/or overexpression of ZNF217 has been reported in breast (Vendrell et al., 2012; 22593193), ovarian (Li et al., 2014; 25031722, Rahman et al., 2012; 22843878), gastric (Yang et al., 2005; 15701848, Shida et al., 2014; 25202062), colon (Rooney et al., 2004; 15476264), prostate (Szczyrba et al., 2012; 22815235), esophageal (Geppert et al., 2014; 24853183), and urothelial carcinomas (Toncheva et al., 2005; 15897688), glioblastoma (Mao et al., 2011; 21483406), and ovarian carcinosarcomas (Schipf et al., 2008; 18193277). Overexpression in these tumors has generally been linked with aggressive tumor behavior and poor clinical prognosis. High levels of ZNF217 expression result in dysregulation of a broad range of genes that may contribute to tumorigenesis (Quinlan et al., 2007; 17572303, Krig et al., 2007; 17259635, Cowger et al., 2007; 17130829), and increased expression or activation of ERBB3 (Krig et al., 2010; 20661224, Vendrell et al., 2012; 22593193), FAK (Vendrell et al., 2012; 22593193), Aurora kinase A (Thollet et al., 2010; 21059223), AKT (Huang et al., 2005; 16203743), and TGF_beta/SMAD signaling (Vendrell et al., 2012; 22593193) has been demonstrated in ZNF217_expressing tumors or cells. There are no available targeted therapies to address genomic alterations in ZNF217. Expression of ZNF217 may predict relapse of estrogen receptor (ER)_positive breast cancer under hormone therapy through its direct interaction with ER_alpha (Nguyen et al., 2014; 24973012, Frietze et al., 2014; 24962896). ZNF217 overexpression has also been associated with resistance to paclitaxel (Thollet et al., 2010; 21059223) and doxorubicin (Huang et al., 2005; 16203743) in breast cancer cell lines. ZNF217 has been suggested as a potential biomarker for treatment with the DNA synthesis inhibitor and AKT inhibitor triciribine in breast cancer based on preclinical findings in cultured cells and xenografts expressing high levels of ZNF217; triciribine treatment also restored sensitivity to doxorubicin in these cells (Littlepage et al., 2012; 22728437).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ATM", "Alteration": "R250*", "Title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP", "Locations": "Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)", "NCTID": "NCT04269200", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Jinan (China)", "NCTID": "NCT04716686", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02630199", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "First_in_human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Sunto (Japan), Chuo_ku (Japan), Kashiwa (Japan), Singapore (Singapore), St. Gallen (Switzerland), Bellinzona (Switzerland), Newcastle Upon Tyne (United Kingdom), Gen\u00e8ve (Switzerland), Sutton (United Kingdom), Edmonton (Canada)", "NCTID": "NCT03188965", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "R250*", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP", "Locations": "Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)", "NCTID": "NCT04269200", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Jinan (China)", "NCTID": "NCT04716686", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02630199", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "First_in_human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Sunto (Japan), Chuo_ku (Japan), Kashiwa (Japan), Singapore (Singapore), St. Gallen (Switzerland), Bellinzona (Switzerland), Newcastle Upon Tyne (United Kingdom), Gen\u00e8ve (Switzerland), Sutton (United Kingdom), Edmonton (Canada)", "NCTID": "NCT03188965", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "BRCA2", "Alteration": "E1879D", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "Aromatase, mTOR, CDK4, CDK6", "Locations": "Texas", "NCTID": "NCT03008408", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, RET, SRC, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Sapanisertib and Ziv_Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "PIGF, VEGFA, VEGFB, mTORC1, mTORC2", "Locations": "Texas", "NCTID": "NCT02159989", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non_Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression", "StudyPhase": "PHASE 1", "Target": "ROS1, ALK, mTOR", "Locations": "Texas", "NCTID": "NCT02321501", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers", "StudyPhase": "PHASE 1", "Target": "mTORC1, mTORC2", "Locations": "Texas", "NCTID": "NCT03017833", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "K335T", "Title": "Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTORC1, mTORC2", "Locations": "Texas", "NCTID": "NCT03430882", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP", "Locations": "Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)", "NCTID": "NCT04269200", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Jinan (China)", "NCTID": "NCT04716686", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FANCL", "Alteration": "splice site 904_2A>C", "Title": "A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer", "StudyPhase": "PHASE 2/3", "Target": "PARP", "Locations": "Toronto (Canada)", "NCTID": "NCT04159155", "Note": "On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "mTOR", "Locations": "Colorado, Michigan, Virginia, Texas", "NCTID": "NCT02397083", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "Aromatase, mTOR, CDK4, CDK6", "Locations": "Texas", "NCTID": "NCT03008408", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy", "StudyPhase": "PHASE 1", "Target": "IDO1, mTOR", "Locations": "Kansas", "NCTID": "NCT03217669", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, RET, SRC, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "R441W", "Title": "Sapanisertib and Ziv_Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "PIGF, VEGFA, VEGFB, mTORC1, mTORC2", "Locations": "Texas", "NCTID": "NCT02159989", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Pembrolizumab (MK_3475) Plus Lenvatinib (E7080/MK_7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT_en9 / MK_7902_001) _China Extension Study", "StudyPhase": "PHASE 3", "Target": "FGFRs, KIT, PD_1, PDGFRA, RET, VEGFRs", "Locations": "Hangzhou (China), Shanghai (China), Nanchang (China), Nanjing (China), Hefei (China), Guangzhou (China), Changsha (China), Wuhan (China), Nanning (China), Chongqing (China)", "NCTID": "NCT04865289", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Single_arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors", "StudyPhase": "PHASE null", "Target": "FGFR1, FGFR2, FGFR3, KIT, VEGFRs", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02450136", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, KIT, PDGFRA, RET, VEGFRs, PD_1", "Locations": "Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington", "NCTID": "NCT03564691", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, VEGFRs, PD_1", "Locations": "Innsbruck (Austria), Essen (Germany), Bologna (Italy), Naples (Italy), Leuven (Belgium), Brussels (Belgium), Ghent (Belgium), Washington, Barcelona (Spain), Madrid (Spain)", "NCTID": "NCT04042116", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "A Study of ICP_192 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFR1, FGFR2, FGFR3, FGFR4", "Locations": "Colorado, Minnesota, Arizona, Florida", "NCTID": "NCT04565275", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.", "StudyPhase": "PHASE 2", "Target": "ABL, FGFRs, FLT3, KIT, RET, VEGFRs", "Locations": "Ohio", "NCTID": "NCT02272998", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Trial Of Pembrolizumab And Nintedanib", "StudyPhase": "PHASE 1", "Target": "FGFR1, FGFR2, FGFR3, FLT3, LCK, LYN, SRC, VEGFRs, PD_1", "Locations": "Villejuif (France)", "NCTID": "NCT02856425", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "N549D", "Title": "Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI_24781 in Patients With Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "HDAC, FGFR1, FGFR2, FGFR3, KIT, VEGFRs", "Locations": "California", "NCTID": "NCT01543763", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "SHP2, MEK", "Locations": "Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois", "NCTID": "NCT03989115", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas", "NCTID": "NCT03905148", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "PF_07284892 in Participants With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, ROS1, ALK, BRAF, EGFR, MEK", "Locations": "California, Michigan, New York, Tennessee, Texas", "NCTID": "NCT04800822", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "mTOR", "Locations": "Colorado, Michigan, Virginia, Texas", "NCTID": "NCT02397083", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NF1", "Alteration": "R1362*, R2450*", "Title": "Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Toronto (Canada)", "NCTID": "NCT02070549", "Note": "On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors", "StudyPhase": "PHASE 4", "Target": "mTOR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02688881", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, PD_L1, ERBB2, ERBB3, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Montana", "NCTID": "NCT04632992", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR", "Locations": "Alaska, Washington", "NCTID": "NCT03994796", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "R88QT1025A", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR", "Locations": "Alaska, Washington", "NCTID": "NCT03994796", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "A Trial of Ipatasertib in Combination With Atezolizumab", "StudyPhase": "PHASE 1/2", "Target": "AKTs, PD_L1", "Locations": "Sutton (United Kingdom)", "NCTID": "NCT03673787", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "mTOR", "Locations": "Colorado, Michigan, Virginia, Texas", "NCTID": "NCT02397083", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3CB", "Alteration": "R321Q", "Title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer", "StudyPhase": "PHASE 1/2", "Target": "PD_1, PI3K", "Locations": "Maryland", "NCTID": "NCT03711058", "Note": "Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PIK3R1", "Alteration": "E476*", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.", "Include": "true"}, {"Gene": "PIK3R1", "Alteration": "E476*", "Title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer", "StudyPhase": "PHASE 1/2", "Target": "PD_1, PI3K", "Locations": "Maryland", "NCTID": "NCT03711058", "Note": "On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.", "Include": "true"}, {"Gene": "PIK3R1", "Alteration": "E476*", "Title": "Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma", "StudyPhase": "PHASE 1", "Target": "PI3K, PD_1", "Locations": "Maryland, Texas", "NCTID": "NCT03502733", "Note": "On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.", "Include": "true"}, {"Gene": "PIK3R1", "Alteration": "E476*", "Title": "Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "StudyPhase": "PHASE 1", "Target": "PI3K, PARP", "Locations": "Texas", "NCTID": "NCT03586661", "Note": "On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP", "Locations": "Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)", "NCTID": "NCT04269200", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Jinan (China)", "NCTID": "NCT04716686", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, PD_L1, ERBB2, ERBB3, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Montana", "NCTID": "NCT04632992", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "R130Q, R173H", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP", "Locations": "Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)", "NCTID": "NCT04269200", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Jinan (China)", "NCTID": "NCT04716686", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "RAD51D", "Alteration": "R253Q", "Title": "A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer", "StudyPhase": "PHASE 2/3", "Target": "PARP", "Locations": "Toronto (Canada)", "NCTID": "NCT04159155", "Note": "Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, RET, mTOR, EGFR, ERBB2, ERBB3, MEK, BRAF, SMO, DDR2, PARP, PD_1, CTLA_4, ERBB4", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "mTOR", "Locations": "Colorado, Michigan, Virginia, Texas", "NCTID": "NCT02397083", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer", "StudyPhase": "PHASE 2", "Target": "Aromatase, mTOR, CDK4, CDK6", "Locations": "Texas", "NCTID": "NCT03008408", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy", "StudyPhase": "PHASE 1", "Target": "IDO1, mTOR", "Locations": "Kansas", "NCTID": "NCT03217669", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TSC1", "Alteration": "Q739*", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, RET, SRC, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "ADORA2A, CD73, PD_1", "Locations": "Taipei (Taiwan), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Missouri, Connecticut, Texas", "NCTID": "NCT04237649", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "ALK, ROS1, TRKA, TRKB, TRKC, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)", "NCTID": "NCT04589845", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "Sasanlimab (PF_06801591, PD_1 Inhibitor) in Participants With Advanced Malignancies", "StudyPhase": "PHASE 1/2", "Target": "PD_1", "Locations": "Taipei (Taiwan), Kaohsiung (Taiwan), Shanghai (China), Nanjing (China), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Chongqing (China), Beijing (China), Chuo_ku (Japan), Kopeysk (Russian Federation)", "NCTID": "NCT04181788", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, CSF1R", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Nagoya (Japan), Koto ku (Japan), Singapore (Singapore), Tel Aviv (Israel), Zurich (Switzerland), Rozzano (Italy), Barcelona (Spain), Hospitalet de LLobregat (Spain)", "NCTID": "NCT02829723", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_L1, PD_1, CTLA_4", "Locations": "Taipei (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Amsterdam (Netherlands), Napoli (Italy), Roma (Italy), Villejuif Cedex (France), Barcelona (Spain)", "NCTID": "NCT03530397", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "Study of Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_3475_158/KEYNOTE_158)", "StudyPhase": "PHASE 2", "Target": "PD_1", "Locations": "Taipei (Taiwan), Makati (Philippines), Seoul (Korea, Republic of), Beijing (China), Chiyoda_Ku, Tokyo (Japan), North Ryde (Australia), Moscow (Russian Federation), Hod Hasharon (Israel), Drammen (Norway), Glostrup (Denmark)", "NCTID": "NCT02628067", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "A First_in_human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti_tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TGF_beta", "Locations": "Taipei 100 (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Seoul (Korea, Republic of), Heidelberg West (Australia), Melbourne (Australia), Tallinn (Estonia), Hannover (Germany), Essen (Germany), Utrecht (Netherlands)", "NCTID": "NCT03192345", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas", "NCTID": "NCT04261439", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, NRP1", "Locations": "Taipei (Taiwan), Seoul (Korea, Republic of), Tokyo (Japan), Chiba (Japan), Meldola (Italy), Modena (Italy), Newcastle upon Tyne (United Kingdom), Monza (Italy), Milano (Italy), Glasgow (United Kingdom)", "NCTID": "NCT03565445", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "372", "Title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TNFRSF18", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Daegu (Korea, Republic of), Chungcheongbukdo (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Washington, California, Nevada", "NCTID": "NCT03799003", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "1730053", "FullCitation": "Popanda O, et al. Biochim. Biophys. Acta (1992) pmid: 1730053", "Include": "true"}, {"number": "1", "ReferenceId": "23263490", "FullCitation": "Palles C, et al. Nat. Genet. (2013) pmid: 23263490", "Include": "true"}, {"number": "2", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "3", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "4", "ReferenceId": "24501277", "FullCitation": "Valle L, et al. Hum. Mol. Genet. (2014) pmid: 24501277", "Include": "true"}, {"number": "5", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "6", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "7", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "8", "ReferenceId": "26822575", "FullCitation": "Rayner E, et al. Nat. Rev. Cancer (2016) pmid: 26822575", "Include": "true"}, {"number": "9", "ReferenceId": "25529843", "FullCitation": "Spier I, et al. Int. J. Cancer (2015) pmid: 25529843", "Include": "true"}, {"number": "10", "ReferenceId": "25228659", "FullCitation": "Shinbrot E, et al. Genome Res. (2014) pmid: 25228659", "Include": "true"}, {"number": "11", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "12", "ReferenceId": "25642631", "FullCitation": "Shlien A, et al. Nat. Genet. (2015) pmid: 25642631", "Include": "true"}, {"number": "13", "ReferenceId": "24788313", "FullCitation": "Rohlin A, et al. Int. J. Oncol. (2014) pmid: 24788313", "Include": "true"}, {"number": "14", "ReferenceId": "8987997", "FullCitation": "Abdus Sattar AK, et al. Biochemistry (1996) pmid: 8987997", "Include": "true"}, {"number": "15", "ReferenceId": "16699561", "FullCitation": "Murphy K, et al. Genome (2006) pmid: 16699561", "Include": "true"}, {"number": "16", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "17", "ReferenceId": "26937754", "FullCitation": "Billingsley CC, et al. Int. J. Gynecol. Cancer (2016) pmid: 26937754", "Include": "true"}, {"number": "18", "ReferenceId": "26763250", "FullCitation": "McConechy MK, et al. Clin. Cancer Res. (2016) pmid: 26763250", "Include": "true"}, {"number": "19", "ReferenceId": "25505230", "FullCitation": "Church DN, et al. J. Natl. Cancer Inst. (2015) pmid: 25505230", "Include": "true"}, {"number": "20", "ReferenceId": "24844595", "FullCitation": "Meng B, et al. Gynecol. Oncol. (2014) pmid: 24844595", "Include": "true"}, {"number": "21", "ReferenceId": "24872110", "FullCitation": "Murali R, et al. Lancet Oncol. (2014) pmid: 24872110", "Include": "true"}, {"number": "22", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "23", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "24", "ReferenceId": "27486176", "FullCitation": "Santin AD, et al. Clin. Cancer Res. (2016) pmid: 27486176", "Include": "true"}, {"number": "25", "ReferenceId": "28188185", "FullCitation": "Gong J, et al. J Natl Compr Canc Netw (2017) pmid: 28188185", "Include": "true"}, {"number": "26", "ReferenceId": "26181000", "FullCitation": "Howitt BE, et al. JAMA Oncol (2015) pmid: 26181000", "Include": "true"}, {"number": "27", "ReferenceId": "24509466", "FullCitation": "Dis. Colon Rectum (2014) pmid: 24509466", "Include": "true"}, {"number": "28", "ReferenceId": "32792570", "FullCitation": "Mur P, et al. Genet Med (2020) pmid: 32792570", "Include": "true"}, {"number": "29", "ReferenceId": "29120461", "FullCitation": "Buchanan DD, et al. Genet Med (2018) pmid: 29120461", "Include": "true"}, {"number": "30", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "31", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "32", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "33", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "34", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "35", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "36", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "37", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "38", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "39", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "40", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "41", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "42", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "43", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "44", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "45", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "46", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "47", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "48", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "49", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "50", "ReferenceId": "26673895", "FullCitation": "K\u0131rl\u0131 K, et al. Elife (2015) pmid: 26673895", "Include": "true"}, {"number": "51", "ReferenceId": "22262852", "FullCitation": "Brodie KM, et al. J. Biol. Chem. (2012) pmid: 22262852", "Include": "true"}, {"number": "52", "ReferenceId": "21642962", "FullCitation": "Puente XS, et al. Nature (2011) pmid: 21642962", "Include": "true"}, {"number": "53", "ReferenceId": "24142997", "FullCitation": "Luthra R, et al. Haematologica (2014) pmid: 24142997", "Include": "true"}, {"number": "54", "ReferenceId": "24113472", "FullCitation": "Jeromin S, et al. Leukemia (2014) pmid: 24113472", "Include": "true"}, {"number": "55", "ReferenceId": "26053404", "FullCitation": "Vollbrecht C, et al. PLoS ONE (2015) pmid: 26053404", "Include": "true"}, {"number": "56", "ReferenceId": "27226433", "FullCitation": "Herling CD, et al. Blood (2016) pmid: 27226433", "Include": "true"}, {"number": "57", "ReferenceId": "27312795", "FullCitation": "Jardin F, et al. Am. J. Hematol. (2016) pmid: 27312795", "Include": "true"}, {"number": "58", "ReferenceId": "24686850", "FullCitation": "Lin DC, et al. Nat. Genet. (2014) pmid: 24686850", "Include": "true"}, {"number": "59", "ReferenceId": "26316624", "FullCitation": "Gui\u00e8ze R, et al. Blood (2015) pmid: 26316624", "Include": "true"}, {"number": "60", "ReferenceId": "27279267", "FullCitation": "Luo J, et al. Int. J. Mol. Med. (2016) pmid: 27279267", "Include": "true"}, {"number": "61", "ReferenceId": "25579209", "FullCitation": "Neggers JE, et al. Chem. Biol. (2015) pmid: 25579209", "Include": "true"}, {"number": "62", "ReferenceId": "22677130", "FullCitation": "Ranganathan P, et al. Blood (2012) pmid: 22677130", "Include": "true"}, {"number": "63", "ReferenceId": "23373539", "FullCitation": "Etchin J, et al. Br. J. Haematol. (2013) pmid: 23373539", "Include": "true"}, {"number": "64", "ReferenceId": "27323910", "FullCitation": "Hing ZA, et al. Leukemia (2016) pmid: 27323910", "Include": "true"}, {"number": "65", "ReferenceId": "27211268", "FullCitation": "Etchin J, et al. Leukemia (2017) pmid: 27211268", "Include": "true"}, {"number": "66", "ReferenceId": "26926685", "FullCitation": "Abdul Razak AR, et al. J. Clin. Oncol. (2016) pmid: 26926685", "Include": "true"}, {"number": "67", "ReferenceId": "23970380", "FullCitation": "Walker CJ, et al. Blood (2013) pmid: 23970380", "Include": "true"}, {"number": "68", "ReferenceId": "26202935", "FullCitation": "Etchin J, et al. Leukemia (2016) pmid: 26202935", "Include": "true"}, {"number": "69", "ReferenceId": "27358488", "FullCitation": "Ranganathan P, et al. Clin. Cancer Res. (2016) pmid: 27358488", "Include": "true"}, {"number": "70", "ReferenceId": "22986101", "FullCitation": "Zhang K, et al. Exp. Hematol. (2013) pmid: 22986101", "Include": "true"}, {"number": "71", "ReferenceId": "23752175", "FullCitation": "Schmidt J, et al. Leukemia (2013) pmid: 23752175", "Include": "true"}, {"number": "72", "ReferenceId": "23034282", "FullCitation": "Lapalombella R, et al. Blood (2012) pmid: 23034282", "Include": "true"}, {"number": "73", "ReferenceId": "26918731", "FullCitation": "Nakayama R, et al. Oncotarget (2016) pmid: 26918731", "Include": "true"}, {"number": "74", "ReferenceId": "23847781", "FullCitation": "Shiloh Y, et al. Nat. Rev. Mol. Cell Biol. (2013) pmid: 23847781", "Include": "true"}, {"number": "75", "ReferenceId": "23851492", "FullCitation": "Cremona CA, et al. Oncogene (2014) pmid: 23851492", "Include": "true"}, {"number": "76", "ReferenceId": "16603769", "FullCitation": "Jiang X, et al. J. Biol. Chem. (2006) pmid: 16603769", "Include": "true"}, {"number": "77", "ReferenceId": "15713674", "FullCitation": "Fernandes N, et al. J. Biol. Chem. (2005) pmid: 15713674", "Include": "true"}, {"number": "78", "ReferenceId": "11805335", "FullCitation": "Scott SP, et al. Proc. Natl. Acad. Sci. U.S.A. (2002) pmid: 11805335", "Include": "true"}, {"number": "79", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "80", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "81", "ReferenceId": "12931023", "FullCitation": "Tsuda H, et al. Oncology (2003) pmid: 12931023", "Include": "true"}, {"number": "82", "ReferenceId": "18519763", "FullCitation": "Suehiro Y, et al. Clin. Cancer Res. (2008) pmid: 18519763", "Include": "true"}, {"number": "83", "ReferenceId": "25608836", "FullCitation": "Shan W, et al. Tumour Biol. (2015) pmid: 25608836", "Include": "true"}, {"number": "84", "ReferenceId": "24508840", "FullCitation": "Mhawech_Fauceglia P, et al. Gynecol. Oncol. (2014) pmid: 24508840", "Include": "true"}, {"number": "85", "ReferenceId": "24037533", "FullCitation": "Michels J, et al. Oncogene (2014) pmid: 24037533", "Include": "true"}, {"number": "86", "ReferenceId": "26510020", "FullCitation": "Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020", "Include": "true"}, {"number": "87", "ReferenceId": "31806540", "FullCitation": "Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540", "Include": "true"}, {"number": "88", "ReferenceId": "32086346", "FullCitation": "Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346", "Include": "true"}, {"number": "89", "ReferenceId": "26282658", "FullCitation": "Bang YJ, et al. J. Clin. Oncol. (2015) pmid: 26282658", "Include": "true"}, {"number": "90", "ReferenceId": "27079472", "FullCitation": "Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472", "Include": "true"}, {"number": "91", "ReferenceId": "20739657", "FullCitation": "Weston VJ, et al. Blood (2010) pmid: 20739657", "Include": "true"}, {"number": "92", "ReferenceId": "20124459", "FullCitation": "Williamson CT, et al. Mol. Cancer Ther. (2010) pmid: 20124459", "Include": "true"}, {"number": "93", "ReferenceId": "24252502", "FullCitation": "Gilardini Montani MS, et al. J. Exp. Clin. Cancer Res. (2013) pmid: 24252502", "Include": "true"}, {"number": "94", "ReferenceId": "16556909", "FullCitation": "Bryant HE, et al. Nucleic Acids Res. (2006) pmid: 16556909", "Include": "true"}, {"number": "95", "ReferenceId": "23729402", "FullCitation": "Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402", "Include": "true"}, {"number": "96", "ReferenceId": "22416035", "FullCitation": "Williamson CT, et al. EMBO Mol Med (2012) pmid: 22416035", "Include": "true"}, {"number": "97", "ReferenceId": "24841718", "FullCitation": "Kubota E, et al. Cell Cycle (2014) pmid: 24841718", "Include": "true"}, {"number": "98", "ReferenceId": "22833573", "FullCitation": "Huehls AM, et al. Mol. Pharmacol. (2012) pmid: 22833573", "Include": "true"}, {"number": "99", "ReferenceId": "32988960", "FullCitation": "Yap TA, et al. Cancer Discov (2021) pmid: 32988960", "Include": "true"}, {"number": "100", "ReferenceId": "25232030", "FullCitation": "Menezes DL, et al. Mol. Cancer Res. (2015) pmid: 25232030", "Include": "true"}, {"number": "101", "ReferenceId": "26517239", "FullCitation": "Vendetti FP, et al. Oncotarget (2015) pmid: 26517239", "Include": "true"}, {"number": "102", "ReferenceId": "28138034", "FullCitation": "Min A, et al. Mol. Cancer Ther. (2017) pmid: 28138034", "Include": "true"}, {"number": "103", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "104", "ReferenceId": "23761041", "FullCitation": "Riabinska A, et al. Sci Transl Med (2013) pmid: 23761041", "Include": "true"}, {"number": "105", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "106", "ReferenceId": "26662178", "FullCitation": "van Os NJ, et al. Clin Genet (2016) pmid: 26662178", "Include": "true"}, {"number": "107", "ReferenceId": "27884168", "FullCitation": "Rothblum_Oviatt C, et al. Orphanet J Rare Dis (2016) pmid: 27884168", "Include": "true"}, {"number": "108", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "109", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "110", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "111", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "112", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "113", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "114", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "115", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "116", "ReferenceId": "9808624", "FullCitation": "Xia Y, et al. Genes Dev. (1998) pmid: 9808624", "Include": "true"}, {"number": "117", "ReferenceId": "12049732", "FullCitation": "Lu Z, et al. Mol. Cell (2002) pmid: 12049732", "Include": "true"}, {"number": "118", "ReferenceId": "11782455", "FullCitation": "Schlesinger TK, et al. J. Biol. Chem. (2002) pmid: 11782455", "Include": "true"}, {"number": "119", "ReferenceId": "18437204", "FullCitation": "Garcia_Closas M, et al. PLoS Genet. (2008) pmid: 18437204", "Include": "true"}, {"number": "120", "ReferenceId": "21475998", "FullCitation": "Slattery ML, et al. Breast Cancer Res. Treat. (2011) pmid: 21475998", "Include": "true"}, {"number": "121", "ReferenceId": "12228710", "FullCitation": "Yang H, et al. Science (2002) pmid: 12228710", "Include": "true"}, {"number": "122", "ReferenceId": "21731065", "FullCitation": "Nat. Struct. Mol. Biol. (2011) pmid: 21731065", "Include": "true"}, {"number": "123", "ReferenceId": "31492746", "FullCitation": "de Jonge MM, et al. Clin. Cancer Res. (2019) pmid: 31492746", "Include": "true"}, {"number": "124", "ReferenceId": "11263938", "FullCitation": "Levine DA, et al. Gynecol. Oncol. (2001) pmid: 11263938", "Include": "true"}, {"number": "125", "ReferenceId": "23562522", "FullCitation": "Segev Y, et al. Gynecol. Oncol. (2013) pmid: 23562522", "Include": "true"}, {"number": "126", "ReferenceId": "25366685", "FullCitation": "Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685", "Include": "true"}, {"number": "127", "ReferenceId": "20609467", "FullCitation": "Tutt A, et al. Lancet (2010) pmid: 20609467", "Include": "true"}, {"number": "128", "ReferenceId": "28578601", "FullCitation": "Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601", "Include": "true"}, {"number": "129", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "130", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "131", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "132", "ReferenceId": "27002934", "FullCitation": "Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934", "Include": "true"}, {"number": "133", "ReferenceId": "28754483", "FullCitation": "Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483", "Include": "true"}, {"number": "134", "ReferenceId": "27617661", "FullCitation": "Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661", "Include": "true"}, {"number": "135", "ReferenceId": "19553641", "FullCitation": "Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641", "Include": "true"}, {"number": "136", "ReferenceId": "20609468", "FullCitation": "Audeh MW, et al. Lancet (2010) pmid: 20609468", "Include": "true"}, {"number": "137", "ReferenceId": "20406929", "FullCitation": "Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929", "Include": "true"}, {"number": "138", "ReferenceId": "21862407", "FullCitation": "Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407", "Include": "true"}, {"number": "139", "ReferenceId": "22203755", "FullCitation": "Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755", "Include": "true"}, {"number": "140", "ReferenceId": "26723501", "FullCitation": "Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501", "Include": "true"}, {"number": "141", "ReferenceId": "30345884", "FullCitation": "Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884", "Include": "true"}, {"number": "142", "ReferenceId": "31157963", "FullCitation": "Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963", "Include": "true"}, {"number": "143", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "144", "ReferenceId": "31299005", "FullCitation": "Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005", "Include": "true"}, {"number": "145", "ReferenceId": "31721781", "FullCitation": "Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781", "Include": "true"}, {"number": "146", "ReferenceId": "27993965", "FullCitation": "Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965", "Include": "true"}, {"number": "147", "ReferenceId": "29605721", "FullCitation": "Jin J, et al. Neoplasia (2018) pmid: 29605721", "Include": "true"}, {"number": "148", "ReferenceId": "25964244", "FullCitation": "Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244", "Include": "true"}, {"number": "149", "ReferenceId": "25847936", "FullCitation": "Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936", "Include": "true"}, {"number": "150", "ReferenceId": "22406760", "FullCitation": "Dann RB, et al. Gynecol. Oncol. (2012) pmid: 22406760", "Include": "true"}, {"number": "151", "ReferenceId": "18559613", "FullCitation": "Evers B, et al. Clin. Cancer Res. (2008) pmid: 18559613", "Include": "true"}, {"number": "152", "ReferenceId": "17656556", "FullCitation": "Soares DG, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17656556", "Include": "true"}, {"number": "153", "ReferenceId": "27561088", "FullCitation": "Miolo G, et al. Cancer Biol. Ther. (2016) pmid: 27561088", "Include": "true"}, {"number": "154", "ReferenceId": "28467918", "FullCitation": "Ghouadni A, et al. Breast (2017) pmid: 28467918", "Include": "true"}, {"number": "155", "ReferenceId": "28626402", "FullCitation": "Case Rep Oncol () pmid: 28626402", "Include": "true"}, {"number": "156", "ReferenceId": "31924332", "FullCitation": "Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332", "Include": "true"}, {"number": "157", "ReferenceId": "26933761", "FullCitation": "Harnicek D, et al. Int. J. Cancer (2016) pmid: 26933761", "Include": "true"}, {"number": "158", "ReferenceId": "30240327", "FullCitation": "Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327", "Include": "true"}, {"number": "159", "ReferenceId": "28368437", "FullCitation": "Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437", "Include": "true"}, {"number": "160", "ReferenceId": "7545954", "FullCitation": "Miki Y, et al. Science (1994) pmid: 7545954", "Include": "true"}, {"number": "161", "ReferenceId": "8524414", "FullCitation": "Wooster R, et al. Nature () pmid: 8524414", "Include": "true"}, {"number": "162", "ReferenceId": "14576434", "FullCitation": "King MC, et al. Science (2003) pmid: 14576434", "Include": "true"}, {"number": "163", "ReferenceId": "16369438", "FullCitation": "MedGenMed (2005) pmid: 16369438", "Include": "true"}, {"number": "164", "ReferenceId": "7907678", "FullCitation": "Ford D, et al. Lancet (1994) pmid: 7907678", "Include": "true"}, {"number": "165", "ReferenceId": "9042908", "FullCitation": "Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908", "Include": "true"}, {"number": "166", "ReferenceId": "8635102", "FullCitation": "Claus EB, et al. Cancer (1996) pmid: 8635102", "Include": "true"}, {"number": "167", "ReferenceId": "9145676", "FullCitation": "Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676", "Include": "true"}, {"number": "168", "ReferenceId": "8841192", "FullCitation": "Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192", "Include": "true"}, {"number": "169", "ReferenceId": "19241424", "FullCitation": "Hall MJ, et al. Cancer (2009) pmid: 19241424", "Include": "true"}, {"number": "170", "ReferenceId": "16203743", "FullCitation": "Huang G, et al. Hum. Mol. Genet. (2005) pmid: 16203743", "Include": "true"}, {"number": "171", "ReferenceId": "19242095", "FullCitation": "Banck MS, et al. Epigenetics (2009) pmid: 19242095", "Include": "true"}, {"number": "172", "ReferenceId": "9671742", "FullCitation": "Collins C, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9671742", "Include": "true"}, {"number": "173", "ReferenceId": "11245413", "FullCitation": "Nonet GH, et al. Cancer Res. (2001) pmid: 11245413", "Include": "true"}, {"number": "174", "ReferenceId": "17266044", "FullCitation": "Li P, et al. Int. J. Cancer (2007) pmid: 17266044", "Include": "true"}, {"number": "175", "ReferenceId": "22593193", "FullCitation": "Vendrell JA, et al. Cancer Res. (2012) pmid: 22593193", "Include": "true"}, {"number": "176", "ReferenceId": "25031722", "FullCitation": "Li J, et al. Int J Clin Exp Pathol (2014) pmid: 25031722", "Include": "true"}, {"number": "177", "ReferenceId": "22843878", "FullCitation": "Rahman MT, et al. Anticancer Res. (2012) pmid: 22843878", "Include": "true"}, {"number": "178", "ReferenceId": "15701848", "FullCitation": "Yang SH, et al. Clin. Cancer Res. (2005) pmid: 15701848", "Include": "true"}, {"number": "179", "ReferenceId": "25202062", "FullCitation": "Shida A, et al. Anticancer Res. (2014) pmid: 25202062", "Include": "true"}, {"number": "180", "ReferenceId": "15476264", "FullCitation": "Rooney PH, et al. J. Pathol. (2004) pmid: 15476264", "Include": "true"}, {"number": "181", "ReferenceId": "22815235", "FullCitation": "Szczyrba J, et al. Int. J. Cancer (2013) pmid: 22815235", "Include": "true"}, {"number": "182", "ReferenceId": "24853183", "FullCitation": "Geppert CI, et al. Br. J. Cancer (2014) pmid: 24853183", "Include": "true"}, {"number": "183", "ReferenceId": "15897688", "FullCitation": "Toncheva D, et al. Tumour Biol. () pmid: 15897688", "Include": "true"}, {"number": "184", "ReferenceId": "21483406", "FullCitation": "Mao XG, et al. Lab. Invest. (2011) pmid: 21483406", "Include": "true"}, {"number": "185", "ReferenceId": "18193277", "FullCitation": "Schipf A, et al. Virchows Arch. (2008) pmid: 18193277", "Include": "true"}, {"number": "186", "ReferenceId": "17572303", "FullCitation": "Quinlan KG, et al. Biochim. Biophys. Acta (2007) pmid: 17572303", "Include": "true"}, {"number": "187", "ReferenceId": "17259635", "FullCitation": "Krig SR, et al. J. Biol. Chem. (2007) pmid: 17259635", "Include": "true"}, {"number": "188", "ReferenceId": "17130829", "FullCitation": "Cowger JJ, et al. Oncogene (2007) pmid: 17130829", "Include": "true"}, {"number": "189", "ReferenceId": "20661224", "FullCitation": "Krig SR, et al. Oncogene (2010) pmid: 20661224", "Include": "true"}, {"number": "190", "ReferenceId": "21059223", "FullCitation": "Thollet A, et al. Mol. Cancer (2010) pmid: 21059223", "Include": "true"}, {"number": "191", "ReferenceId": "24973012", "FullCitation": "Nguyen NT, et al. Mol Oncol (2014) pmid: 24973012", "Include": "true"}, {"number": "192", "ReferenceId": "24962896", "FullCitation": "Frietze S, et al. BMC Genomics (2014) pmid: 24962896", "Include": "true"}, {"number": "193", "ReferenceId": "22728437", "FullCitation": "Littlepage LE, et al. Cancer Discov (2012) pmid: 22728437", "Include": "true"}, {"number": "194", "ReferenceId": "15769748", "FullCitation": "Clap\u00e9ron A, et al. J. Biol. Chem. (2005) pmid: 15769748", "Include": "true"}, {"number": "195", "ReferenceId": "19563753", "FullCitation": "Phillips JE, et al. Cell (2009) pmid: 19563753", "Include": "true"}, {"number": "196", "ReferenceId": "19568426", "FullCitation": "Gombert WM, et al. PLoS ONE (2009) pmid: 19568426", "Include": "true"}, {"number": "197", "ReferenceId": "20101205", "FullCitation": "Soto_Reyes E, et al. Oncogene (2010) pmid: 20101205", "Include": "true"}, {"number": "198", "ReferenceId": "21296871", "FullCitation": "Woloszynska_Read A, et al. Clin. Cancer Res. (2011) pmid: 21296871", "Include": "true"}, {"number": "199", "ReferenceId": "24794443", "FullCitation": "Kemp CJ, et al. Cell Rep (2014) pmid: 24794443", "Include": "true"}, {"number": "200", "ReferenceId": "23908591", "FullCitation": "M\u00e9ndez_Catal\u00e1 CF, et al. Neoplasia (2013) pmid: 23908591", "Include": "true"}, {"number": "201", "ReferenceId": "23553099", "FullCitation": "Tiffen JC, et al. Int. J. Cancer (2013) pmid: 23553099", "Include": "true"}, {"number": "202", "ReferenceId": "10699051", "FullCitation": "Petrij F, et al. J. Med. Genet. (2000) pmid: 10699051", "Include": "true"}, {"number": "203", "ReferenceId": "8782817", "FullCitation": "Borrow J, et al. Nat. Genet. (1996) pmid: 8782817", "Include": "true"}, {"number": "204", "ReferenceId": "27537276", "FullCitation": "Kao YC, et al. Genes Chromosomes Cancer (2017) pmid: 27537276", "Include": "true"}, {"number": "205", "ReferenceId": "31932680", "FullCitation": "Hofvander J, et al. Mod. Pathol. (2020) pmid: 31932680", "Include": "true"}, {"number": "206", "ReferenceId": "25735316", "FullCitation": "Grasso CS, et al. Ann. Oncol. (2015) pmid: 25735316", "Include": "true"}, {"number": "207", "ReferenceId": "25790293", "FullCitation": "Ma X, et al. Nat Commun (2015) pmid: 25790293", "Include": "true"}, {"number": "208", "ReferenceId": "25713363", "FullCitation": "Green MR, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25713363", "Include": "true"}, {"number": "209", "ReferenceId": "25027518", "FullCitation": "Loeffler M, et al. Leukemia (2015) pmid: 25027518", "Include": "true"}, {"number": "210", "ReferenceId": "18528428", "FullCitation": "Gervais C, et al. Leukemia (2008) pmid: 18528428", "Include": "true"}, {"number": "211", "ReferenceId": "19194466", "FullCitation": "Haferlach T, et al. Leukemia (2009) pmid: 19194466", "Include": "true"}, {"number": "212", "ReferenceId": "25671298", "FullCitation": "Mensah AA, et al. Oncotarget (2015) pmid: 25671298", "Include": "true"}, {"number": "213", "ReferenceId": "16118227", "FullCitation": "Sun XJ, et al. J. Biol. Chem. (2005) pmid: 16118227", "Include": "true"}, {"number": "214", "ReferenceId": "9700202", "FullCitation": "Faber PW, et al. Hum. Mol. Genet. (1998) pmid: 9700202", "Include": "true"}, {"number": "215", "ReferenceId": "19698110", "FullCitation": "Al Sarakbi W, et al. BMC Cancer (2009) pmid: 19698110", "Include": "true"}, {"number": "216", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "217", "ReferenceId": "29522714", "FullCitation": "Chen Z, et al. Biochem Biophys Res Commun (2018) pmid: 29522714", "Include": "true"}, {"number": "218", "ReferenceId": "32202636", "FullCitation": "Chen BY, et al. Blood (2020) pmid: 32202636", "Include": "true"}, {"number": "219", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "220", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "221", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "222", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "223", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "224", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "225", "ReferenceId": "23932335", "FullCitation": "Trovik J, et al. Eur. J. Cancer (2013) pmid: 23932335", "Include": "true"}, {"number": "226", "ReferenceId": "22678923", "FullCitation": "Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923", "Include": "true"}, {"number": "227", "ReferenceId": "20006376", "FullCitation": "Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376", "Include": "true"}, {"number": "228", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "229", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "230", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "231", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "232", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "233", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "234", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "235", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "236", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "237", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "238", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "239", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "240", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "241", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "242", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "243", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "244", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "245", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "246", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "247", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "248", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "249", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "250", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "251", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "252", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "253", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "254", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "255", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "256", "ReferenceId": "15094156", "FullCitation": "Pearce ST, et al. Crit. Rev. Oncol. Hematol. (2004) pmid: 15094156", "Include": "true"}, {"number": "257", "ReferenceId": "23319822", "FullCitation": "Wik E, et al. Clin. Cancer Res. (2013) pmid: 23319822", "Include": "true"}, {"number": "258", "ReferenceId": "24023309", "FullCitation": "Rahman MT, et al. Anticancer Res. (2013) pmid: 24023309", "Include": "true"}, {"number": "259", "ReferenceId": "28560298", "FullCitation": "Straubhar A, et al. Gynecol Oncol Rep (2017) pmid: 28560298", "Include": "true"}, {"number": "260", "ReferenceId": "24076063", "FullCitation": "Thangavelu A, et al. Gynecol. Oncol. (2013) pmid: 24076063", "Include": "true"}, {"number": "261", "ReferenceId": "28221866", "FullCitation": "Gershenson DM, et al. J. Clin. Oncol. (2017) pmid: 28221866", "Include": "true"}, {"number": "262", "ReferenceId": "24925537", "FullCitation": "Esfahani K, et al. BMJ Case Rep (2014) pmid: 24925537", "Include": "true"}, {"number": "263", "ReferenceId": "18457865", "FullCitation": "Ramirez PT, et al. Gynecol. Oncol. (2008) pmid: 18457865", "Include": "true"}, {"number": "264", "ReferenceId": "30345905", "FullCitation": "Turner NC, et al. N. Engl. J. Med. (2018) pmid: 30345905", "Include": "true"}, {"number": "265", "ReferenceId": "27269946", "FullCitation": "Fribbens C, et al. J. Clin. Oncol. (2016) pmid: 27269946", "Include": "true"}, {"number": "266", "ReferenceId": "27174596", "FullCitation": "Spoerke JM, et al. Nat Commun (2016) pmid: 27174596", "Include": "true"}, {"number": "267", "ReferenceId": "30987772", "FullCitation": "Gaillard SL, et al. Gynecol. Oncol. (2019) pmid: 30987772", "Include": "true"}, {"number": "268", "ReferenceId": "26560360", "FullCitation": "Schiavon G, et al. Sci Transl Med (2015) pmid: 26560360", "Include": "true"}, {"number": "269", "ReferenceId": "27532364", "FullCitation": "Chandarlapaty S, et al. JAMA Oncol (2016) pmid: 27532364", "Include": "true"}, {"number": "270", "ReferenceId": "30828692", "FullCitation": "Stover EH, et al. JCO Precis Oncol (2018) pmid: 30828692", "Include": "true"}, {"number": "271", "ReferenceId": "12906785", "FullCitation": "Tee AR, et al. Curr. Biol. (2003) pmid: 12906785", "Include": "true"}, {"number": "272", "ReferenceId": "12869586", "FullCitation": "Inoki K, et al. Genes Dev. (2003) pmid: 12869586", "Include": "true"}, {"number": "273", "ReferenceId": "10915759", "FullCitation": "Miloloza A, et al. Hum. Mol. Genet. (2000) pmid: 10915759", "Include": "true"}, {"number": "274", "ReferenceId": "20547222", "FullCitation": "Hoogeveen_Westerveld M, et al. Biochim. Biophys. Acta (2010) pmid: 20547222", "Include": "true"}, {"number": "275", "ReferenceId": "11741833", "FullCitation": "Hodges AK, et al. Hum. Mol. Genet. (2001) pmid: 11741833", "Include": "true"}, {"number": "276", "ReferenceId": "33575875", "FullCitation": "Mallela K, et al. Mol Cell Biochem (2021) pmid: 33575875", "Include": "true"}, {"number": "277", "ReferenceId": "33727259", "FullCitation": "Adib E, et al. Clin Cancer Res (2021) pmid: 33727259", "Include": "true"}, {"number": "278", "ReferenceId": "31653662", "FullCitation": "Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662", "Include": "true"}, {"number": "279", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "280", "ReferenceId": "25796537", "FullCitation": "Ali SM, et al. Eur. Urol. (2015) pmid: 25796537", "Include": "true"}, {"number": "281", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "282", "ReferenceId": "26831717", "FullCitation": "Kwiatkowski DJ, et al. Clin. Cancer Res. (2016) pmid: 26831717", "Include": "true"}, {"number": "283", "ReferenceId": "30256787", "FullCitation": "Hamieh L, et al. PLoS Genet (2018) pmid: 30256787", "Include": "true"}, {"number": "284", "ReferenceId": "31335987", "FullCitation": "Roldan_Romero JM, et al. Int J Cancer (2020) pmid: 31335987", "Include": "true"}, {"number": "285", "ReferenceId": "2039135", "FullCitation": "Ann. N. Y. Acad. Sci. (1991) pmid: 2039135", "Include": "true"}, {"number": "286", "ReferenceId": "9242607", "FullCitation": "van Slegtenhorst M, et al. Science (1997) pmid: 9242607", "Include": "true"}, {"number": "287", "ReferenceId": "17005952", "FullCitation": "Crino PB, et al. N. Engl. J. Med. (2006) pmid: 17005952", "Include": "true"}, {"number": "288", "ReferenceId": "18722871", "FullCitation": "Curatolo P, et al. Lancet (2008) pmid: 18722871", "Include": "true"}, {"number": "289", "ReferenceId": "15109494", "FullCitation": "Tarsounas M, et al. Cell (2004) pmid: 15109494", "Include": "true"}, {"number": "290", "ReferenceId": "21821141", "FullCitation": "Suwaki N, et al. Semin. Cell Dev. Biol. (2011) pmid: 21821141", "Include": "true"}, {"number": "291", "ReferenceId": "15162012", "FullCitation": "Sasaki MS, et al. Cytogenet. Genome Res. (2004) pmid: 15162012", "Include": "true"}, {"number": "292", "ReferenceId": "15781618", "FullCitation": "Smiraldo PG, et al. Cancer Res. (2005) pmid: 15781618", "Include": "true"}, {"number": "293", "ReferenceId": "27734215", "FullCitation": "Graffeo R, et al. Breast Cancer Res. Treat. (2016) pmid: 27734215", "Include": "true"}, {"number": "294", "ReferenceId": "22415235", "FullCitation": "Osher DJ, et al. Br. J. Cancer (2012) pmid: 22415235", "Include": "true"}, {"number": "295", "ReferenceId": "22652533", "FullCitation": "Pelttari LM, et al. J. Med. Genet. (2012) pmid: 22652533", "Include": "true"}, {"number": "296", "ReferenceId": "24130102", "FullCitation": "Guti\u00e9rrez_Enr\u00edquez S, et al. Int. J. Cancer (2014) pmid: 24130102", "Include": "true"}, {"number": "297", "ReferenceId": "21822267", "FullCitation": "Loveday C, et al. Nat. Genet. (2011) pmid: 21822267", "Include": "true"}, {"number": "298", "ReferenceId": "26261251", "FullCitation": "Song H, et al. J. Clin. Oncol. (2015) pmid: 26261251", "Include": "true"}, {"number": "299", "ReferenceId": "28646019", "FullCitation": "Rivera B, et al. Cancer Res. (2017) pmid: 28646019", "Include": "true"}, {"number": "300", "ReferenceId": "28588062", "FullCitation": "Kondrashova O, et al. Cancer Discov (2017) pmid: 28588062", "Include": "true"}, {"number": "301", "ReferenceId": "16522646", "FullCitation": "Hinz JM, et al. Nucleic Acids Res. (2006) pmid: 16522646", "Include": "true"}, {"number": "302", "ReferenceId": "16717288", "FullCitation": "Wiese C, et al. Nucleic Acids Res. (2006) pmid: 16717288", "Include": "true"}, {"number": "303", "ReferenceId": "22986143", "FullCitation": "Wickramanayake A, et al. Gynecol. Oncol. (2012) pmid: 22986143", "Include": "true"}, {"number": "304", "ReferenceId": "26057125", "FullCitation": "Janatova M, et al. PLoS ONE (2015) pmid: 26057125", "Include": "true"}, {"number": "305", "ReferenceId": "28591191", "FullCitation": "Stafford JL, et al. PLoS ONE (2017) pmid: 28591191", "Include": "true"}, {"number": "306", "ReferenceId": "30111881", "FullCitation": "Konstanta I, et al. J. Hum. Genet. (2018) pmid: 30111881", "Include": "true"}, {"number": "307", "ReferenceId": "30165555", "FullCitation": "Chen X, et al. Ann. Oncol. (2018) pmid: 30165555", "Include": "true"}, {"number": "308", "ReferenceId": "17510365", "FullCitation": "Major MB, et al. Science (2007) pmid: 17510365", "Include": "true"}, {"number": "309", "ReferenceId": "19079258", "FullCitation": "Jenkins ZA, et al. Nat. Genet. (2009) pmid: 19079258", "Include": "true"}, {"number": "310", "ReferenceId": "20209645", "FullCitation": "Perdu B, et al. J. Bone Miner. Res. (2010) pmid: 20209645", "Include": "true"}, {"number": "311", "ReferenceId": "18391980", "FullCitation": "Perotti D, et al. Oncogene (2008) pmid: 18391980", "Include": "true"}, {"number": "312", "ReferenceId": "18311776", "FullCitation": "Ruteshouser EC, et al. Genes Chromosomes Cancer (2008) pmid: 18311776", "Include": "true"}, {"number": "313", "ReferenceId": "17204608", "FullCitation": "Rivera MN, et al. Science (2007) pmid: 17204608", "Include": "true"}, {"number": "314", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "315", "ReferenceId": "23622243", "FullCitation": "Li F, et al. Cell (2013) pmid: 23622243", "Include": "true"}, {"number": "316", "ReferenceId": "21720545", "FullCitation": "Wu H, et al. PLoS ONE (2011) pmid: 21720545", "Include": "true"}, {"number": "317", "ReferenceId": "23391514", "FullCitation": "Edelbrock MA, et al. Mutat. Res. () pmid: 23391514", "Include": "true"}, {"number": "318", "ReferenceId": "11709755", "FullCitation": "Berends MJ, et al. Am. J. Hum. Genet. (2002) pmid: 11709755", "Include": "true"}, {"number": "319", "ReferenceId": "17531815", "FullCitation": "Warren JJ, et al. Mol. Cell (2007) pmid: 17531815", "Include": "true"}, {"number": "320", "ReferenceId": "22277660", "FullCitation": "Geng H, et al. J. Biol. Chem. (2012) pmid: 22277660", "Include": "true"}, {"number": "321", "ReferenceId": "21642682", "FullCitation": "Bonadona V, et al. JAMA (2011) pmid: 21642682", "Include": "true"}, {"number": "322", "ReferenceId": "20028993", "FullCitation": "Baglietto L, et al. J. Natl. Cancer Inst. (2010) pmid: 20028993", "Include": "true"}, {"number": "323", "ReferenceId": "23765559", "FullCitation": "Lu KH, et al. Fam. Cancer (2013) pmid: 23765559", "Include": "true"}, {"number": "324", "ReferenceId": "21742371", "FullCitation": "Shih KK, et al. Gynecol. Oncol. (2011) pmid: 21742371", "Include": "true"}, {"number": "325", "ReferenceId": "25504677", "FullCitation": "Joly MO, et al. Hum. Mutat. (2015) pmid: 25504677", "Include": "true"}, {"number": "326", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "327", "ReferenceId": "25117503", "FullCitation": "Rosty C, et al. Fam. Cancer (2014) pmid: 25117503", "Include": "true"}, {"number": "328", "ReferenceId": "25636458", "FullCitation": "McConechy MK, et al. Gynecol. Oncol. (2015) pmid: 25636458", "Include": "true"}, {"number": "329", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "330", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "331", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "332", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "333", "ReferenceId": "16083711", "FullCitation": "Raevaara TE, et al. Gastroenterology (2005) pmid: 16083711", "Include": "true"}, {"number": "334", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "335", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "336", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "337", "ReferenceId": "18709565", "FullCitation": "Wimmer K, et al. Hum. Genet. (2008) pmid: 18709565", "Include": "true"}, {"number": "338", "ReferenceId": "24737826", "FullCitation": "Wimmer K, et al. J. Med. Genet. (2014) pmid: 24737826", "Include": "true"}, {"number": "339", "ReferenceId": "17259933", "FullCitation": "Scott RH, et al. Nat Clin Pract Oncol (2007) pmid: 17259933", "Include": "true"}, {"number": "340", "ReferenceId": "20015892", "FullCitation": "Ripperger T, et al. Haematologica (2010) pmid: 20015892", "Include": "true"}, {"number": "341", "ReferenceId": "26544533", "FullCitation": "Baris HN, et al. Pediatr Blood Cancer (2016) pmid: 26544533", "Include": "true"}, {"number": "342", "ReferenceId": "23365135", "FullCitation": "Ooi A, et al. Cancer Res. (2013) pmid: 23365135", "Include": "true"}, {"number": "343", "ReferenceId": "23912815", "FullCitation": "Genschik P, et al. EMBO J. (2013) pmid: 23912815", "Include": "true"}, {"number": "344", "ReferenceId": "23308193", "FullCitation": "Grau L, et al. PLoS ONE (2013) pmid: 23308193", "Include": "true"}, {"number": "345", "ReferenceId": "20978349", "FullCitation": "Kossatz U, et al. J. Clin. Invest. (2010) pmid: 20978349", "Include": "true"}, {"number": "346", "ReferenceId": "18418043", "FullCitation": "Huang CH, et al. Cell Cycle (2008) pmid: 18418043", "Include": "true"}, {"number": "347", "ReferenceId": "20530665", "FullCitation": "Taniguchi CM, et al. Cancer Res. (2010) pmid: 20530665", "Include": "true"}, {"number": "348", "ReferenceId": "16679293", "FullCitation": "Luo J, et al. Cell Metab. (2006) pmid: 16679293", "Include": "true"}, {"number": "349", "ReferenceId": "14504291", "FullCitation": "Ueki K, et al. J. Biol. Chem. (2003) pmid: 14504291", "Include": "true"}, {"number": "350", "ReferenceId": "11781359", "FullCitation": "Mauvais_Jarvis F, et al. J. Clin. Invest. (2002) pmid: 11781359", "Include": "true"}, {"number": "351", "ReferenceId": "28630349", "FullCitation": "Thorpe LM, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28630349", "Include": "true"}, {"number": "352", "ReferenceId": "30755611", "FullCitation": "Li X, et al. Nat Commun (2019) pmid: 30755611", "Include": "true"}, {"number": "353", "ReferenceId": "16006513", "FullCitation": "Luo J, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16006513", "Include": "true"}, {"number": "354", "ReferenceId": "19962665", "FullCitation": "Jaiswal BS, et al. Cancer Cell (2009) pmid: 19962665", "Include": "true"}, {"number": "355", "ReferenceId": "21984976", "FullCitation": "Cheung LW, et al. Cancer Discov (2011) pmid: 21984976", "Include": "true"}, {"number": "356", "ReferenceId": "24651434", "FullCitation": "Ko HR, et al. Cell Death Dis (2014) pmid: 24651434", "Include": "true"}, {"number": "357", "ReferenceId": "23166678", "FullCitation": "Quayle SN, et al. PLoS ONE (2012) pmid: 23166678", "Include": "true"}, {"number": "358", "ReferenceId": "20713702", "FullCitation": "Sun M, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20713702", "Include": "true"}, {"number": "359", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "360", "ReferenceId": "21478295", "FullCitation": "Urick ME, et al. Cancer Res. (2011) pmid: 21478295", "Include": "true"}, {"number": "361", "ReferenceId": "18079394", "FullCitation": "Huang CH, et al. Science (2007) pmid: 18079394", "Include": "true"}, {"number": "362", "ReferenceId": "16917505", "FullCitation": "Bousquet C, et al. EMBO J. (2006) pmid: 16917505", "Include": "true"}, {"number": "363", "ReferenceId": "28143957", "FullCitation": "Oliver MD, et al. Biosci. Rep. (2017) pmid: 28143957", "Include": "true"}, {"number": "364", "ReferenceId": "11606375", "FullCitation": "Philp AJ, et al. Cancer Res. (2001) pmid: 11606375", "Include": "true"}, {"number": "365", "ReferenceId": "25488983", "FullCitation": "Lucas CL, et al. J. Exp. Med. (2014) pmid: 25488983", "Include": "true"}, {"number": "366", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "367", "ReferenceId": "25284480", "FullCitation": "Cheung LW, et al. Cancer Cell (2014) pmid: 25284480", "Include": "true"}, {"number": "368", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "369", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "370", "ReferenceId": "26657142", "FullCitation": "Ye K, et al. Nat. Med. (2016) pmid: 26657142", "Include": "true"}, {"number": "371", "ReferenceId": "26501081", "FullCitation": "Munkley J, et al. Oncoscience (2015) pmid: 26501081", "Include": "true"}, {"number": "372", "ReferenceId": "24229379", "FullCitation": "Cizkova M, et al. BMC Cancer (2013) pmid: 24229379", "Include": "true"}, {"number": "373", "ReferenceId": "23980085", "FullCitation": "Qian ZR, et al. J. Clin. Oncol. (2013) pmid: 23980085", "Include": "true"}, {"number": "374", "ReferenceId": "25528496", "FullCitation": "Matulonis U, et al. Gynecol. Oncol. (2015) pmid: 25528496", "Include": "true"}, {"number": "375", "ReferenceId": "25605819", "FullCitation": "Pitz MW, et al. Neuro_oncology (2015) pmid: 25605819", "Include": "true"}, {"number": "376", "ReferenceId": "27893038", "FullCitation": "Basho RK, et al. JAMA Oncol (2017) pmid: 27893038", "Include": "true"}, {"number": "377", "ReferenceId": "27016228", "FullCitation": "Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228", "Include": "true"}, {"number": "378", "ReferenceId": "30420444", "FullCitation": "Day TA, et al. Clin. Cancer Res. (2019) pmid: 30420444", "Include": "true"}, {"number": "379", "ReferenceId": "25193464", "FullCitation": "Ou O, et al. Cancer Lett. (2014) pmid: 25193464", "Include": "true"}, {"number": "380", "ReferenceId": "15366705", "FullCitation": "Kobielak A, et al. Nat. Rev. Mol. Cell Biol. (2004) pmid: 15366705", "Include": "true"}, {"number": "381", "ReferenceId": "19458087", "FullCitation": "Bajpai S, et al. J. Biol. Chem. (2009) pmid: 19458087", "Include": "true"}, {"number": "382", "ReferenceId": "21610251", "FullCitation": "Silvis MR, et al. Sci Signal (2011) pmid: 21610251", "Include": "true"}, {"number": "383", "ReferenceId": "24509793", "FullCitation": "Piao HL, et al. Nat. Cell Biol. (2014) pmid: 24509793", "Include": "true"}, {"number": "384", "ReferenceId": "18566211", "FullCitation": "Inge LJ, et al. Mol. Cancer Ther. (2008) pmid: 18566211", "Include": "true"}, {"number": "385", "ReferenceId": "29625048", "FullCitation": "Hoadley KA, et al. Cell (2018) pmid: 29625048", "Include": "true"}, {"number": "386", "ReferenceId": "24265153", "FullCitation": "Van Allen EM, et al. Cancer Discov (2014) pmid: 24265153", "Include": "true"}, {"number": "387", "ReferenceId": "26182300", "FullCitation": "Hansford S, et al. JAMA Oncol (2015) pmid: 26182300", "Include": "true"}, {"number": "388", "ReferenceId": "23208944", "FullCitation": "Majewski IJ, et al. J. Pathol. (2013) pmid: 23208944", "Include": "true"}, {"number": "389", "ReferenceId": "20393555", "FullCitation": "Ding L, et al. Nature (2010) pmid: 20393555", "Include": "true"}, {"number": "390", "ReferenceId": "25153418", "FullCitation": "Qian J, et al. Clin. Chem. Lab. Med. (2014) pmid: 25153418", "Include": "true"}, {"number": "391", "ReferenceId": "19826047", "FullCitation": "Ye Y, et al. Cancer Res. (2009) pmid: 19826047", "Include": "true"}, {"number": "392", "ReferenceId": "17159988", "FullCitation": "Liu TX, et al. Nat. Med. (2007) pmid: 17159988", "Include": "true"}, {"number": "393", "ReferenceId": "24685333", "FullCitation": "Chen XX, et al. Leuk. Res. (2014) pmid: 24685333", "Include": "true"}, {"number": "394", "ReferenceId": "27129146", "FullCitation": "Li M, et al. Oncotarget (2016) pmid: 27129146", "Include": "true"}, {"number": "395", "ReferenceId": "21119682", "FullCitation": "Harhaj EW, et al. Cell Res. (2011) pmid: 21119682", "Include": "true"}, {"number": "396", "ReferenceId": "15258597", "FullCitation": "Wertz IE, et al. Nature (2004) pmid: 15258597", "Include": "true"}, {"number": "397", "ReferenceId": "26649818", "FullCitation": "Wertz IE, et al. Nature (2015) pmid: 26649818", "Include": "true"}, {"number": "398", "ReferenceId": "19608751", "FullCitation": "Honma K, et al. Blood (2009) pmid: 19608751", "Include": "true"}, {"number": "399", "ReferenceId": "26909601", "FullCitation": "Wang X, et al. Oncotarget (2016) pmid: 26909601", "Include": "true"}, {"number": "400", "ReferenceId": "27072986", "FullCitation": "Couch G, et al. Cancer Prev Res (Phila) (2016) pmid: 27072986", "Include": "true"}, {"number": "401", "ReferenceId": "26485275", "FullCitation": "Wang Y, et al. PLoS ONE (2015) pmid: 26485275", "Include": "true"}, {"number": "402", "ReferenceId": "23929716", "FullCitation": "Salim H, et al. Genes Chromosomes Cancer (2013) pmid: 23929716", "Include": "true"}, {"number": "403", "ReferenceId": "26437781", "FullCitation": "Saitoh Y, et al. Leukemia (2016) pmid: 26437781", "Include": "true"}, {"number": "404", "ReferenceId": "26199174", "FullCitation": "Johansson P, et al. Int. J. Cancer (2016) pmid: 26199174", "Include": "true"}, {"number": "405", "ReferenceId": "26159495", "FullCitation": "Chen S, et al. Leuk. Res. (2015) pmid: 26159495", "Include": "true"}, {"number": "406", "ReferenceId": "20574050", "FullCitation": "Broyl A, et al. Blood (2010) pmid: 20574050", "Include": "true"}, {"number": "407", "ReferenceId": "25856582", "FullCitation": "Troppan K, et al. PLoS ONE (2015) pmid: 25856582", "Include": "true"}, {"number": "408", "ReferenceId": "24008839", "FullCitation": "Yamaguchi N, et al. Sci Rep (2013) pmid: 24008839", "Include": "true"}, {"number": "409", "ReferenceId": "18223652", "FullCitation": "Coornaert B, et al. Nat. Immunol. (2008) pmid: 18223652", "Include": "true"}, {"number": "410", "ReferenceId": "17297453", "FullCitation": "Vendrell JA, et al. Oncogene (2007) pmid: 17297453", "Include": "true"}, {"number": "411", "ReferenceId": "20186265", "FullCitation": "Hjelmeland AB, et al. PLoS Biol. (2010) pmid: 20186265", "Include": "true"}, {"number": "412", "ReferenceId": "22585859", "FullCitation": "Bellail AC, et al. Cancer Discov (2012) pmid: 22585859", "Include": "true"}, {"number": "413", "ReferenceId": "26768118", "FullCitation": "Hantel C, et al. Mol. Cell. Endocrinol. (2016) pmid: 26768118", "Include": "true"}, {"number": "414", "ReferenceId": "22843550", "FullCitation": "Ungerb\u00e4ck J, et al. Carcinogenesis (2012) pmid: 22843550", "Include": "true"}, {"number": "415", "ReferenceId": "22704353", "FullCitation": "Bavi P, et al. Clin Epigenetics (2011) pmid: 22704353", "Include": "true"}, {"number": "416", "ReferenceId": "20383180", "FullCitation": "Hymowitz SG, et al. Nat. Rev. Cancer (2010) pmid: 20383180", "Include": "true"}, {"number": "417", "ReferenceId": "21289309", "FullCitation": "Zhu YX, et al. Blood (2011) pmid: 21289309", "Include": "true"}, {"number": "418", "ReferenceId": "15134788", "FullCitation": "Weil R, et al. Curr. Opin. Immunol. (2004) pmid: 15134788", "Include": "true"}, {"number": "419", "ReferenceId": "23474202", "FullCitation": "Paul S, et al. Trends Immunol. (2013) pmid: 23474202", "Include": "true"}, {"number": "420", "ReferenceId": "27135977", "FullCitation": "Juilland M, et al. Curr. Opin. Hematol. (2016) pmid: 27135977", "Include": "true"}, {"number": "421", "ReferenceId": "26776161", "FullCitation": "Bognar MK, et al. Oncogene (2016) pmid: 26776161", "Include": "true"}, {"number": "422", "ReferenceId": "23149938", "FullCitation": "Chan W, et al. Mol. Cell. Biol. (2013) pmid: 23149938", "Include": "true"}, {"number": "423", "ReferenceId": "25352053", "FullCitation": "Brohl AS, et al. J. Clin. Immunol. (2015) pmid: 25352053", "Include": "true"}, {"number": "424", "ReferenceId": "23027925", "FullCitation": "Jeelall YS, et al. J. Exp. Med. (2012) pmid: 23027925", "Include": "true"}, {"number": "425", "ReferenceId": "18323416", "FullCitation": "Lenz G, et al. Science (2008) pmid: 18323416", "Include": "true"}, {"number": "426", "ReferenceId": "20799731", "FullCitation": "Lamason RL, et al. Biochemistry (2010) pmid: 20799731", "Include": "true"}, {"number": "427", "ReferenceId": "21266526", "FullCitation": "Dong G, et al. Clin. Cancer Res. (2011) pmid: 21266526", "Include": "true"}, {"number": "428", "ReferenceId": "19412164", "FullCitation": "Compagno M, et al. Nature (2009) pmid: 19412164", "Include": "true"}, {"number": "429", "ReferenceId": "26551667", "FullCitation": "da Silva Almeida AC, et al. Nat. Genet. (2015) pmid: 26551667", "Include": "true"}, {"number": "430", "ReferenceId": "27369867", "FullCitation": "Vallois D, et al. Blood (2016) pmid: 27369867", "Include": "true"}, {"number": "431", "ReferenceId": "27224912", "FullCitation": "Wu C, et al. Oncotarget (2016) pmid: 27224912", "Include": "true"}, {"number": "432", "ReferenceId": "26540570", "FullCitation": "Nagel D, et al. Oncotarget (2015) pmid: 26540570", "Include": "true"}, {"number": "433", "ReferenceId": "21324920", "FullCitation": "Naylor TL, et al. Cancer Res. (2011) pmid: 21324920", "Include": "true"}, {"number": "434", "ReferenceId": "23129749", "FullCitation": "Snow AL, et al. J. Exp. Med. (2012) pmid: 23129749", "Include": "true"}, {"number": "435", "ReferenceId": "22397314", "FullCitation": "Bu R, et al. Leuk. Lymphoma (2012) pmid: 22397314", "Include": "true"}, {"number": "436", "ReferenceId": "23699601", "FullCitation": "Morin RD, et al. Blood (2013) pmid: 23699601", "Include": "true"}, {"number": "437", "ReferenceId": "21796119", "FullCitation": "Morin RD, et al. Nature (2011) pmid: 21796119", "Include": "true"}, {"number": "438", "ReferenceId": "20544211", "FullCitation": "Montesinos_Rongen M, et al. Acta Neuropathol. (2010) pmid: 20544211", "Include": "true"}, {"number": "439", "ReferenceId": "25991819", "FullCitation": "Braggio E, et al. Clin. Cancer Res. (2015) pmid: 25991819", "Include": "true"}, {"number": "440", "ReferenceId": "22891273", "FullCitation": "Rossi D, et al. J. Exp. Med. (2012) pmid: 22891273", "Include": "true"}, {"number": "441", "ReferenceId": "22102703", "FullCitation": "Yan Q, et al. Haematologica (2012) pmid: 22102703", "Include": "true"}, {"number": "442", "ReferenceId": "26551670", "FullCitation": "Wang L, et al. Nat. Genet. (2015) pmid: 26551670", "Include": "true"}, {"number": "443", "ReferenceId": "16484591", "FullCitation": "Oshiro A, et al. Blood (2006) pmid: 16484591", "Include": "true"}, {"number": "444", "ReferenceId": "18633432", "FullCitation": "Fujiwara SI, et al. Leukemia (2008) pmid: 18633432", "Include": "true"}, {"number": "445", "ReferenceId": "25384343", "FullCitation": "Ma Y, et al. Eur. J. Med. Res. (2014) pmid: 25384343", "Include": "true"}, {"number": "446", "ReferenceId": "22842228", "FullCitation": "Krauthammer M, et al. Nat. Genet. (2012) pmid: 22842228", "Include": "true"}, {"number": "447", "ReferenceId": "22817889", "FullCitation": "Hodis E, et al. Cell (2012) pmid: 22817889", "Include": "true"}, {"number": "448", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "449", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "450", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "451", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "452", "ReferenceId": "20685844", "FullCitation": "Thome M, et al. Cold Spring Harb Perspect Biol (2010) pmid: 20685844", "Include": "true"}, {"number": "453", "ReferenceId": "22435566", "FullCitation": "Lim KH, et al. Immunol. Rev. (2012) pmid: 22435566", "Include": "true"}, {"number": "454", "ReferenceId": "20525923", "FullCitation": "Milhollen MA, et al. Blood (2010) pmid: 20525923", "Include": "true"}, {"number": "455", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "456", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "457", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "458", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "459", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "460", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "461", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "462", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "463", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "464", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "465", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "466", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "467", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "468", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "469", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "470", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "471", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "472", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "473", "ReferenceId": "15473860", "FullCitation": "Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860", "Include": "true"}, {"number": "474", "ReferenceId": "15361208", "FullCitation": "Pijnenborg JM, et al. Int. J. Gynecol. Cancer () pmid: 15361208", "Include": "true"}, {"number": "475", "ReferenceId": "12439748", "FullCitation": "Moreno_Bueno G, et al. Oncogene (2002) pmid: 12439748", "Include": "true"}, {"number": "476", "ReferenceId": "12097272", "FullCitation": "Zysman M, et al. Cancer Res. (2002) pmid: 12097272", "Include": "true"}, {"number": "477", "ReferenceId": "21813170", "FullCitation": "Singh M, et al. Gynecol. Oncol. (2011) pmid: 21813170", "Include": "true"}, {"number": "478", "ReferenceId": "21363919", "FullCitation": "Tanwar PS, et al. Cancer Res. (2011) pmid: 21363919", "Include": "true"}, {"number": "479", "ReferenceId": "30635339", "FullCitation": "Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339", "Include": "true"}, {"number": "480", "ReferenceId": "20348907", "FullCitation": "Zhang L, et al. Nature (2010) pmid: 20348907", "Include": "true"}, {"number": "481", "ReferenceId": "19026633", "FullCitation": "Lu W, et al. Eur. J. Pharmacol. (2009) pmid: 19026633", "Include": "true"}, {"number": "482", "ReferenceId": "18281498", "FullCitation": "Tuynman JB, et al. Cancer Res. (2008) pmid: 18281498", "Include": "true"}, {"number": "483", "ReferenceId": "23539443", "FullCitation": "Lau T, et al. Cancer Res. (2013) pmid: 23539443", "Include": "true"}, {"number": "484", "ReferenceId": "23159591", "FullCitation": "Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591", "Include": "true"}, {"number": "485", "ReferenceId": "21090969", "FullCitation": "Annu Rev Pathol (2011) pmid: 21090969", "Include": "true"}, {"number": "486", "ReferenceId": "18844223", "FullCitation": "Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223", "Include": "true"}, {"number": "487", "ReferenceId": "19822006", "FullCitation": "Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006", "Include": "true"}, {"number": "488", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "489", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "490", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "491", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "492", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "493", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "494", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "495", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "496", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "497", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "498", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "499", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "500", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "501", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "502", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "503", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "504", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "505", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "506", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "507", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "508", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "509", "ReferenceId": "28502730", "FullCitation": "Akgumus G, et al. J Mol Diagn (2017) pmid: 28502730", "Include": "true"}, {"number": "510", "ReferenceId": "25624430", "FullCitation": "Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430", "Include": "true"}, {"number": "511", "ReferenceId": "26479420", "FullCitation": "Al_Rohil RN, et al. Cancer (2016) pmid: 26479420", "Include": "true"}, {"number": "512", "ReferenceId": "23219661", "FullCitation": "Garcia_Dios DA, et al. Gynecol. Oncol. (2013) pmid: 23219661", "Include": "true"}, {"number": "513", "ReferenceId": "16322209", "FullCitation": "Oda K, et al. Cancer Res. (2005) pmid: 16322209", "Include": "true"}, {"number": "514", "ReferenceId": "23949151", "FullCitation": "Akiyama_Abe A, et al. Br. J. Cancer (2013) pmid: 23949151", "Include": "true"}, {"number": "515", "ReferenceId": "24262879", "FullCitation": "McIntyre JB, et al. Gynecol. Oncol. (2014) pmid: 24262879", "Include": "true"}, {"number": "516", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "517", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "518", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "519", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "520", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "521", "ReferenceId": "27105424", "FullCitation": "Park HS, et al. PLoS ONE (2016) pmid: 27105424", "Include": "true"}, {"number": "522", "ReferenceId": "25426553", "FullCitation": "Hou MM, et al. Oncotarget (2014) pmid: 25426553", "Include": "true"}, {"number": "523", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "524", "ReferenceId": "24440717", "FullCitation": "Janku F, et al. Cell Rep (2014) pmid: 24440717", "Include": "true"}, {"number": "525", "ReferenceId": "22927482", "FullCitation": "Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482", "Include": "true"}, {"number": "526", "ReferenceId": "21890452", "FullCitation": "Moroney JW, et al. Clin. Cancer Res. (2011) pmid: 21890452", "Include": "true"}, {"number": "527", "ReferenceId": "26787751", "FullCitation": "Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751", "Include": "true"}, {"number": "528", "ReferenceId": "2941002", "FullCitation": "Aust Fam Physician (1986) pmid: 2941002", "Include": "true"}, {"number": "529", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "530", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "531", "ReferenceId": "20813970", "FullCitation": "Esteva FJ, et al. Am. J. Pathol. (2010) pmid: 20813970", "Include": "true"}, {"number": "532", "ReferenceId": "25332247", "FullCitation": "Baselga J, et al. J. Clin. Oncol. (2014) pmid: 25332247", "Include": "true"}, {"number": "533", "ReferenceId": "20581867", "FullCitation": "Chakrabarty A, et al. Oncogene (2010) pmid: 20581867", "Include": "true"}, {"number": "534", "ReferenceId": "19633047", "FullCitation": "Kataoka Y, et al. Ann. Oncol. (2010) pmid: 19633047", "Include": "true"}, {"number": "535", "ReferenceId": "21676217", "FullCitation": "Wang L, et al. BMC Cancer (2011) pmid: 21676217", "Include": "true"}, {"number": "536", "ReferenceId": "10679188", "FullCitation": "Biochem. Biophys. Res. Commun. (2000) pmid: 10679188", "Include": "true"}, {"number": "537", "ReferenceId": "22149432", "FullCitation": "Dellinger TH, et al. Expert Rev Anticancer Ther (2012) pmid: 22149432", "Include": "true"}, {"number": "538", "ReferenceId": "11161379", "FullCitation": "Saegusa M, et al. Br. J. Cancer (2001) pmid: 11161379", "Include": "true"}, {"number": "539", "ReferenceId": "23765252", "FullCitation": "McConechy MK, et al. Mod. Pathol. (2014) pmid: 23765252", "Include": "true"}, {"number": "540", "ReferenceId": "23760948", "FullCitation": "Huang M, et al. Cancer (2013) pmid: 23760948", "Include": "true"}, {"number": "541", "ReferenceId": "22430211", "FullCitation": "Yeramian A, et al. Oncogene (2013) pmid: 22430211", "Include": "true"}, {"number": "542", "ReferenceId": "11957146", "FullCitation": "Machin P, et al. Hum. Pathol. (2002) pmid: 11957146", "Include": "true"}, {"number": "543", "ReferenceId": "22955108", "FullCitation": "Peir\u00f3 G, et al. Hum. Pathol. (2013) pmid: 22955108", "Include": "true"}, {"number": "544", "ReferenceId": "28281553", "FullCitation": "Kurnit KC, et al. Mod. Pathol. (2017) pmid: 28281553", "Include": "true"}, {"number": "545", "ReferenceId": "25214561", "FullCitation": "Liu Y, et al. J. Natl. Cancer Inst. (2014) pmid: 25214561", "Include": "true"}, {"number": "546", "ReferenceId": "19820688", "FullCitation": "Rosen DG, et al. Mod. Pathol. (2010) pmid: 19820688", "Include": "true"}, {"number": "547", "ReferenceId": "17504383", "FullCitation": "Athanassiadou P, et al. Int. J. Gynecol. Cancer () pmid: 17504383", "Include": "true"}, {"number": "548", "ReferenceId": "19403928", "FullCitation": "Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928", "Include": "true"}, {"number": "549", "ReferenceId": "21695255", "FullCitation": "Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255", "Include": "true"}, {"number": "550", "ReferenceId": "18768809", "FullCitation": "Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809", "Include": "true"}, {"number": "551", "ReferenceId": "20347502", "FullCitation": "Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502", "Include": "true"}, {"number": "552", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "553", "ReferenceId": "15378020", "FullCitation": "Niida A, et al. Oncogene (2004) pmid: 15378020", "Include": "true"}, {"number": "554", "ReferenceId": "15592430", "FullCitation": "Chamorro MN, et al. EMBO J. (2005) pmid: 15592430", "Include": "true"}, {"number": "555", "ReferenceId": "28574171", "FullCitation": "Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171", "Include": "true"}, {"number": "556", "ReferenceId": "21841793", "FullCitation": "Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793", "Include": "true"}, {"number": "557", "ReferenceId": "23868008", "FullCitation": "Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008", "Include": "true"}, {"number": "558", "ReferenceId": "26349011", "FullCitation": "Shang H, et al. Cancer (2015) pmid: 26349011", "Include": "true"}, {"number": "559", "ReferenceId": "24429522", "FullCitation": "Kode A, et al. Nature (2014) pmid: 24429522", "Include": "true"}, {"number": "560", "ReferenceId": "25231399", "FullCitation": "Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399", "Include": "true"}, {"number": "561", "ReferenceId": "22964660", "FullCitation": "Zhu J, et al. Carcinogenesis (2012) pmid: 22964660", "Include": "true"}, {"number": "562", "ReferenceId": "22356261", "FullCitation": "Kogan Y, et al. Biochem. J. (2012) pmid: 22356261", "Include": "true"}, {"number": "563", "ReferenceId": "22811581", "FullCitation": "Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581", "Include": "true"}, {"number": "564", "ReferenceId": "18094723", "FullCitation": "Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723", "Include": "true"}, {"number": "565", "ReferenceId": "17909001", "FullCitation": "Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001", "Include": "true"}, {"number": "566", "ReferenceId": "23359684", "FullCitation": "Zhao S, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23359684", "Include": "true"}, {"number": "567", "ReferenceId": "23104009", "FullCitation": "Le Gallo M, et al. Nat. Genet. (2012) pmid: 23104009", "Include": "true"}, {"number": "568", "ReferenceId": "22923510", "FullCitation": "Kuhn E, et al. J. Natl. Cancer Inst. (2012) pmid: 22923510", "Include": "true"}, {"number": "569", "ReferenceId": "12183400", "FullCitation": "Spruck CH, et al. Cancer Res. (2002) pmid: 12183400", "Include": "true"}, {"number": "570", "ReferenceId": "14648662", "FullCitation": "Cassia R, et al. J. Pathol. (2003) pmid: 14648662", "Include": "true"}, {"number": "571", "ReferenceId": "22548670", "FullCitation": "Tu K, et al. Hepatol. Res. (2012) pmid: 22548670", "Include": "true"}, {"number": "572", "ReferenceId": "19739118", "FullCitation": "Iwatsuki M, et al. Int. J. Cancer (2010) pmid: 19739118", "Include": "true"}, {"number": "573", "ReferenceId": "22576686", "FullCitation": "Yokobori T, et al. Int. J. Oncol. (2012) pmid: 22576686", "Include": "true"}, {"number": "574", "ReferenceId": "19366810", "FullCitation": "Yokobori T, et al. Cancer Res. (2009) pmid: 19366810", "Include": "true"}, {"number": "575", "ReferenceId": "24165483", "FullCitation": "Yokobori T, et al. Mol. Cancer Res. (2014) pmid: 24165483", "Include": "true"}, {"number": "576", "ReferenceId": "14999283", "FullCitation": "Rajagopalan H, et al. Nature (2004) pmid: 14999283", "Include": "true"}, {"number": "577", "ReferenceId": "23381582", "FullCitation": "Cheng Y, et al. J. Invest. Dermatol. (2013) pmid: 23381582", "Include": "true"}, {"number": "578", "ReferenceId": "26954701", "FullCitation": "Xu Y, et al. Biomarkers (2016) pmid: 26954701", "Include": "true"}, {"number": "579", "ReferenceId": "18787170", "FullCitation": "Mao JH, et al. Science (2008) pmid: 18787170", "Include": "true"}, {"number": "580", "ReferenceId": "25749036", "FullCitation": "Yang H, et al. Oncotarget (2015) pmid: 25749036", "Include": "true"}, {"number": "581", "ReferenceId": "24360397", "FullCitation": "Villaruz LC, et al. Lung Cancer (2014) pmid: 24360397", "Include": "true"}, {"number": "582", "ReferenceId": "21368834", "FullCitation": "Wertz IE, et al. Nature (2011) pmid: 21368834", "Include": "true"}, {"number": "583", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "584", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "585", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "586", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "587", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "588", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "589", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "590", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "591", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "592", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "593", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "594", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "595", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "596", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "597", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "598", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "599", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "600", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "601", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "602", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "603", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "604", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "605", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "606", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "607", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "608", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "609", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "610", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "611", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "612", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "613", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "614", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "615", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "616", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "617", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "618", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "619", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "620", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "621", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "622", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "623", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "624", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "625", "ReferenceId": "18757403", "FullCitation": "Byron SA, et al. Cancer Res. (2008) pmid: 18757403", "Include": "true"}, {"number": "626", "ReferenceId": "22498935", "FullCitation": "Peterson LM, et al. Int. J. Gynecol. Pathol. (2012) pmid: 22498935", "Include": "true"}, {"number": "627", "ReferenceId": "23613406", "FullCitation": "Daniilidou K, et al. J BUON () pmid: 23613406", "Include": "true"}, {"number": "628", "ReferenceId": "23288720", "FullCitation": "van der Zee M, et al. J. Pathol. (2013) pmid: 23288720", "Include": "true"}, {"number": "629", "ReferenceId": "22503752", "FullCitation": "Joshi A, et al. Am. J. Pathol. (2012) pmid: 22503752", "Include": "true"}, {"number": "630", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "631", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "632", "ReferenceId": "24651628", "FullCitation": "Meyer LA, et al. Int J Gynecol Cancer (2014) pmid: 24651628", "Include": "true"}, {"number": "633", "ReferenceId": "21788564", "FullCitation": "Oza AM, et al. J. Clin. Oncol. (2011) pmid: 21788564", "Include": "true"}, {"number": "634", "ReferenceId": "24166148", "FullCitation": "Mackay HJ, et al. Cancer (2014) pmid: 24166148", "Include": "true"}, {"number": "635", "ReferenceId": "24456823", "FullCitation": "Fleming GF, et al. Gynecol. Oncol. (2014) pmid: 24456823", "Include": "true"}, {"number": "636", "ReferenceId": "25173583", "FullCitation": "Tsoref D, et al. Gynecol. Oncol. (2014) pmid: 25173583", "Include": "true"}, {"number": "637", "ReferenceId": "23238879", "FullCitation": "Tr\u00e9dan O, et al. Target Oncol (2013) pmid: 23238879", "Include": "true"}, {"number": "638", "ReferenceId": "20681032", "FullCitation": "Slomovitz BM, et al. Cancer (2010) pmid: 20681032", "Include": "true"}, {"number": "639", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "640", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "641", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "642", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "643", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "644", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "645", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "646", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "647", "ReferenceId": "32532747", "FullCitation": "Yap TA, et al. Cancer Discov (2020) pmid: 32532747", "Include": "true"}, {"number": "648", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "649", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "650", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "651", "ReferenceId": "12093742", "FullCitation": "Pace P, et al. EMBO J. (2002) pmid: 12093742", "Include": "true"}, {"number": "652", "ReferenceId": "21568838", "FullCitation": "Deakyne JS, et al. Biochemistry Mosc. (2011) pmid: 21568838", "Include": "true"}, {"number": "653", "ReferenceId": "17938197", "FullCitation": "Alpi A, et al. Mol. Cell. Biol. (2007) pmid: 17938197", "Include": "true"}, {"number": "654", "ReferenceId": "19111657", "FullCitation": "Alpi AF, et al. Mol. Cell (2008) pmid: 19111657", "Include": "true"}, {"number": "655", "ReferenceId": "12973351", "FullCitation": "Meetei AR, et al. Nat. Genet. (2003) pmid: 12973351", "Include": "true"}, {"number": "656", "ReferenceId": "16916645", "FullCitation": "Machida YJ, et al. Mol. Cell (2006) pmid: 16916645", "Include": "true"}, {"number": "657", "ReferenceId": "21775430", "FullCitation": "Hodson C, et al. J. Biol. Chem. (2011) pmid: 21775430", "Include": "true"}, {"number": "658", "ReferenceId": "24389026", "FullCitation": "Hodson C, et al. Structure (2014) pmid: 24389026", "Include": "true"}, {"number": "659", "ReferenceId": "17352736", "FullCitation": "Seki S, et al. Genes Cells (2007) pmid: 17352736", "Include": "true"}, {"number": "660", "ReferenceId": "19405097", "FullCitation": "Ali AM, et al. Hum. Mutat. (2009) pmid: 19405097", "Include": "true"}, {"number": "661", "ReferenceId": "29335925", "FullCitation": "Fostira F, et al. Breast Cancer Res. Treat. (2018) pmid: 29335925", "Include": "true"}, {"number": "662", "ReferenceId": "27084275", "FullCitation": "Hart SN, et al. BMJ Open (2016) pmid: 27084275", "Include": "true"}, {"number": "663", "ReferenceId": "32235514", "FullCitation": "Del Valle J, et al. Cancers (Basel) (2020) pmid: 32235514", "Include": "true"}, {"number": "664", "ReferenceId": "23613520", "FullCitation": "Chandrasekharappa SC, et al. Blood (2013) pmid: 23613520", "Include": "true"}, {"number": "665", "ReferenceId": "28881617", "FullCitation": "Dicks E, et al. Oncotarget (2017) pmid: 28881617", "Include": "true"}, {"number": "666", "ReferenceId": "30446494", "FullCitation": "Qu X, et al. Blood (2019) pmid: 30446494", "Include": "true"}, {"number": "667", "ReferenceId": "1904223", "FullCitation": "Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223", "Include": "true"}, {"number": "668", "ReferenceId": "8628317", "FullCitation": "Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317", "Include": "true"}, {"number": "669", "ReferenceId": "2121371", "FullCitation": "Ballester R, et al. Cell (1990) pmid: 2121371", "Include": "true"}, {"number": "670", "ReferenceId": "2116237", "FullCitation": "Xu GF, et al. Cell (1990) pmid: 2116237", "Include": "true"}, {"number": "671", "ReferenceId": "2121370", "FullCitation": "Martin GA, et al. Cell (1990) pmid: 2121370", "Include": "true"}, {"number": "672", "ReferenceId": "22807134", "FullCitation": "Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134", "Include": "true"}, {"number": "673", "ReferenceId": "9300663", "FullCitation": "Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663", "Include": "true"}, {"number": "674", "ReferenceId": "11258625", "FullCitation": "Messiaen LM, et al. Genet. Med. () pmid: 11258625", "Include": "true"}, {"number": "675", "ReferenceId": "10607834", "FullCitation": "Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834", "Include": "true"}, {"number": "676", "ReferenceId": "15863657", "FullCitation": "Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657", "Include": "true"}, {"number": "677", "ReferenceId": "8264648", "FullCitation": "Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648", "Include": "true"}, {"number": "678", "ReferenceId": "30068706", "FullCitation": "Soumerai TE, et al. Clin. Cancer Res. (2018) pmid: 30068706", "Include": "true"}, {"number": "679", "ReferenceId": "20062086", "FullCitation": "Murayama_Hosokawa S, et al. Oncogene (2010) pmid: 20062086", "Include": "true"}, {"number": "680", "ReferenceId": "28029918", "FullCitation": "Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918", "Include": "true"}, {"number": "681", "ReferenceId": "33903938", "FullCitation": "Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938", "Include": "true"}, {"number": "682", "ReferenceId": "33751171", "FullCitation": "Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171", "Include": "true"}, {"number": "683", "ReferenceId": "33939292", "FullCitation": "Ronsley R, et al. Cancer Med (2021) pmid: 33939292", "Include": "true"}, {"number": "684", "ReferenceId": "31151904", "FullCitation": "Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904", "Include": "true"}, {"number": "685", "ReferenceId": "32780261", "FullCitation": "Manoharan N, et al. J Neurooncol (2020) pmid: 32780261", "Include": "true"}, {"number": "686", "ReferenceId": "30097824", "FullCitation": "Kondyli M, et al. J Neurooncol (2018) pmid: 30097824", "Include": "true"}, {"number": "687", "ReferenceId": "33082744", "FullCitation": "Awada G, et al. Case Rep Oncol () pmid: 33082744", "Include": "true"}, {"number": "688", "ReferenceId": "32669708", "FullCitation": "Middleton G, et al. Nature (2020) pmid: 32669708", "Include": "true"}, {"number": "689", "ReferenceId": "25314964", "FullCitation": "Weiss B, et al. Neuro_oncology (2015) pmid: 25314964", "Include": "true"}, {"number": "690", "ReferenceId": "18164202", "FullCitation": "Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202", "Include": "true"}, {"number": "691", "ReferenceId": "15937108", "FullCitation": "Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108", "Include": "true"}, {"number": "692", "ReferenceId": "24913553", "FullCitation": "Malone CF, et al. Cancer Discov (2014) pmid: 24913553", "Include": "true"}, {"number": "693", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "694", "ReferenceId": "20027112", "FullCitation": "Jett K, et al. Genet. Med. (2010) pmid: 20027112", "Include": "true"}, {"number": "695", "ReferenceId": "22240541", "FullCitation": "Patil S, et al. Oncologist (2012) pmid: 22240541", "Include": "true"}, {"number": "696", "ReferenceId": "23036231", "FullCitation": "Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231", "Include": "true"}, {"number": "697", "ReferenceId": "8544190", "FullCitation": "Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190", "Include": "true"}, {"number": "698", "ReferenceId": "19117870", "FullCitation": "Williams VC, et al. Pediatrics (2009) pmid: 19117870", "Include": "true"}, {"number": "699", "ReferenceId": "16380997", "FullCitation": "Phillips WA, et al. Int. J. Cancer (2006) pmid: 16380997", "Include": "true"}, {"number": "700", "ReferenceId": "23734178", "FullCitation": "Dbouk HA, et al. PLoS ONE (2013) pmid: 23734178", "Include": "true"}, {"number": "701", "ReferenceId": "25982275", "FullCitation": "Pazarentzos E, et al. Oncogene (2016) pmid: 25982275", "Include": "true"}, {"number": "702", "ReferenceId": "28002804", "FullCitation": "Karlsson T, et al. Oncotarget (2017) pmid: 28002804", "Include": "true"}, {"number": "703", "ReferenceId": "18755892", "FullCitation": "Wee S, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18755892", "Include": "true"}, {"number": "704", "ReferenceId": "18594509", "FullCitation": "Jia S, et al. Nature (2008) pmid: 18594509", "Include": "true"}, {"number": "705", "ReferenceId": "24737887", "FullCitation": "Schmit F, et al. Proc. Natl. Acad. Sci. U.S.A. (2014) pmid: 24737887", "Include": "true"}, {"number": "706", "ReferenceId": "11021964", "FullCitation": "Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964", "Include": "true"}, {"number": "707", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "708", "ReferenceId": "23527311", "FullCitation": "Reintjes N, et al. PLoS ONE (2013) pmid: 23527311", "Include": "true"}, {"number": "709", "ReferenceId": "18552176", "FullCitation": "Dutt A, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18552176", "Include": "true"}, {"number": "710", "ReferenceId": "22383975", "FullCitation": "Byron SA, et al. PLoS ONE (2012) pmid: 22383975", "Include": "true"}, {"number": "711", "ReferenceId": "12952211", "FullCitation": "Ratisoontorn C, et al. Connect. Tissue Res. (2003) pmid: 12952211", "Include": "true"}, {"number": "712", "ReferenceId": "15863029", "FullCitation": "Mohammadi M, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863029", "Include": "true"}, {"number": "713", "ReferenceId": "15282208", "FullCitation": "Ibrahimi OA, et al. Hum. Mol. Genet. (2004) pmid: 15282208", "Include": "true"}, {"number": "714", "ReferenceId": "17525745", "FullCitation": "Pollock PM, et al. Oncogene (2007) pmid: 17525745", "Include": "true"}, {"number": "715", "ReferenceId": "21908617", "FullCitation": "Kapeli K, et al. J. Biol. Chem. (2011) pmid: 21908617", "Include": "true"}, {"number": "716", "ReferenceId": "21454610", "FullCitation": "Eathiraj S, et al. J. Biol. Chem. (2011) pmid: 21454610", "Include": "true"}, {"number": "717", "ReferenceId": "26048680", "FullCitation": "Tanizaki J, et al. Cancer Res. (2015) pmid: 26048680", "Include": "true"}, {"number": "718", "ReferenceId": "9266968", "FullCitation": "Lorenzi MV, et al. Oncogene (1997) pmid: 9266968", "Include": "true"}, {"number": "719", "ReferenceId": "8205545", "FullCitation": "Itoh H, et al. Cancer Res. (1994) pmid: 8205545", "Include": "true"}, {"number": "720", "ReferenceId": "17803937", "FullCitation": "Chen H, et al. Mol. Cell (2007) pmid: 17803937", "Include": "true"}, {"number": "721", "ReferenceId": "7668257", "FullCitation": "Park WJ, et al. Am. J. Hum. Genet. (1995) pmid: 7668257", "Include": "true"}, {"number": "722", "ReferenceId": "7719344", "FullCitation": "Wilkie AO, et al. Nat. Genet. (1995) pmid: 7719344", "Include": "true"}, {"number": "723", "ReferenceId": "16418739", "FullCitation": "Lajeunie E, et al. Eur. J. Hum. Genet. (2006) pmid: 16418739", "Include": "true"}, {"number": "724", "ReferenceId": "24411056", "FullCitation": "Chen CP, et al. Taiwan J Obstet Gynecol (2013) pmid: 24411056", "Include": "true"}, {"number": "725", "ReferenceId": "19610084", "FullCitation": "Slavotinek A, et al. Am. J. Med. Genet. A (2009) pmid: 19610084", "Include": "true"}, {"number": "726", "ReferenceId": "23468082", "FullCitation": "Gozgit JM, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23468082", "Include": "true"}, {"number": "727", "ReferenceId": "8696350", "FullCitation": "Przylepa KA, et al. Nat. Genet. (1996) pmid: 8696350", "Include": "true"}, {"number": "728", "ReferenceId": "11781872", "FullCitation": "Kan SH, et al. Am. J. Hum. Genet. (2002) pmid: 11781872", "Include": "true"}, {"number": "729", "ReferenceId": "23300780", "FullCitation": "Krakstad C, et al. PLoS ONE (2012) pmid: 23300780", "Include": "true"}, {"number": "730", "ReferenceId": "21725289", "FullCitation": "Gatius S, et al. Mod. Pathol. (2011) pmid: 21725289", "Include": "true"}, {"number": "731", "ReferenceId": "18292933", "FullCitation": "Ishikawa A, et al. Int. J. Oncol. (2008) pmid: 18292933", "Include": "true"}, {"number": "732", "ReferenceId": "9070494", "FullCitation": "Siegfried S, et al. Cancer (1997) pmid: 9070494", "Include": "true"}, {"number": "733", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "734", "ReferenceId": "31371345", "FullCitation": "Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345", "Include": "true"}, {"number": "735", "ReferenceId": "32203698", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698", "Include": "true"}, {"number": "736", "ReferenceId": "27870574", "FullCitation": "Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574", "Include": "true"}, {"number": "737", "ReferenceId": "27179038", "FullCitation": "Pearson A, et al. Cancer Discov (2016) pmid: 27179038", "Include": "true"}, {"number": "738", "ReferenceId": "29177434", "FullCitation": "Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434", "Include": "true"}, {"number": "739", "ReferenceId": "31195180", "FullCitation": "Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180", "Include": "true"}, {"number": "740", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "741", "ReferenceId": "33926920", "FullCitation": "Cleary JM, et al. Cancer Discov (2021) pmid: 33926920", "Include": "true"}, {"number": "742", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "743", "ReferenceId": "31109923", "FullCitation": "Goyal L, et al. Cancer Discov (2019) pmid: 31109923", "Include": "true"}, {"number": "744", "ReferenceId": "30420614", "FullCitation": "Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614", "Include": "true"}, {"number": "745", "ReferenceId": "24550739", "FullCitation": "Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739", "Include": "true"}, {"number": "746", "ReferenceId": "23786770", "FullCitation": "Liao RG, et al. Cancer Res. (2013) pmid: 23786770", "Include": "true"}, {"number": "747", "ReferenceId": "22238366", "FullCitation": "Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366", "Include": "true"}, {"number": "748", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "749", "ReferenceId": "24856830", "FullCitation": "Solomon DA, et al. BMB Rep (2014) pmid: 24856830", "Include": "true"}, {"number": "750", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "751", "ReferenceId": "24484537", "FullCitation": "Evers L, et al. Genome Med (2014) pmid: 24484537", "Include": "true"}, {"number": "752", "ReferenceId": "24121792", "FullCitation": "Guo G, et al. Nat. Genet. (2013) pmid: 24121792", "Include": "true"}, {"number": "753", "ReferenceId": "24121789", "FullCitation": "Solomon DA, et al. Nat. Genet. (2013) pmid: 24121789", "Include": "true"}, {"number": "754", "ReferenceId": "21852505", "FullCitation": "Solomon DA, et al. Science (2011) pmid: 21852505", "Include": "true"}, {"number": "755", "ReferenceId": "25006131", "FullCitation": "Thota S, et al. Blood (2014) pmid: 25006131", "Include": "true"}, {"number": "756", "ReferenceId": "24121791", "FullCitation": "Balb\u00e1s_Mart\u00ednez C, et al. Nat. Genet. (2013) pmid: 24121791", "Include": "true"}, {"number": "757", "ReferenceId": "23955599", "FullCitation": "Kon A, et al. Nat. Genet. (2013) pmid: 23955599", "Include": "true"}, {"number": "758", "ReferenceId": "24270882", "FullCitation": "Taylor CF, et al. Hum. Mol. Genet. (2014) pmid: 24270882", "Include": "true"}, {"number": "759", "ReferenceId": "25223734", "FullCitation": "Tirode F, et al. Cancer Discov (2014) pmid: 25223734", "Include": "true"}, {"number": "760", "ReferenceId": "25010205", "FullCitation": "Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205", "Include": "true"}, {"number": "761", "ReferenceId": "23926200", "FullCitation": "Hoang ML, et al. Sci Transl Med (2013) pmid: 23926200", "Include": "true"}, {"number": "762", "ReferenceId": "27500726", "FullCitation": "Shen CH, et al. Nat. Med. (2016) pmid: 27500726", "Include": "true"}, {"number": "763", "ReferenceId": "24356817", "FullCitation": "Bailey ML, et al. Mol. Cancer Ther. (2014) pmid: 24356817", "Include": "true"}, {"number": "764", "ReferenceId": "12617994", "FullCitation": "Gupta_Rossi N, et al. Mol. Immunol. (2003) pmid: 12617994", "Include": "true"}, {"number": "765", "ReferenceId": "22585168", "FullCitation": "Weigert O, et al. Cancer Discov (2012) pmid: 22585168", "Include": "true"}, {"number": "766", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "767", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "768", "ReferenceId": "21447625", "FullCitation": "Vicent GP, et al. Genes Dev. (2011) pmid: 21447625", "Include": "true"}, {"number": "769", "ReferenceId": "21671394", "FullCitation": "Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394", "Include": "true"}, {"number": "770", "ReferenceId": "31128216", "FullCitation": "Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216", "Include": "true"}, {"number": "771", "ReferenceId": "28007623", "FullCitation": "Augert A, et al. J Thorac Oncol (2017) pmid: 28007623", "Include": "true"}, {"number": "772", "ReferenceId": "29627316", "FullCitation": "Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316", "Include": "true"}, {"number": "773", "ReferenceId": "29950560", "FullCitation": "Hillman RT, et al. Nat Commun (2018) pmid: 29950560", "Include": "true"}, {"number": "774", "ReferenceId": "29532228", "FullCitation": "Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228", "Include": "true"}, {"number": "775", "ReferenceId": "23916100", "FullCitation": "Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100", "Include": "true"}, {"number": "776", "ReferenceId": "23249563", "FullCitation": "Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563", "Include": "true"}, {"number": "777", "ReferenceId": "22829774", "FullCitation": "Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774", "Include": "true"}, {"number": "778", "ReferenceId": "23185534", "FullCitation": "Bower K, et al. PLoS ONE (2012) pmid: 23185534", "Include": "true"}, {"number": "779", "ReferenceId": "21719641", "FullCitation": "Heaphy CM, et al. Science (2011) pmid: 21719641", "Include": "true"}, {"number": "780", "ReferenceId": "25229770", "FullCitation": "Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770", "Include": "true"}, {"number": "781", "ReferenceId": "17296936", "FullCitation": "Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936", "Include": "true"}, {"number": "782", "ReferenceId": "14729260", "FullCitation": "Garrick D, et al. Gene (2004) pmid: 14729260", "Include": "true"}, {"number": "783", "ReferenceId": "21666677", "FullCitation": "Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677", "Include": "true"}, {"number": "784", "ReferenceId": "25593184", "FullCitation": "Flynn RL, et al. Science (2015) pmid: 25593184", "Include": "true"}, {"number": "785", "ReferenceId": "7697714", "FullCitation": "Gibbons RJ, et al. Cell (1995) pmid: 7697714", "Include": "true"}, {"number": "786", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "787", "ReferenceId": "25608029", "FullCitation": "Fishbein L, et al. Nat Commun (2015) pmid: 25608029", "Include": "true"}, {"number": "788", "ReferenceId": "22416102", "FullCitation": "Cheung NK, et al. JAMA (2012) pmid: 22416102", "Include": "true"}, {"number": "789", "ReferenceId": "22367537", "FullCitation": "Molenaar JJ, et al. Nature (2012) pmid: 22367537", "Include": "true"}, {"number": "790", "ReferenceId": "23334666", "FullCitation": "Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666", "Include": "true"}, {"number": "791", "ReferenceId": "23702928", "FullCitation": "Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928", "Include": "true"}, {"number": "792", "ReferenceId": "24148618", "FullCitation": "Marinoni I, et al. Gastroenterology (2014) pmid: 24148618", "Include": "true"}, {"number": "793", "ReferenceId": "24468746", "FullCitation": "Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746", "Include": "true"}, {"number": "794", "ReferenceId": "26936505", "FullCitation": "Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505", "Include": "true"}, {"number": "795", "ReferenceId": "23104868", "FullCitation": "Kannan K, et al. Oncotarget (2012) pmid: 23104868", "Include": "true"}, {"number": "796", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "797", "ReferenceId": "25427834", "FullCitation": "Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834", "Include": "true"}, {"number": "798", "ReferenceId": "25143301", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301", "Include": "true"}, {"number": "799", "ReferenceId": "31551363", "FullCitation": "Liang J, et al. Cancer Res (2020) pmid: 31551363", "Include": "true"}, {"number": "800", "ReferenceId": "34118569", "FullCitation": "Garbarino J, et al. Transl Oncol (2021) pmid: 34118569", "Include": "true"}, {"number": "801", "ReferenceId": "32846370", "FullCitation": "George SL, et al. EBioMedicine (2020) pmid: 32846370", "Include": "true"}, {"number": "802", "ReferenceId": "11331609", "FullCitation": "Shi Y, et al. Genes Dev. (2001) pmid: 11331609", "Include": "true"}, {"number": "803", "ReferenceId": "12897056", "FullCitation": "Ariyoshi M, et al. Genes Dev. (2003) pmid: 12897056", "Include": "true"}, {"number": "804", "ReferenceId": "12594956", "FullCitation": "Kuroda K, et al. Immunity (2003) pmid: 12594956", "Include": "true"}, {"number": "805", "ReferenceId": "12374742", "FullCitation": "Oswald F, et al. EMBO J. (2002) pmid: 12374742", "Include": "true"}, {"number": "806", "ReferenceId": "19379690", "FullCitation": "Kopan R, et al. Cell (2009) pmid: 19379690", "Include": "true"}, {"number": "807", "ReferenceId": "23778141", "FullCitation": "Stephens PJ, et al. J. Clin. Invest. (2013) pmid: 23778141", "Include": "true"}, {"number": "808", "ReferenceId": "32167863", "FullCitation": "Makker V, et al. J. Clin. Oncol. (2020) pmid: 32167863", "Include": "true"}, {"number": "809", "ReferenceId": "28489510", "FullCitation": "Ott PA, et al. J Clin Oncol (2017) pmid: 28489510", "Include": "true"}, {"number": "810", "ReferenceId": "26970723", "FullCitation": "Fehrenbacher L, et al. Lancet (2016) pmid: 26970723", "Include": "true"}, {"number": "811", "ReferenceId": "25428504", "FullCitation": "Herbst RS, et al. Nature (2014) pmid: 25428504", "Include": "true"}, {"number": "812", "ReferenceId": "26952546", "FullCitation": "Rosenberg JE, et al. Lancet (2016) pmid: 26952546", "Include": "true"}, {"number": "813", "ReferenceId": "25428503", "FullCitation": "Powles T, et al. Nature (2014) pmid: 25428503", "Include": "true"}, {"number": "814", "ReferenceId": "31780255", "FullCitation": "Geoerger B, et al. Lancet Oncol. (2020) pmid: 31780255", "Include": "true"}, {"number": "815", "ReferenceId": "26755520", "FullCitation": "McDermott DF, et al. J. Clin. Oncol. (2016) pmid: 26755520", "Include": "true"}, {"number": "816", "ReferenceId": "30918950", "FullCitation": "Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950", "Include": "true"}, {"number": "817", "ReferenceId": "31204078", "FullCitation": "Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31204078", "Include": "true"}, {"number": "818", "ReferenceId": "24912489", "FullCitation": "Wheler JJ, et al. Oncotarget (2014) pmid: 24912489", "Include": "true"}, {"number": "819", "ReferenceId": "25649062", "FullCitation": "Noriega_Iriondo MF, et al. Hered Cancer Clin Pract (2015) pmid: 25649062", "Include": "true"}, {"number": "820", "ReferenceId": "23066039", "FullCitation": "Janku F, et al. Cancer Res. (2013) pmid: 23066039", "Include": "true"}, {"number": "821", "ReferenceId": "22271473", "FullCitation": "Janku F, et al. J. Clin. Oncol. (2012) pmid: 22271473", "Include": "true"}, {"number": "822", "ReferenceId": "21216929", "FullCitation": "Janku F, et al. Mol. Cancer Ther. (2011) pmid: 21216929", "Include": "true"}, {"number": "823", "ReferenceId": "25878190", "FullCitation": "Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190", "Include": "true"}, {"number": "824", "ReferenceId": "29863979", "FullCitation": "Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979", "Include": "true"}, {"number": "825", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "826", "ReferenceId": "23423489", "FullCitation": "Plummer R, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23423489", "Include": "true"}, {"number": "827", "ReferenceId": "19047122", "FullCitation": "Plummer R, et al. Clin. Cancer Res. (2008) pmid: 19047122", "Include": "true"}, {"number": "828", "ReferenceId": "28222073", "FullCitation": "Wilson RH, et al. Br. J. Cancer (2017) pmid: 28222073", "Include": "true"}, {"number": "829", "ReferenceId": "26961146", "FullCitation": "Matulonis UA, et al. Ann. Oncol. (2016) pmid: 26961146", "Include": "true"}, {"number": "830", "ReferenceId": "22452356", "FullCitation": "Ledermann J, et al. N. Engl. J. Med. (2012) pmid: 22452356", "Include": "true"}, {"number": "831", "ReferenceId": "24882434", "FullCitation": "Ledermann J, et al. Lancet Oncol. (2014) pmid: 24882434", "Include": "true"}, {"number": "832", "ReferenceId": "32343890", "FullCitation": "de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890", "Include": "true"}, {"number": "833", "ReferenceId": "30541756", "FullCitation": "Seligson ND, et al. Oncologist (2019) pmid: 30541756", "Include": "true"}, {"number": "834", "ReferenceId": "31068370", "FullCitation": "Lin J, et al. Clin. Cancer Res. (2019) pmid: 31068370", "Include": "true"}, {"number": "835", "ReferenceId": "29680362", "FullCitation": "Necchi A, et al. Eur. J. Cancer (2018) pmid: 29680362", "Include": "true"}, {"number": "836", "ReferenceId": "3253274", "FullCitation": "Vinitski S, et al. Heart Vessels (1988) pmid: 3253274", "Include": "true"}, {"number": "837", "ReferenceId": "29937315", "FullCitation": "Gockley AA, et al. Gynecol. Oncol. (2018) pmid: 29937315", "Include": "true"}, {"number": "838", "ReferenceId": "25025963", "FullCitation": "Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963", "Include": "true"}, {"number": "839", "ReferenceId": "21447615", "FullCitation": "Kollmannsberger C, et al. Ann. Oncol. (2012) pmid: 21447615", "Include": "true"}, {"number": "840", "ReferenceId": "23262204", "FullCitation": "Alvarez EA, et al. Gynecol. Oncol. (2013) pmid: 23262204", "Include": "true"}, {"number": "841", "ReferenceId": "29588307", "FullCitation": "Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307", "Include": "true"}, {"number": "842", "ReferenceId": "31461377", "FullCitation": "Konstantinopoulos PA, et al. J. Clin. Oncol. (2019) pmid: 31461377", "Include": "true"}, {"number": "843", "ReferenceId": "25891304", "FullCitation": "Postow MA, et al. N. Engl. J. Med. (2015) pmid: 25891304", "Include": "true"}, {"number": "844", "ReferenceId": "26027431", "FullCitation": "Larkin J, et al. N. Engl. J. Med. (2015) pmid: 26027431", "Include": "true"}, {"number": "845", "ReferenceId": "25399552", "FullCitation": "Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399552", "Include": "true"}, {"number": "846", "ReferenceId": "24590637", "FullCitation": "Topalian SL, et al. J. Clin. Oncol. (2014) pmid: 24590637", "Include": "true"}, {"number": "847", "ReferenceId": "25795410", "FullCitation": "Weber JS, et al. Lancet Oncol. (2015) pmid: 25795410", "Include": "true"}, {"number": "848", "ReferenceId": "26028407", "FullCitation": "Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407", "Include": "true"}, {"number": "849", "ReferenceId": "26412456", "FullCitation": "Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456", "Include": "true"}, {"number": "850", "ReferenceId": "31100038", "FullCitation": "Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038", "Include": "true"}, {"number": "851", "ReferenceId": "28131785", "FullCitation": "Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785", "Include": "true"}, {"number": "852", "ReferenceId": "25452452", "FullCitation": "Motzer RJ, et al. J. Clin. Oncol. (2015) pmid: 25452452", "Include": "true"}, {"number": "853", "ReferenceId": "22658127", "FullCitation": "Topalian SL, et al. N. Engl. J. Med. (2012) pmid: 22658127", "Include": "true"}, {"number": "854", "ReferenceId": "20516446", "FullCitation": "Brahmer JR, et al. J. Clin. Oncol. (2010) pmid: 20516446", "Include": "true"}, {"number": "855", "ReferenceId": "26406148", "FullCitation": "Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148", "Include": "true"}, {"number": "856", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "857", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "858", "ReferenceId": "22658128", "FullCitation": "Brahmer JR, et al. N. Engl. J. Med. (2012) pmid: 22658128", "Include": "true"}, {"number": "859", "ReferenceId": "26351349", "FullCitation": "Hamanishi J, et al. J. Clin. Oncol. (2015) pmid: 26351349", "Include": "true"}, {"number": "860", "ReferenceId": "31074244", "FullCitation": "Normann MC, et al. J Gynecol Oncol (2019) pmid: 31074244", "Include": "true"}, {"number": "861", "ReferenceId": "27269741", "FullCitation": "Antonia SJ, et al. Lancet Oncol. (2016) pmid: 27269741", "Include": "true"}, {"number": "862", "ReferenceId": "30110194", "FullCitation": "Janjigian YY, et al. J. Clin. Oncol. (2018) pmid: 30110194", "Include": "true"}, {"number": "863", "ReferenceId": "25482239", "FullCitation": "Ansell SM, et al. N. Engl. J. Med. (2015) pmid: 25482239", "Include": "true"}, {"number": "864", "ReferenceId": "27451390", "FullCitation": "Younes A, et al. Lancet Oncol. (2016) pmid: 27451390", "Include": "true"}, {"number": "865", "ReferenceId": "30361170", "FullCitation": "Hodi FS, et al. Lancet Oncol. (2018) pmid: 30361170", "Include": "true"}, {"number": "866", "ReferenceId": "27622997", "FullCitation": "Hodi FS, et al. Lancet Oncol. (2016) pmid: 27622997", "Include": "true"}, {"number": "867", "ReferenceId": "31562797", "FullCitation": "Larkin J, et al. N. Engl. J. Med. (2019) pmid: 31562797", "Include": "true"}, {"number": "868", "ReferenceId": "31562796", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796", "Include": "true"}, {"number": "869", "ReferenceId": "31427204", "FullCitation": "Motzer RJ, et al. Lancet Oncol. (2019) pmid: 31427204", "Include": "true"}, {"number": "870", "ReferenceId": "29562145", "FullCitation": "Motzer RJ, et al. N. Engl. J. Med. (2018) pmid: 29562145", "Include": "true"}, {"number": "871", "ReferenceId": "28778959", "FullCitation": "Kollipara R, et al. Oncologist (2017) pmid: 28778959", "Include": "true"}, {"number": "872", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "873", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "874", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "875", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "876", "ReferenceId": "30110579", "FullCitation": "Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579", "Include": "true"}, {"number": "877", "ReferenceId": "30124753", "FullCitation": "Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753", "Include": "true"}, {"number": "878", "ReferenceId": "28242752", "FullCitation": "de Bono J, et al. Cancer Discov (2017) pmid: 28242752", "Include": "true"}, {"number": "879", "ReferenceId": "30099369", "FullCitation": "Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369", "Include": "true"}, {"number": "880", "ReferenceId": "28339824", "FullCitation": "Banerjee A, et al. Neuro_oncology (2017) pmid: 28339824", "Include": "true"}, {"number": "881", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "882", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "883", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "884", "ReferenceId": "20179232", "FullCitation": "Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232", "Include": "true"}, {"number": "885", "ReferenceId": "22293660", "FullCitation": "Boers_Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660", "Include": "true"}, {"number": "886", "ReferenceId": "25667274", "FullCitation": "Lopez_Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274", "Include": "true"}, {"number": "887", "ReferenceId": "20802351", "FullCitation": "Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351", "Include": "true"}, {"number": "888", "ReferenceId": "25887099", "FullCitation": "Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099", "Include": "true"}, {"number": "889", "ReferenceId": "26666244", "FullCitation": "Deming DA, et al. Invest New Drugs (2016) pmid: 26666244", "Include": "true"}, {"number": "890", "ReferenceId": "30042150", "FullCitation": "Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150", "Include": "true"}, {"number": "891", "ReferenceId": "28424891", "FullCitation": "Infante JR, et al. Invest New Drugs (2017) pmid: 28424891", "Include": "true"}, {"number": "892", "ReferenceId": "28264648", "FullCitation": "LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648", "Include": "true"}, {"number": "893", "ReferenceId": "25516890", "FullCitation": "Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890", "Include": "true"}, {"number": "894", "ReferenceId": "25268371", "FullCitation": "Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_09_28 20:19:44", "OpName": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "994x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "372 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "_3 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": {"comment": {"commentedBy": "Douglas Lin, M.D.", "commentedDts": "2021_09_28T20:18:20.000Z", "text": "The genomic profile is compatible with a POLE_ultramutated endometrial carcinoma."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "UTERUS", "disease_ontology": "Uterus endometrial adenocarcinoma endometrioid", "flowcell_analysis": "2000017789", "gender": "female", "pathology_diagnosis": "Endometrioid Carcinoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.7.0", "purity_assessment": "8.7", "specimen": "ORD_1194331_01*US1153674.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1194331_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Uterus", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "1008.49", "name": "SQ_US1153674.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.3107", "cds_effect": "1095C>A", "depth": "811", "equivocal": "false", "functional_effect": "missense", "gene": "MAF", "percent_reads": "31.07", "position": "chr16:79632705", "protein_effect": "N365K", "status": "unknown", "strand": "_", "transcript": "NM_005360", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3472", "cds_effect": "1231G>C", "depth": "720", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "34.72", "position": "chr12:133250289", "protein_effect": "V411L", "status": "known", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3223", "cds_effect": "1735G>T", "depth": "636", "equivocal": "false", "functional_effect": "missense", "gene": "MERTK", "percent_reads": "32.23", "position": "chr2:112760713", "protein_effect": "D579Y", "status": "unknown", "strand": "+", "transcript": "NM_006343", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3432", "cds_effect": "1422A>C", "depth": "641", "equivocal": "false", "functional_effect": "missense", "gene": "NBN", "percent_reads": "34.32", "position": "chr8:90965895", "protein_effect": "E474D", "status": "unknown", "strand": "_", "transcript": "NM_002485", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3775", "cds_effect": "5102C>A", "depth": "845", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "37.75", "position": "chr3:142224075", "protein_effect": "S1701Y", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.35", "cds_effect": "2177A>C", "depth": "680", "equivocal": "false", "functional_effect": "missense", "gene": "CDK12", "percent_reads": "35.0", "position": "chr17:37649072", "protein_effect": "K726T", "status": "unknown", "strand": "+", "transcript": "NM_016507", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3172", "cds_effect": "2353G>A", "depth": "908", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "31.72", "position": "chr6:117704623", "protein_effect": "V785M", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.328", "cds_effect": "2115G>T", "depth": "991", "equivocal": "false", "functional_effect": "missense", "gene": "RBM10", "percent_reads": "32.8", "position": "chrX:47044715", "protein_effect": "E705D", "status": "unknown", "strand": "+", "transcript": "NM_005676", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3599", "cds_effect": "6998G>A", "depth": "978", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "35.99", "position": "chr9:139391193", "protein_effect": "G2333D", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2846", "cds_effect": "2765G>T", "depth": "889", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "28.46", "position": "chr6:117687286", "protein_effect": "R922I", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.1101", "cds_effect": "1732C>A", "depth": "899", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "11.01", "position": "chr12:56488213", "protein_effect": "H578N", "status": "unknown", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3232", "cds_effect": "7720C>A", "depth": "1086", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "32.32", "position": "chr5:112179011", "protein_effect": "L2574I", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.353", "cds_effect": "2552G>A", "depth": "966", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "35.3", "position": "chr1:27089596", "protein_effect": "G851D", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3059", "cds_effect": "67C>A", "depth": "765", "equivocal": "false", "functional_effect": "missense", "gene": "BTK", "percent_reads": "30.59", "position": "chrX:100630206", "protein_effect": "L23I", "status": "unknown", "strand": "_", "transcript": "NM_000061", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3717", "cds_effect": "652G>A", "depth": "748", "equivocal": "false", "functional_effect": "missense", "gene": "ESR1", "percent_reads": "37.17", "position": "chr6:152201798", "protein_effect": "D218N", "status": "unknown", "strand": "+", "transcript": "NM_000125", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3464", "cds_effect": "896C>A", "depth": "791", "equivocal": "false", "functional_effect": "missense", "gene": "HGF", "percent_reads": "34.64", "position": "chr7:81359065", "protein_effect": "P299H", "status": "unknown", "strand": "_", "transcript": "NM_000601", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.7148", "cds_effect": "7348C>T", "depth": "845", "equivocal": "false", "functional_effect": "nonsense", "gene": "NF1", "percent_reads": "71.48", "position": "chr17:29677227", "protein_effect": "R2450*", "status": "known", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3722", "cds_effect": "1038G>T", "depth": "1080", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "37.22", "position": "chr4:55133825", "protein_effect": "R346S", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3354", "cds_effect": "351G>T", "depth": "790", "equivocal": "false", "functional_effect": "missense", "gene": "DIS3", "percent_reads": "33.54", "position": "chr13:73355019", "protein_effect": "E117D", "status": "unknown", "strand": "_", "transcript": "NM_014953", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.341", "cds_effect": "2410C>A", "depth": "698", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "34.1", "position": "chr5:38958555", "protein_effect": "L804I", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3557", "cds_effect": "1489G>A", "depth": "776", "equivocal": "false", "functional_effect": "missense", "gene": "KEL", "percent_reads": "35.57", "position": "chr7:142641412", "protein_effect": "D497N", "status": "unknown", "strand": "_", "transcript": "NM_000420", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3669", "cds_effect": "700C>T", "depth": "586", "equivocal": "false", "functional_effect": "missense", "gene": "U2AF1", "percent_reads": "36.69", "position": "chr21:44513235", "protein_effect": "R234C", "status": "unknown", "strand": "_", "transcript": "NM_006758", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3502", "cds_effect": "2822C>A", "depth": "931", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "35.02", "position": "chr11:118344696", "protein_effect": "S941Y", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.338", "cds_effect": "1407G>T", "depth": "938", "equivocal": "false", "functional_effect": "missense", "gene": "DAXX", "percent_reads": "33.8", "position": "chr6:33287846", "protein_effect": "Q469H", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3574", "cds_effect": "400T>G", "depth": "747", "equivocal": "false", "functional_effect": "missense", "gene": "CRKL", "percent_reads": "35.74", "position": "chr22:21288155", "protein_effect": "F134V", "status": "unknown", "strand": "+", "transcript": "NM_005207", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.322", "cds_effect": "189G>T", "depth": "736", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "32.2", "position": "chr17:29483129", "protein_effect": "K63N", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3632", "cds_effect": "1087C>T", "depth": "782", "equivocal": "false", "functional_effect": "missense", "gene": "VEGFA", "percent_reads": "36.32", "position": "chr6:43749694", "protein_effect": "P363S", "status": "unknown", "strand": "+", "transcript": "NM_001025366", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4659", "cds_effect": "2489G>A", "depth": "983", "equivocal": "false", "functional_effect": "missense", "gene": "LTK", "percent_reads": "46.59", "position": "chr15:41796300", "protein_effect": "S830N", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3627", "cds_effect": "721C>T", "depth": "579", "equivocal": "false", "functional_effect": "missense", "gene": "AKT3", "percent_reads": "36.27", "position": "chr1:243736326", "protein_effect": "R241W", "status": "unknown", "strand": "_", "transcript": "NM_005465", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3507", "cds_effect": "2848C>A", "depth": "921", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "35.07", "position": "chr11:118344722", "protein_effect": "L950I", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3399", "cds_effect": "1165C>T", "depth": "965", "equivocal": "false", "functional_effect": "missense", "gene": "BRAF", "percent_reads": "33.99", "position": "chr7:140487360", "protein_effect": "R389C", "status": "unknown", "strand": "_", "transcript": "NM_004333", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3836", "cds_effect": "2421A>C", "depth": "782", "equivocal": "false", "functional_effect": "missense", "gene": "INPP4B", "percent_reads": "38.36", "position": "chr4:143007363", "protein_effect": "E807D", "status": "unknown", "strand": "_", "transcript": "NM_003866", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3208", "cds_effect": "2158G>A", "depth": "907", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "32.08", "position": "chr12:115109720", "protein_effect": "E720K", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4726", "cds_effect": "164G>A", "depth": "749", "equivocal": "false", "functional_effect": "missense", "gene": "RAD52", "percent_reads": "47.26", "position": "chr12:1040408", "protein_effect": "R55H", "status": "unknown", "strand": "_", "transcript": "NM_134424", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3441", "cds_effect": "1676A>G", "depth": "715", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK3", "percent_reads": "34.41", "position": "chr15:88524501", "protein_effect": "E559G", "status": "unknown", "strand": "_", "transcript": "NM_001007156", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.355", "cds_effect": "598A>C", "depth": "1217", "equivocal": "false", "functional_effect": "missense", "gene": "KLHL6", "percent_reads": "35.5", "position": "chr3:183226158", "protein_effect": "N200H", "status": "unknown", "strand": "_", "transcript": "NM_130446", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4525", "cds_effect": "1653C>G", "depth": "926", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "45.25", "position": "chrX:66863134", "protein_effect": "D551E", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3261", "cds_effect": "1480G>T", "depth": "742", "equivocal": "false", "functional_effect": "nonsense", "gene": "KEL", "percent_reads": "32.61", "position": "chr7:142641421", "protein_effect": "E494*", "status": "likely", "strand": "_", "transcript": "NM_000420", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3645", "cds_effect": "6610C>T", "depth": "963", "equivocal": "false", "functional_effect": "nonsense", "gene": "APC", "percent_reads": "36.45", "position": "chr5:112177901", "protein_effect": "R2204*", "status": "likely", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3168", "cds_effect": "1110+1G>T", "depth": "865", "equivocal": "false", "functional_effect": "splice", "gene": "CDK8", "percent_reads": "31.68", "position": "chr13:26975485", "protein_effect": "splice site 1110+1G>T", "status": "unknown", "strand": "+", "transcript": "NM_001260", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3697", "cds_effect": "4202G>A", "depth": "1155", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "36.97", "position": "chr20:31024717", "protein_effect": "G1401E", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.329", "cds_effect": "22G>T", "depth": "772", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "32.9", "position": "chr16:2098638", "protein_effect": "D8Y", "status": "unknown", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4019", "cds_effect": "64G>A", "depth": "821", "equivocal": "false", "functional_effect": "missense", "gene": "GSK3B", "percent_reads": "40.19", "position": "chr3:119812218", "protein_effect": "A22T", "status": "unknown", "strand": "_", "transcript": "NM_002093", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3393", "cds_effect": "2704C>T", "depth": "1123", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "33.93", "position": "chr12:427465", "protein_effect": "R902W", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.323", "cds_effect": "665G>A", "depth": "712", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "32.3", "position": "chr5:38982057", "protein_effect": "R222Q", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3324", "cds_effect": "598G>T", "depth": "1092", "equivocal": "false", "functional_effect": "missense", "gene": "IDH2", "percent_reads": "33.24", "position": "chr15:90631671", "protein_effect": "D200Y", "status": "unknown", "strand": "_", "transcript": "NM_002168", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3217", "cds_effect": "352+1G>A", "depth": "858", "equivocal": "false", "functional_effect": "splice", "gene": "PIK3CA", "percent_reads": "32.17", "position": "chr3:178916966", "protein_effect": "splice site 352+1G>A", "status": "unknown", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3499", "cds_effect": "825G>T", "depth": "723", "equivocal": "false", "functional_effect": "missense", "gene": "IKZF1", "percent_reads": "34.99", "position": "chr7:50459536", "protein_effect": "K275N", "status": "unknown", "strand": "+", "transcript": "NM_006060", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3464", "cds_effect": "2863C>T", "depth": "638", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIK3CB", "percent_reads": "34.64", "position": "chr3:138376611", "protein_effect": "R955*", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3106", "cds_effect": "911G>A", "depth": "718", "equivocal": "false", "functional_effect": "missense", "gene": "MAP2K4", "percent_reads": "31.06", "position": "chr17:12032475", "protein_effect": "R304Q", "status": "unknown", "strand": "+", "transcript": "NM_003010", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3645", "cds_effect": "1987C>T", "depth": "1196", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB1", "percent_reads": "36.45", "position": "chr3:134911522", "protein_effect": "R663W", "status": "unknown", "strand": "+", "transcript": "NM_004441", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3074", "cds_effect": "2719C>T", "depth": "1106", "equivocal": "false", "functional_effect": "nonsense", "gene": "ATRX", "percent_reads": "30.74", "position": "chrX:76938029", "protein_effect": "R907*", "status": "known", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.01", "cds_effect": "758G>A", "depth": "800", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51D", "percent_reads": "1.0", "position": "chr17:33428365", "protein_effect": "R253Q", "status": "known", "strand": "_", "transcript": "NM_002878", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0225", "cds_effect": "811C>T", "depth": "843", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "2.25", "position": "chr7:2979436", "protein_effect": "R271W", "status": "known", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3476", "cds_effect": "1129A>C", "depth": "820", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CB", "percent_reads": "34.76", "position": "chr3:138433483", "protein_effect": "N377H", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3792", "cds_effect": "4762G>A", "depth": "886", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "37.92", "position": "chr12:49438728", "protein_effect": "E1588K", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0502", "cds_effect": "1004G>A", "depth": "737", "equivocal": "false", "functional_effect": "missense", "gene": "KDR", "percent_reads": "5.02", "position": "chr4:55976908", "protein_effect": "G335D", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3002", "cds_effect": "1260G>T", "depth": "846", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "30.02", "position": "chr7:2976752", "protein_effect": "E420D", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.1925", "cds_effect": "1769A>C", "depth": "748", "equivocal": "false", "functional_effect": "missense", "gene": "PTPN11", "percent_reads": "19.25", "position": "chr12:112942555", "protein_effect": "K590T", "status": "unknown", "strand": "+", "transcript": "NM_002834", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3251", "cds_effect": "463_1G>T", "depth": "646", "equivocal": "false", "functional_effect": "splice", "gene": "STAG2", "percent_reads": "32.51", "position": "chrX:123179013", "protein_effect": "splice site 463_1G>T", "status": "likely", "strand": "+", "transcript": "NM_006603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2624", "cds_effect": "508A>C", "depth": "1071", "equivocal": "false", "functional_effect": "missense", "gene": "FAM123B", "percent_reads": "26.24", "position": "chrX:63412659", "protein_effect": "K170Q", "status": "unknown", "strand": "_", "transcript": "NM_152424", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3615", "cds_effect": "2425G>T", "depth": "758", "equivocal": "false", "functional_effect": "nonsense", "gene": "SF3B1", "percent_reads": "36.15", "position": "chr2:198266195", "protein_effect": "E809*", "status": "unknown", "strand": "_", "transcript": "NM_012433", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3117", "cds_effect": "701T>C", "depth": "969", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB1", "percent_reads": "31.17", "position": "chr3:134670790", "protein_effect": "V234A", "status": "unknown", "strand": "+", "transcript": "NM_004441", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3764", "cds_effect": "826G>A", "depth": "829", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "37.64", "position": "chr13:110437575", "protein_effect": "D276N", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3526", "cds_effect": "640C>T", "depth": "760", "equivocal": "false", "functional_effect": "missense", "gene": "CDK6", "percent_reads": "35.26", "position": "chr7:92300747", "protein_effect": "R214C", "status": "unknown", "strand": "_", "transcript": "NM_001259", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3496", "cds_effect": "1390G>A", "depth": "801", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "34.96", "position": "chr9:139412255", "protein_effect": "D464N", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3113", "cds_effect": "212A>C", "depth": "697", "equivocal": "false", "functional_effect": "missense", "gene": "CCND2", "percent_reads": "31.13", "position": "chr12:4385187", "protein_effect": "K71T", "status": "unknown", "strand": "+", "transcript": "NM_001759", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3289", "cds_effect": "560G>T", "depth": "757", "equivocal": "false", "functional_effect": "missense", "gene": "NF2", "percent_reads": "32.89", "position": "chr22:30051626", "protein_effect": "R187I", "status": "unknown", "strand": "+", "transcript": "NM_000268", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.367", "cds_effect": "295G>A", "depth": "793", "equivocal": "false", "functional_effect": "missense", "gene": "CBFB", "percent_reads": "36.7", "position": "chr16:67100597", "protein_effect": "A99T", "status": "unknown", "strand": "+", "transcript": "NM_022845", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.376", "cds_effect": "6406C>A", "depth": "976", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "37.6", "position": "chr5:112177697", "protein_effect": "L2136I", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0077", "cds_effect": "337T>G", "depth": "909", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "0.77", "position": "chr17:7579350", "protein_effect": "F113V", "status": "known", "strand": "_", "subclonal": "true", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3537", "cds_effect": "2600A>C", "depth": "950", "equivocal": "false", "functional_effect": "missense", "gene": "CTNNA1", "percent_reads": "35.37", "position": "chr5:138269657", "protein_effect": "K867T", "status": "unknown", "strand": "+", "transcript": "NM_001903", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0746", "cds_effect": "2495T>G", "depth": "764", "equivocal": "false", "functional_effect": "missense", "gene": "PTPRO", "percent_reads": "7.46", "position": "chr12:15704542", "protein_effect": "L832R", "status": "unknown", "strand": "+", "transcript": "NM_030667", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.336", "cds_effect": "853T>G", "depth": "997", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "33.6", "position": "chr3:178921371", "protein_effect": "L285V", "status": "unknown", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3983", "cds_effect": "3677G>A", "depth": "831", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "39.83", "position": "chrX:129156941", "protein_effect": "R1226H", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3257", "cds_effect": "614T>G", "depth": "1142", "equivocal": "false", "functional_effect": "missense", "gene": "EP300", "percent_reads": "32.57", "position": "chr22:41513710", "protein_effect": "M205R", "status": "unknown", "strand": "+", "transcript": "NM_001429", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3774", "cds_effect": "1381C>A", "depth": "681", "equivocal": "false", "functional_effect": "missense", "gene": "FH", "percent_reads": "37.74", "position": "chr1:241663746", "protein_effect": "P461T", "status": "unknown", "strand": "_", "transcript": "NM_000143", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3475", "cds_effect": "208G>A", "depth": "846", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK2", "percent_reads": "34.75", "position": "chr9:87285871", "protein_effect": "E70K", "status": "unknown", "strand": "+", "transcript": "NM_006180", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2728", "cds_effect": "471A>C", "depth": "799", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "27.28", "position": "chr10:89692987", "protein_effect": "E157D", "status": "unknown", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3631", "cds_effect": "867C>A", "depth": "785", "equivocal": "false", "functional_effect": "missense", "gene": "TNFAIP3", "percent_reads": "36.31", "position": "chr6:138198274", "protein_effect": "H289Q", "status": "unknown", "strand": "+", "transcript": "NM_006290", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3634", "cds_effect": "313T>C", "depth": "919", "equivocal": "false", "functional_effect": "missense", "gene": "IKZF1", "percent_reads": "36.34", "position": "chr7:50444383", "protein_effect": "S105P", "status": "unknown", "strand": "+", "transcript": "NM_006060", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3456", "cds_effect": "2245G>T", "depth": "1007", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA1", "percent_reads": "34.56", "position": "chr17:41245303", "protein_effect": "D749Y", "status": "unknown", "strand": "_", "transcript": "NM_007294", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.329", "cds_effect": "3703C>A", "depth": "924", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "32.9", "position": "chr12:133226355", "protein_effect": "L1235I", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3402", "cds_effect": "1986G>T", "depth": "926", "equivocal": "false", "functional_effect": "missense", "gene": "DAXX", "percent_reads": "34.02", "position": "chr6:33286951", "protein_effect": "K662N", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3477", "cds_effect": "1256T>C", "depth": "719", "equivocal": "false", "functional_effect": "missense", "gene": "AKT3", "percent_reads": "34.77", "position": "chr1:243675724", "protein_effect": "V419A", "status": "unknown", "strand": "_", "transcript": "NM_005465", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3462", "cds_effect": "3725G>A", "depth": "751", "equivocal": "false", "functional_effect": "missense", "gene": "MSH6", "percent_reads": "34.62", "position": "chr2:48033421", "protein_effect": "R1242H", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3604", "cds_effect": "1289T>G", "depth": "1218", "equivocal": "false", "functional_effect": "missense", "gene": "ERG", "percent_reads": "36.04", "position": "chr21:39755476", "protein_effect": "F430C", "status": "unknown", "strand": "_", "transcript": "NM_182918", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.056", "cds_effect": "3482G>A", "depth": "982", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB2", "percent_reads": "5.6", "position": "chr17:37884011", "protein_effect": "R1161Q", "status": "unknown", "strand": "+", "transcript": "NM_004448", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3572", "cds_effect": "1130T>G", "depth": "683", "equivocal": "false", "functional_effect": "missense", "gene": "CUL3", "percent_reads": "35.72", "position": "chr2:225370749", "protein_effect": "F377C", "status": "unknown", "strand": "_", "transcript": "NM_003590", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0575", "cds_effect": "4358A>G", "depth": "731", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "5.75", "position": "chr5:38946611", "protein_effect": "H1453R", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3496", "cds_effect": "389G>A", "depth": "941", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "34.96", "position": "chr10:89692905", "protein_effect": "R130Q", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2718", "cds_effect": "2480A>C", "depth": "1008", "equivocal": "false", "functional_effect": "missense", "gene": "LTK", "percent_reads": "27.18", "position": "chr15:41796309", "protein_effect": "K827T", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.332", "cds_effect": "1939G>T", "depth": "1015", "equivocal": "false", "functional_effect": "nonsense", "gene": "EPHA3", "percent_reads": "33.2", "position": "chr3:89468405", "protein_effect": "E647*", "status": "unknown", "strand": "+", "transcript": "NM_005233", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3384", "cds_effect": "910C>T", "depth": "721", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "33.84", "position": "chr12:115115416", "protein_effect": "R304W", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3456", "cds_effect": "1390T>G", "depth": "897", "equivocal": "false", "functional_effect": "missense", "gene": "SMAD2", "percent_reads": "34.56", "position": "chr18:45368212", "protein_effect": "S464A", "status": "unknown", "strand": "_", "transcript": "NM_005901", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3584", "cds_effect": "1067G>A", "depth": "971", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "35.84", "position": "chr17:59878687", "protein_effect": "R356Q", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3506", "cds_effect": "1835T>G", "depth": "790", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "35.06", "position": "chr5:38960516", "protein_effect": "L612R", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.083", "cds_effect": "1091C>T", "depth": "843", "equivocal": "false", "functional_effect": "missense", "gene": "IKZF1", "percent_reads": "8.3", "position": "chr7:50467856", "protein_effect": "S364L", "status": "unknown", "strand": "+", "transcript": "NM_006060", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3502", "cds_effect": "1604G>A", "depth": "871", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "35.02", "position": "chr1:16245981", "protein_effect": "R535Q", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.009", "cds_effect": "2246G>A", "depth": "777", "equivocal": "false", "functional_effect": "missense", "gene": "XPO1", "percent_reads": "0.9", "position": "chr2:61715367", "protein_effect": "R749Q", "status": "known", "strand": "_", "transcript": "NM_003400", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3896", "cds_effect": "67C>T", "depth": "670", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "38.96", "position": "chr5:112090654", "protein_effect": "L23F", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3541", "cds_effect": "7915C>A", "depth": "884", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "35.41", "position": "chr17:29684332", "protein_effect": "L2639I", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3456", "cds_effect": "2833_2834insA", "depth": "489", "equivocal": "false", "functional_effect": "frameshift", "gene": "FLT1", "percent_reads": "34.56", "position": "chr13:28897046", "protein_effect": "M945fs*15", "status": "unknown", "strand": "_", "transcript": "NM_002019", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3285", "cds_effect": "241C>T", "depth": "1096", "equivocal": "false", "functional_effect": "missense", "gene": "MERTK", "percent_reads": "32.85", "position": "chr2:112686876", "protein_effect": "P81S", "status": "unknown", "strand": "+", "transcript": "NM_006343", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3497", "cds_effect": "6668A>G", "depth": "755", "equivocal": "false", "functional_effect": "missense", "gene": "MTOR", "percent_reads": "34.97", "position": "chr1:11182178", "protein_effect": "Q2223R", "status": "unknown", "strand": "_", "transcript": "NM_004958", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3453", "cds_effect": "1700C>T", "depth": "698", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "34.53", "position": "chr7:2968286", "protein_effect": "P567L", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3514", "cds_effect": "1273C>T", "depth": "814", "equivocal": "false", "functional_effect": "missense", "gene": "EED", "percent_reads": "35.14", "position": "chr11:85989514", "protein_effect": "L425F", "status": "unknown", "strand": "+", "transcript": "NM_003797", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3589", "cds_effect": "202C>A", "depth": "1081", "equivocal": "false", "functional_effect": "missense", "gene": "EP300", "percent_reads": "35.89", "position": "chr22:41513298", "protein_effect": "L68I", "status": "unknown", "strand": "+", "transcript": "NM_001429", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3292", "cds_effect": "3328C>T", "depth": "1215", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "32.92", "position": "chr5:38950622", "protein_effect": "R1110C", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3605", "cds_effect": "631A>G", "depth": "896", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "36.05", "position": "chr17:7578218", "protein_effect": "T211A", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.333", "cds_effect": "499C>A", "depth": "1123", "equivocal": "false", "functional_effect": "missense", "gene": "HSD3B1", "percent_reads": "33.3", "position": "chr1:120056645", "protein_effect": "L167M", "status": "unknown", "strand": "+", "transcript": "NM_000862", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3477", "cds_effect": "2612C>T", "depth": "837", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "34.77", "position": "chrX:66943532", "protein_effect": "A871V", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3593", "cds_effect": "6154G>A", "depth": "977", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "35.93", "position": "chr11:108186796", "protein_effect": "E2052K", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3692", "cds_effect": "10240A>G", "depth": "826", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "36.92", "position": "chr13:32972890", "protein_effect": "T3414A", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3695", "cds_effect": "1022G>T", "depth": "912", "equivocal": "false", "functional_effect": "missense", "gene": "PDK1", "percent_reads": "36.95", "position": "chr2:173451082", "protein_effect": "R341I", "status": "unknown", "strand": "+", "transcript": "NM_002610", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4326", "cds_effect": "2408G>A", "depth": "705", "equivocal": "false", "functional_effect": "missense", "gene": "JAK2", "percent_reads": "43.26", "position": "chr9:5080657", "protein_effect": "R803Q", "status": "unknown", "strand": "+", "transcript": "NM_004972", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3336", "cds_effect": "6058G>A", "depth": "1103", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "33.36", "position": "chr13:32914550", "protein_effect": "E2020K", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.067", "cds_effect": "762A>C", "depth": "1223", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "6.7", "position": "chr3:142281482", "protein_effect": "E254D", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3566", "cds_effect": "323C>T", "depth": "659", "equivocal": "false", "functional_effect": "missense", "gene": "FGF3", "percent_reads": "35.66", "position": "chr11:69631089", "protein_effect": "S108L", "status": "unknown", "strand": "_", "transcript": "NM_005247", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3165", "cds_effect": "1206A>C", "depth": "714", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "31.65", "position": "chr6:117714443", "protein_effect": "E402D", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3486", "cds_effect": "232G>A", "depth": "958", "equivocal": "false", "functional_effect": "missense", "gene": "CDK8", "percent_reads": "34.86", "position": "chr13:26923236", "protein_effect": "V78I", "status": "unknown", "strand": "+", "transcript": "NM_001260", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3255", "cds_effect": "2472G>T", "depth": "1023", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "32.55", "position": "chr20:31022987", "protein_effect": "E824D", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3436", "cds_effect": "4365_4366AG>CA", "depth": "1010", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "34.36", "position": "chr13:32912857", "protein_effect": "E1455_E1456>DK", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2842", "cds_effect": "1666G>T", "depth": "1010", "equivocal": "false", "functional_effect": "nonsense", "gene": "PDGFRA", "percent_reads": "28.42", "position": "chr4:55141020", "protein_effect": "E556*", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3644", "cds_effect": "135G>T", "depth": "752", "equivocal": "false", "functional_effect": "missense", "gene": "NT5C2", "percent_reads": "36.44", "position": "chr10:104899203", "protein_effect": "K45N", "status": "unknown", "strand": "_", "transcript": "NM_001134373", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3491", "cds_effect": "1321C>T", "depth": "951", "equivocal": "false", "functional_effect": "missense", "gene": "FBXW7", "percent_reads": "34.91", "position": "chr4:153249457", "protein_effect": "R441W", "status": "known", "strand": "_", "transcript": "NM_033632", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.343", "cds_effect": "976G>A", "depth": "1338", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF217", "percent_reads": "34.3", "position": "chr20:52198390", "protein_effect": "D326N", "status": "known", "strand": "_", "transcript": "NM_006526", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.368", "cds_effect": "837A>C", "depth": "1174", "equivocal": "false", "functional_effect": "missense", "gene": "PALB2", "percent_reads": "36.8", "position": "chr16:23647030", "protein_effect": "K279N", "status": "unknown", "strand": "_", "transcript": "NM_024675", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3414", "cds_effect": "205_1G>A", "depth": "873", "equivocal": "false", "functional_effect": "splice", "gene": "CDK8", "percent_reads": "34.14", "position": "chr13:26923208", "protein_effect": "splice site 205_1G>A", "status": "unknown", "strand": "+", "transcript": "NM_001260", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3678", "cds_effect": "110G>A", "depth": "522", "equivocal": "false", "functional_effect": "missense", "gene": "FGF4", "percent_reads": "36.78", "position": "chr11:69589743", "protein_effect": "G37D", "status": "unknown", "strand": "_", "transcript": "NM_002007", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3196", "cds_effect": "2770G>A", "depth": "1042", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "31.96", "position": "chr11:76255363", "protein_effect": "E924K", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3558", "cds_effect": "6920C>T", "depth": "1113", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "35.58", "position": "chr5:112178211", "protein_effect": "S2307L", "status": "known", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3577", "cds_effect": "667C>A", "depth": "875", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "35.77", "position": "chr9:98244310", "protein_effect": "L223I", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3443", "cds_effect": "857G>A", "depth": "1092", "equivocal": "false", "functional_effect": "missense", "gene": "FAM123B", "percent_reads": "34.43", "position": "chrX:63412310", "protein_effect": "S286N", "status": "unknown", "strand": "_", "transcript": "NM_152424", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.5059", "cds_effect": "1697T>C", "depth": "939", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "50.59", "position": "chr1:156846256", "protein_effect": "M566T", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3575", "cds_effect": "5278_1G>T", "depth": "870", "equivocal": "false", "functional_effect": "splice", "gene": "SETD2", "percent_reads": "35.75", "position": "chr3:47127805", "protein_effect": "splice site 5278_1G>T", "status": "likely", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3339", "cds_effect": "697_2A>C", "depth": "611", "equivocal": "false", "functional_effect": "splice", "gene": "AKT3", "percent_reads": "33.39", "position": "chr1:243736352", "protein_effect": "splice site 697_2A>C", "status": "unknown", "strand": "_", "transcript": "NM_005465", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3793", "cds_effect": "1292A>C", "depth": "1102", "equivocal": "false", "functional_effect": "missense", "gene": "MSH6", "percent_reads": "37.93", "position": "chr2:48026414", "protein_effect": "K431T", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3485", "cds_effect": "5803T>C", "depth": "964", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "34.85", "position": "chr4:106197470", "protein_effect": "Y1935H", "status": "unknown", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3483", "cds_effect": "1805T>G", "depth": "689", "equivocal": "false", "functional_effect": "nonsense", "gene": "CUL3", "percent_reads": "34.83", "position": "chr2:225360586", "protein_effect": "L602*", "status": "likely", "strand": "_", "transcript": "NM_003590", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3603", "cds_effect": "2128T>G", "depth": "877", "equivocal": "false", "functional_effect": "missense", "gene": "FLT3", "percent_reads": "36.03", "position": "chr13:28601304", "protein_effect": "F710V", "status": "unknown", "strand": "_", "transcript": "NM_004119", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3325", "cds_effect": "134G>A", "depth": "770", "equivocal": "false", "functional_effect": "missense", "gene": "REL", "percent_reads": "33.25", "position": "chr2:61118941", "protein_effect": "R45Q", "status": "unknown", "strand": "+", "transcript": "NM_002908", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3484", "cds_effect": "1426G>T", "depth": "732", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIK3R1", "percent_reads": "34.84", "position": "chr5:67590364", "protein_effect": "E476*", "status": "likely", "strand": "+", "transcript": "NM_181523", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.101", "cds_effect": "5637G>T", "depth": "1050", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "10.1", "position": "chr13:32914129", "protein_effect": "E1879D", "status": "known", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3559", "cds_effect": "2215C>T", "depth": "885", "equivocal": "false", "functional_effect": "nonsense", "gene": "TSC1", "percent_reads": "35.59", "position": "chr9:135778168", "protein_effect": "Q739*", "status": "likely", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3651", "cds_effect": "664C>T", "depth": "734", "equivocal": "false", "functional_effect": "missense", "gene": "IDH1", "percent_reads": "36.51", "position": "chr2:209108185", "protein_effect": "R222C", "status": "unknown", "strand": "_", "transcript": "NM_005896", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3836", "cds_effect": "148G>T", "depth": "829", "equivocal": "false", "functional_effect": "nonsense", "gene": "CREBBP", "percent_reads": "38.36", "position": "chr16:3900948", "protein_effect": "E50*", "status": "likely", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3311", "cds_effect": "731C>T", "depth": "1063", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "33.11", "position": "chrX:129147479", "protein_effect": "S244L", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3263", "cds_effect": "904_2A>C", "depth": "754", "equivocal": "false", "functional_effect": "splice", "gene": "FANCL", "percent_reads": "32.63", "position": "chr2:58388775", "protein_effect": "splice site 904_2A>C", "status": "likely", "strand": "_", "transcript": "NM_018062", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3666", "cds_effect": "393_394CC>TA", "depth": "1023", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "36.66", "position": "chr20:57478807", "protein_effect": "L132M", "status": "unknown", "strand": "+", "transcript": "NM_000516", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3627", "cds_effect": "820C>A", "depth": "714", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51", "percent_reads": "36.27", "position": "chr15:41023298", "protein_effect": "L274I", "status": "unknown", "strand": "+", "transcript": "NM_001164270", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3231", "cds_effect": "632G>A", "depth": "1176", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "32.31", "position": "chr16:3900464", "protein_effect": "G211E", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2086", "cds_effect": "1181G>A", "depth": "1146", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "20.86", "position": "chr20:31021182", "protein_effect": "R394H", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3275", "cds_effect": "1090T>G", "depth": "1081", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "32.75", "position": "chrX:66766078", "protein_effect": "Y364D", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3546", "cds_effect": "730A>G", "depth": "784", "equivocal": "false", "functional_effect": "missense", "gene": "NT5C2", "percent_reads": "35.46", "position": "chr10:104857089", "protein_effect": "K244E", "status": "unknown", "strand": "_", "transcript": "NM_001134373", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3071", "cds_effect": "1195A>C", "depth": "775", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "30.71", "position": "chr6:117714454", "protein_effect": "N399H", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3237", "cds_effect": "518G>A", "depth": "973", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "32.37", "position": "chr10:89711900", "protein_effect": "R173H", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3672", "cds_effect": "11327T>G", "depth": "956", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "36.72", "position": "chr12:49427161", "protein_effect": "L3776R", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3078", "cds_effect": "931G>A", "depth": "835", "equivocal": "false", "functional_effect": "missense", "gene": "KEL", "percent_reads": "30.78", "position": "chr7:142651037", "protein_effect": "A311T", "status": "unknown", "strand": "_", "transcript": "NM_000420", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3055", "cds_effect": "1409G>A", "depth": "874", "equivocal": "false", "functional_effect": "missense", "gene": "MED12", "percent_reads": "30.55", "position": "chrX:70342648", "protein_effect": "R470H", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0638", "cds_effect": "1420C>T", "depth": "1144", "equivocal": "false", "functional_effect": "missense", "gene": "RET", "percent_reads": "6.38", "position": "chr10:43606811", "protein_effect": "R474W", "status": "unknown", "strand": "+", "transcript": "NM_020975", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3165", "cds_effect": "1115A>G", "depth": "1011", "equivocal": "false", "functional_effect": "missense", "gene": "CDK8", "percent_reads": "31.65", "position": "chr13:26975607", "protein_effect": "N372S", "status": "unknown", "strand": "+", "transcript": "NM_001260", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3474", "cds_effect": "1423A>C", "depth": "662", "equivocal": "false", "functional_effect": "missense", "gene": "TSC1", "percent_reads": "34.74", "position": "chr9:135782133", "protein_effect": "K475Q", "status": "unknown", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3255", "cds_effect": "1181A>G", "depth": "719", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "32.55", "position": "chr11:119148961", "protein_effect": "E394G", "status": "unknown", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3687", "cds_effect": "98C>T", "depth": "830", "equivocal": "false", "functional_effect": "missense", "gene": "BTK", "percent_reads": "36.87", "position": "chrX:100630175", "protein_effect": "T33I", "status": "unknown", "strand": "_", "transcript": "NM_000061", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.32", "cds_effect": "4000T>G", "depth": "903", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "32.0", "position": "chrX:39922070", "protein_effect": "L1334V", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0535", "cds_effect": "2678G>A", "depth": "1084", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "5.35", "position": "chr12:427491", "protein_effect": "R893Q", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3496", "cds_effect": "4592A>G", "depth": "798", "equivocal": "false", "functional_effect": "missense", "gene": "EP300", "percent_reads": "34.96", "position": "chr22:41568642", "protein_effect": "E1531G", "status": "unknown", "strand": "+", "transcript": "NM_001429", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3659", "cds_effect": "760_2A>C", "depth": "973", "equivocal": "false", "functional_effect": "splice", "gene": "MITF", "percent_reads": "36.59", "position": "chr3:69998200", "protein_effect": "splice site 760_2A>C", "status": "unknown", "strand": "+", "transcript": "NM_006722", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3531", "cds_effect": "2140T>C", "depth": "909", "equivocal": "false", "functional_effect": "missense", "gene": "KEL", "percent_reads": "35.31", "position": "chr7:142638398", "protein_effect": "Y714H", "status": "unknown", "strand": "_", "transcript": "NM_000420", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3512", "cds_effect": "210C>A", "depth": "820", "equivocal": "false", "functional_effect": "missense", "gene": "CHEK1", "percent_reads": "35.12", "position": "chr11:125497646", "protein_effect": "F70L", "status": "unknown", "strand": "+", "transcript": "NM_001274", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3547", "cds_effect": "1159G>T", "depth": "1015", "equivocal": "false", "functional_effect": "nonsense", "gene": "FAM123B", "percent_reads": "35.47", "position": "chrX:63412008", "protein_effect": "E387*", "status": "likely", "strand": "_", "transcript": "NM_152424", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3564", "cds_effect": "2722G>T", "depth": "1010", "equivocal": "false", "functional_effect": "nonsense", "gene": "ROS1", "percent_reads": "35.64", "position": "chr6:117687329", "protein_effect": "E908*", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3394", "cds_effect": "944T>G", "depth": "993", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "33.94", "position": "chr20:57485110", "protein_effect": "F315C", "status": "unknown", "strand": "+", "transcript": "NM_000516", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3468", "cds_effect": "802T>C", "depth": "1018", "equivocal": "false", "functional_effect": "missense", "gene": "FANCG", "percent_reads": "34.68", "position": "chr9:35076843", "protein_effect": "Y268H", "status": "unknown", "strand": "_", "transcript": "NM_004629", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.369", "cds_effect": "337C>T", "depth": "1103", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR4", "percent_reads": "36.9", "position": "chr5:176517636", "protein_effect": "L113F", "status": "unknown", "strand": "+", "transcript": "NM_213647", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3815", "cds_effect": "557C>A", "depth": "852", "equivocal": "false", "functional_effect": "missense", "gene": "VEGFA", "percent_reads": "38.15", "position": "chr6:43752346", "protein_effect": "S186Y", "status": "unknown", "strand": "+", "transcript": "NM_001171629", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3489", "cds_effect": "2647A>C", "depth": "940", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "34.89", "position": "chr6:117687404", "protein_effect": "I883L", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3371", "cds_effect": "1693C>A", "depth": "703", "equivocal": "false", "functional_effect": "missense", "gene": "HGF", "percent_reads": "33.71", "position": "chr7:81335667", "protein_effect": "L565I", "status": "unknown", "strand": "_", "transcript": "NM_000601", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2669", "cds_effect": "998T>A", "depth": "622", "equivocal": "false", "functional_effect": "missense", "gene": "FLT1", "percent_reads": "26.69", "position": "chr13:29004295", "protein_effect": "F333Y", "status": "unknown", "strand": "_", "transcript": "NM_002019", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3792", "cds_effect": "1904G>A", "depth": "807", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "37.92", "position": "chr3:142275399", "protein_effect": "R635Q", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3668", "cds_effect": "187G>T", "depth": "946", "equivocal": "false", "functional_effect": "missense", "gene": "MLH1", "percent_reads": "36.68", "position": "chr3:37038180", "protein_effect": "D63Y", "status": "unknown", "strand": "+", "transcript": "NM_000249", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3455", "cds_effect": "671G>T", "depth": "851", "equivocal": "false", "functional_effect": "missense", "gene": "FGF12", "percent_reads": "34.55", "position": "chr3:191861859", "protein_effect": "R224M", "status": "unknown", "strand": "_", "transcript": "NM_021032", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3286", "cds_effect": "1477C>T", "depth": "1047", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "32.86", "position": "chr11:108121669", "protein_effect": "R493C", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3571", "cds_effect": "2053G>A", "depth": "1190", "equivocal": "false", "functional_effect": "missense", "gene": "KDR", "percent_reads": "35.71", "position": "chr4:55968610", "protein_effect": "E685K", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3836", "cds_effect": "1004A>C", "depth": "670", "equivocal": "false", "functional_effect": "missense", "gene": "CTNNB1", "percent_reads": "38.36", "position": "chr3:41268766", "protein_effect": "K335T", "status": "known", "strand": "+", "transcript": "NM_001904", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.344", "cds_effect": "722C>T", "depth": "965", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "34.4", "position": "chr4:106155821", "protein_effect": "A241V", "status": "unknown", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3719", "cds_effect": "1722C>A", "depth": "761", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "37.19", "position": "chr3:49935642", "protein_effect": "F574L", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3762", "cds_effect": "1528A>G", "depth": "848", "equivocal": "false", "functional_effect": "missense", "gene": "GATA6", "percent_reads": "37.62", "position": "chr18:19762912", "protein_effect": "N510D", "status": "unknown", "strand": "+", "transcript": "NM_005257", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3402", "cds_effect": "2104G>A", "depth": "873", "equivocal": "false", "functional_effect": "missense", "gene": "DNMT3A", "percent_reads": "34.02", "position": "chr2:25463578", "protein_effect": "D702N", "status": "unknown", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3408", "cds_effect": "489T>G", "depth": "845", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51C", "percent_reads": "34.08", "position": "chr17:56774138", "protein_effect": "S163R", "status": "unknown", "strand": "+", "transcript": "NM_058216", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3348", "cds_effect": "862C>T", "depth": "938", "equivocal": "false", "functional_effect": "missense", "gene": "BTK", "percent_reads": "33.48", "position": "chrX:100614313", "protein_effect": "R288W", "status": "unknown", "strand": "_", "transcript": "NM_000061", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3753", "cds_effect": "14T>C", "depth": "1207", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "37.53", "position": "chr10:89624240", "protein_effect": "I5T", "status": "unknown", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3581", "cds_effect": "259C>T", "depth": "916", "equivocal": "false", "functional_effect": "nonsense", "gene": "TNFAIP3", "percent_reads": "35.81", "position": "chr6:138192623", "protein_effect": "R87*", "status": "likely", "strand": "+", "transcript": "NM_006290", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3354", "cds_effect": "1841G>A", "depth": "811", "equivocal": "false", "functional_effect": "missense", "gene": "KEAP1", "percent_reads": "33.54", "position": "chr19:10597362", "protein_effect": "R614Q", "status": "unknown", "strand": "_", "transcript": "NM_012289", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3433", "cds_effect": "638C>T", "depth": "999", "equivocal": "false", "functional_effect": "missense", "gene": "FGF23", "percent_reads": "34.33", "position": "chr12:4479627", "protein_effect": "A213V", "status": "unknown", "strand": "_", "transcript": "NM_020638", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0793", "cds_effect": "2866C>T", "depth": "1009", "equivocal": "false", "functional_effect": "missense", "gene": "KIT", "percent_reads": "7.93", "position": "chr4:55604658", "protein_effect": "R956W", "status": "unknown", "strand": "+", "transcript": "NM_000222", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.33", "cds_effect": "624A>C", "depth": "994", "equivocal": "false", "functional_effect": "missense", "gene": "CTCF", "percent_reads": "33.0", "position": "chr16:67645359", "protein_effect": "K208N", "status": "unknown", "strand": "+", "transcript": "NM_006565", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3518", "cds_effect": "10721C>T", "depth": "847", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "35.18", "position": "chr11:118377337", "protein_effect": "T3574M", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3626", "cds_effect": "385C>T", "depth": "626", "equivocal": "false", "functional_effect": "nonsense", "gene": "CTCF", "percent_reads": "36.26", "position": "chr16:67660469", "protein_effect": "R129*", "status": "known", "strand": "+", "transcript": "NM_001191022", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3446", "cds_effect": "827C>T", "depth": "830", "equivocal": "false", "functional_effect": "missense", "gene": "SMAD2", "percent_reads": "34.46", "position": "chr18:45375016", "protein_effect": "S276L", "status": "unknown", "strand": "_", "transcript": "NM_005901", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3815", "cds_effect": "10978A>G", "depth": "810", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "38.15", "position": "chr11:118380749", "protein_effect": "I3660V", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3393", "cds_effect": "126_127insT", "depth": "731", "equivocal": "false", "functional_effect": "frameshift", "gene": "ABL1", "percent_reads": "33.93", "position": "chr9:133589832", "protein_effect": "V43fs*4", "status": "unknown", "strand": "+", "transcript": "NM_007313", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3626", "cds_effect": "1004G>A", "depth": "1150", "equivocal": "false", "functional_effect": "missense", "gene": "EMSY", "percent_reads": "36.26", "position": "chr11:76183780", "protein_effect": "S335N", "status": "unknown", "strand": "+", "transcript": "NM_020193", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3401", "cds_effect": "1595G>A", "depth": "991", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "34.01", "position": "chr5:56168741", "protein_effect": "R532Q", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.369", "cds_effect": "2615C>T", "depth": "1111", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "36.9", "position": "chr16:3820836", "protein_effect": "T872M", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3483", "cds_effect": "1645A>G", "depth": "1091", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR2", "percent_reads": "34.83", "position": "chr10:123258036", "protein_effect": "N549D", "status": "known", "strand": "_", "transcript": "NM_000141", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3024", "cds_effect": "1270C>A", "depth": "969", "equivocal": "false", "functional_effect": "missense", "gene": "GABRA6", "percent_reads": "30.24", "position": "chr5:161128687", "protein_effect": "L424I", "status": "unknown", "strand": "+", "transcript": "NM_000811", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0117", "cds_effect": "15640C>T", "depth": "937", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "1.17", "position": "chr12:49420109", "protein_effect": "R5214C", "status": "known", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3604", "cds_effect": "1352G>A", "depth": "985", "equivocal": "false", "functional_effect": "missense", "gene": "SF3B1", "percent_reads": "36.04", "position": "chr2:198270084", "protein_effect": "R451Q", "status": "unknown", "strand": "_", "transcript": "NM_012433", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2805", "cds_effect": "3898C>A", "depth": "884", "equivocal": "false", "functional_effect": "missense", "gene": "MED12", "percent_reads": "28.05", "position": "chrX:70349915", "protein_effect": "L1300M", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0533", "cds_effect": "463T>G", "depth": "694", "equivocal": "false", "functional_effect": "missense", "gene": "FGF12", "percent_reads": "5.33", "position": "chr3:191888397", "protein_effect": "Y155D", "status": "unknown", "strand": "_", "transcript": "NM_021032", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3643", "cds_effect": "1312C>T", "depth": "851", "equivocal": "false", "functional_effect": "missense", "gene": "MED12", "percent_reads": "36.43", "position": "chrX:70342421", "protein_effect": "R438C", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3065", "cds_effect": "962T>G", "depth": "868", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51B", "percent_reads": "30.65", "position": "chr14:68934893", "protein_effect": "L321R", "status": "unknown", "strand": "+", "transcript": "NM_133509", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3576", "cds_effect": "452G>T", "depth": "990", "equivocal": "false", "functional_effect": "missense", "gene": "FGF3", "percent_reads": "35.76", "position": "chr11:69625341", "protein_effect": "R151I", "status": "unknown", "strand": "_", "transcript": "NM_005247", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3593", "cds_effect": "2983G>A", "depth": "974", "equivocal": "false", "functional_effect": "missense", "gene": "MSH6", "percent_reads": "35.93", "position": "chr2:48028105", "protein_effect": "E995K", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3503", "cds_effect": "3946A>C", "depth": "862", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "35.03", "position": "chr13:32912438", "protein_effect": "N1316H", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2629", "cds_effect": "1252C>T", "depth": "1088", "equivocal": "false", "functional_effect": "missense", "gene": "NF2", "percent_reads": "26.29", "position": "chr22:30069387", "protein_effect": "R418C", "status": "unknown", "strand": "+", "transcript": "NM_000268", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3235", "cds_effect": "1351C>T", "depth": "680", "equivocal": "false", "functional_effect": "nonsense", "gene": "CTNNA1", "percent_reads": "32.35", "position": "chr5:138240092", "protein_effect": "R451*", "status": "known", "strand": "+", "transcript": "NM_001903", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3412", "cds_effect": "748C>T", "depth": "929", "equivocal": "false", "functional_effect": "nonsense", "gene": "ATM", "percent_reads": "34.12", "position": "chr11:108115600", "protein_effect": "R250*", "status": "known", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3418", "cds_effect": "1424C>T", "depth": "790", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "34.18", "position": "chr20:57429744", "protein_effect": "A475V", "status": "unknown", "strand": "+", "transcript": "NM_080425", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.351", "cds_effect": "850C>T", "depth": "772", "equivocal": "false", "functional_effect": "missense", "gene": "SPOP", "percent_reads": "35.1", "position": "chr17:47679357", "protein_effect": "R284C", "status": "unknown", "strand": "_", "transcript": "NM_003563", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0509", "cds_effect": "2510G>T", "depth": "1022", "equivocal": "false", "functional_effect": "missense", "gene": "NF1", "percent_reads": "5.09", "position": "chr17:29556143", "protein_effect": "W837L", "status": "unknown", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2987", "cds_effect": "877G>A", "depth": "1175", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "29.87", "position": "chrX:39933722", "protein_effect": "V293I", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3626", "cds_effect": "1385G>A", "depth": "946", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "36.26", "position": "chr11:119149377", "protein_effect": "R462Q", "status": "unknown", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0577", "cds_effect": "1087C>A", "depth": "659", "equivocal": "false", "functional_effect": "missense", "gene": "SGK1", "percent_reads": "5.77", "position": "chr6:134492005", "protein_effect": "L363I", "status": "unknown", "strand": "_", "transcript": "NM_005627", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3447", "cds_effect": "277C>T", "depth": "760", "equivocal": "false", "functional_effect": "missense", "gene": "JAK1", "percent_reads": "34.47", "position": "chr1:65344760", "protein_effect": "R93C", "status": "unknown", "strand": "_", "transcript": "NM_002227", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3311", "cds_effect": "683G>A", "depth": "900", "equivocal": "false", "functional_effect": "missense", "gene": "TSC1", "percent_reads": "33.11", "position": "chr9:135796804", "protein_effect": "R228Q", "status": "unknown", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3602", "cds_effect": "688C>T", "depth": "1044", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIK3CA", "percent_reads": "36.02", "position": "chr3:178919203", "protein_effect": "R230*", "status": "unknown", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3419", "cds_effect": "1921G>T", "depth": "968", "equivocal": "false", "functional_effect": "nonsense", "gene": "MSH6", "percent_reads": "34.19", "position": "chr2:48027043", "protein_effect": "E641*", "status": "likely", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.361", "cds_effect": "962G>A", "depth": "698", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CB", "percent_reads": "36.1", "position": "chr3:138453486", "protein_effect": "R321Q", "status": "known", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3403", "cds_effect": "1555C>G", "depth": "670", "equivocal": "false", "functional_effect": "missense", "gene": "KDM6A", "percent_reads": "34.03", "position": "chrX:44922694", "protein_effect": "R519G", "status": "unknown", "strand": "+", "transcript": "NM_021140", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3835", "cds_effect": "933G>T", "depth": "1017", "equivocal": "false", "functional_effect": "missense", "gene": "CASP8", "percent_reads": "38.35", "position": "chr2:202149618", "protein_effect": "E311D", "status": "unknown", "strand": "+", "transcript": "NM_001228", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4969", "cds_effect": "1067G>A", "depth": "1119", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "49.69", "position": "chr3:49939976", "protein_effect": "G356D", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3316", "cds_effect": "830T>G", "depth": "760", "equivocal": "false", "functional_effect": "missense", "gene": "AKT3", "percent_reads": "33.16", "position": "chr1:243727140", "protein_effect": "L277R", "status": "unknown", "strand": "_", "transcript": "NM_005465", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.343", "cds_effect": "1877T>C", "depth": "962", "equivocal": "false", "functional_effect": "missense", "gene": "EPHA3", "percent_reads": "34.3", "position": "chr3:89462405", "protein_effect": "V626A", "status": "unknown", "strand": "+", "transcript": "NM_005233", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0948", "cds_effect": "529C>T", "depth": "949", "equivocal": "false", "functional_effect": "missense", "gene": "POLD1", "percent_reads": "9.48", "position": "chr19:50905321", "protein_effect": "R177C", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3504", "cds_effect": "148G>A", "depth": "939", "equivocal": "false", "functional_effect": "missense", "gene": "PDCD1", "percent_reads": "35.04", "position": "chr2:242795061", "protein_effect": "A50T", "status": "unknown", "strand": "_", "transcript": "NM_005018", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3723", "cds_effect": "581C>T", "depth": "873", "equivocal": "false", "functional_effect": "missense", "gene": "PARP1", "percent_reads": "37.23", "position": "chr1:226578147", "protein_effect": "A194V", "status": "unknown", "strand": "_", "transcript": "NM_001618", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3586", "cds_effect": "2674C>A", "depth": "912", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "35.86", "position": "chr17:59763428", "protein_effect": "L892I", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.012", "cds_effect": "310G>A", "depth": "830", "equivocal": "false", "functional_effect": "missense", "gene": "KLHL6", "percent_reads": "1.2", "position": "chr3:183245782", "protein_effect": "D104N", "status": "known", "strand": "_", "transcript": "NM_130446", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3509", "cds_effect": "275G>T", "depth": "761", "equivocal": "false", "functional_effect": "missense", "gene": "GSK3B", "percent_reads": "35.09", "position": "chr3:119720900", "protein_effect": "R92I", "status": "unknown", "strand": "_", "transcript": "NM_002093", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3549", "cds_effect": "348G>T", "depth": "1037", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB1", "percent_reads": "35.49", "position": "chr3:134670437", "protein_effect": "E116D", "status": "unknown", "strand": "+", "transcript": "NM_004441", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.1784", "cds_effect": "1122_1G>T", "depth": "863", "equivocal": "false", "functional_effect": "splice", "gene": "PDGFRA", "percent_reads": "17.84", "position": "chr4:55136799", "protein_effect": "splice site 1122_1G>T", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4511", "cds_effect": "664G>C", "depth": "747", "equivocal": "false", "functional_effect": "missense", "gene": "PARP2", "percent_reads": "45.11", "position": "chr14:20822268", "protein_effect": "E222Q", "status": "unknown", "strand": "+", "transcript": "NM_005484", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0599", "cds_effect": "9950T>G", "depth": "1019", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "5.99", "position": "chr13:32972600", "protein_effect": "L3317R", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3406", "cds_effect": "3496C>T", "depth": "869", "equivocal": "false", "functional_effect": "nonsense", "gene": "MET", "percent_reads": "34.06", "position": "chr7:116418985", "protein_effect": "R1166*", "status": "unknown", "strand": "+", "transcript": "NM_000245", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2947", "cds_effect": "829T>G", "depth": "543", "equivocal": "false", "functional_effect": "missense", "gene": "INPP4B", "percent_reads": "29.47", "position": "chr4:143159024", "protein_effect": "L277V", "status": "unknown", "strand": "_", "transcript": "NM_003866", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3246", "cds_effect": "1439C>G", "depth": "1254", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "32.46", "position": "chrX:76939309", "protein_effect": "T480R", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3399", "cds_effect": "79G>A", "depth": "818", "equivocal": "false", "functional_effect": "missense", "gene": "BCOR", "percent_reads": "33.99", "position": "chrX:39937104", "protein_effect": "E27K", "status": "unknown", "strand": "_", "transcript": "NM_017745", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3155", "cds_effect": "303G>T", "depth": "843", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5C", "percent_reads": "31.55", "position": "chrX:53247506", "protein_effect": "K101N", "status": "unknown", "strand": "_", "transcript": "NM_004187", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3496", "cds_effect": "698A>G", "depth": "801", "equivocal": "false", "functional_effect": "missense", "gene": "GABRA6", "percent_reads": "34.96", "position": "chr5:161117231", "protein_effect": "Y233C", "status": "unknown", "strand": "+", "transcript": "NM_000811", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3308", "cds_effect": "2113G>A", "depth": "928", "equivocal": "false", "functional_effect": "missense", "gene": "IKBKE", "percent_reads": "33.08", "position": "chr1:206667320", "protein_effect": "E705K", "status": "unknown", "strand": "+", "transcript": "NM_014002", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.337", "cds_effect": "312_313TG>CA", "depth": "825", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "33.7", "position": "chr9:139418259", "protein_effect": "A105T", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3804", "cds_effect": "671T>G", "depth": "652", "equivocal": "false", "functional_effect": "missense", "gene": "CUL3", "percent_reads": "38.04", "position": "chr2:225376283", "protein_effect": "F224C", "status": "unknown", "strand": "_", "transcript": "NM_003590", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3455", "cds_effect": "4084C>T", "depth": "738", "equivocal": "false", "functional_effect": "nonsense", "gene": "NF1", "percent_reads": "34.55", "position": "chr17:29576111", "protein_effect": "R1362*", "status": "known", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3234", "cds_effect": "3063_1G>A", "depth": "1002", "equivocal": "false", "functional_effect": "splice", "gene": "TEK", "percent_reads": "32.34", "position": "chr9:27218774", "protein_effect": "splice site 3063_1G>A", "status": "unknown", "strand": "+", "transcript": "NM_000459", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3515", "cds_effect": "622G>A", "depth": "990", "equivocal": "false", "functional_effect": "missense", "gene": "CRKL", "percent_reads": "35.15", "position": "chr22:21288377", "protein_effect": "A208T", "status": "unknown", "strand": "+", "transcript": "NM_005207", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3606", "cds_effect": "673G>T", "depth": "649", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIK3CB", "percent_reads": "36.06", "position": "chr3:138456677", "protein_effect": "E225*", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3626", "cds_effect": "2789T>C", "depth": "888", "equivocal": "false", "functional_effect": "missense", "gene": "TSC1", "percent_reads": "36.26", "position": "chr9:135772834", "protein_effect": "L930P", "status": "unknown", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3615", "cds_effect": "310G>A", "depth": "758", "equivocal": "false", "functional_effect": "missense", "gene": "RAF1", "percent_reads": "36.15", "position": "chr3:12653459", "protein_effect": "E104K", "status": "unknown", "strand": "_", "transcript": "NM_002880", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3623", "cds_effect": "1088C>T", "depth": "701", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "36.23", "position": "chr12:115114129", "protein_effect": "S363L", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3605", "cds_effect": "1264C>T", "depth": "993", "equivocal": "false", "functional_effect": "missense", "gene": "MED12", "percent_reads": "36.05", "position": "chrX:70342373", "protein_effect": "R422W", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3608", "cds_effect": "1892C>T", "depth": "607", "equivocal": "false", "functional_effect": "missense", "gene": "DOT1L", "percent_reads": "36.08", "position": "chr19:2214564", "protein_effect": "S631L", "status": "unknown", "strand": "+", "transcript": "NM_032482", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3625", "cds_effect": "1955G>T", "depth": "960", "equivocal": "false", "functional_effect": "missense", "gene": "KDR", "percent_reads": "36.25", "position": "chr4:55970842", "protein_effect": "R652I", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2317", "cds_effect": "1399A>C", "depth": "1273", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "23.17", "position": "chrX:76939349", "protein_effect": "K467Q", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3733", "cds_effect": "3521C>T", "depth": "1125", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "37.33", "position": "chr13:110434880", "protein_effect": "S1174L", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3579", "cds_effect": "1496C>T", "depth": "827", "equivocal": "false", "functional_effect": "missense", "gene": "BRD4", "percent_reads": "35.79", "position": "chr19:15367830", "protein_effect": "S499L", "status": "unknown", "strand": "_", "transcript": "NM_014299", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3504", "cds_effect": "11A>G", "depth": "842", "equivocal": "false", "functional_effect": "missense", "gene": "NRAS", "percent_reads": "35.04", "position": "chr1:115258771", "protein_effect": "Y4C", "status": "unknown", "strand": "_", "transcript": "NM_002524", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.1769", "cds_effect": "3642C>A", "depth": "752", "equivocal": "false", "functional_effect": "missense", "gene": "STAG2", "percent_reads": "17.69", "position": "chrX:123229269", "protein_effect": "F1214L", "status": "unknown", "strand": "+", "transcript": "NM_006603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3207", "cds_effect": "1056G>T", "depth": "920", "equivocal": "false", "functional_effect": "missense", "gene": "KEL", "percent_reads": "32.07", "position": "chr7:142650912", "protein_effect": "E352D", "status": "unknown", "strand": "_", "transcript": "NM_000420", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3599", "cds_effect": "3750_3751insA", "depth": "942", "equivocal": "false", "functional_effect": "frameshift", "gene": "KDR", "percent_reads": "35.99", "position": "chr4:55948714", "protein_effect": "V1251fs*5", "status": "unknown", "strand": "_", "transcript": "NM_002253", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3467", "cds_effect": "3464A>C", "depth": "1122", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "34.67", "position": "chr5:38950486", "protein_effect": "K1155T", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3151", "cds_effect": "2102G>A", "depth": "1171", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "31.51", "position": "chrX:76938646", "protein_effect": "R701H", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.363", "cds_effect": "263G>A", "depth": "1000", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "36.3", "position": "chr3:178916876", "protein_effect": "R88Q", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.37", "cds_effect": "3073A>G", "depth": "1135", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "37.0", "position": "chr3:178952018", "protein_effect": "T1025A", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3453", "cds_effect": "457G>A", "depth": "695", "equivocal": "false", "functional_effect": "missense", "gene": "STAG2", "percent_reads": "34.53", "position": "chrX:123176490", "protein_effect": "D153N", "status": "unknown", "strand": "+", "transcript": "NM_006603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4798", "cds_effect": "569C>T", "depth": "1313", "equivocal": "false", "functional_effect": "missense", "gene": "SETD2", "percent_reads": "47.98", "position": "chr3:47165557", "protein_effect": "P190L", "status": "unknown", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.36", "cds_effect": "2626C>T", "depth": "850", "equivocal": "false", "functional_effect": "missense", "gene": "PBRM1", "percent_reads": "36.0", "position": "chr3:52637690", "protein_effect": "R876C", "status": "unknown", "strand": "_", "transcript": "NM_018313", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0533", "cds_effect": "1031T>G", "depth": "751", "equivocal": "false", "functional_effect": "missense", "gene": "INPP4B", "percent_reads": "5.33", "position": "chr4:143129619", "protein_effect": "L344R", "status": "unknown", "strand": "_", "transcript": "NM_003866", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3611", "cds_effect": "3217A>G", "depth": "911", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "36.11", "position": "chr4:55161386", "protein_effect": "M1073V", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3553", "cds_effect": "247G>A", "depth": "1213", "equivocal": "false", "functional_effect": "missense", "gene": "IGF1R", "percent_reads": "35.53", "position": "chr15:99250943", "protein_effect": "E83K", "status": "unknown", "strand": "+", "transcript": "NM_000875", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3331", "cds_effect": "2740G>T", "depth": "1267", "equivocal": "false", "functional_effect": "nonsense", "gene": "MAP3K1", "percent_reads": "33.31", "position": "chr5:56177767", "protein_effect": "G914*", "status": "likely", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3591", "cds_effect": "8180C>T", "depth": "1153", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "35.91", "position": "chr1:16260915", "protein_effect": "A2727V", "status": "known", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3373", "cds_effect": "2174C>A", "depth": "1186", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK3", "percent_reads": "33.73", "position": "chr15:88423619", "protein_effect": "P725H", "status": "unknown", "strand": "_", "transcript": "NM_002530", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0558", "cds_effect": "2161C>T", "depth": "1201", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK3", "percent_reads": "5.58", "position": "chr15:88423632", "protein_effect": "R721C", "status": "unknown", "strand": "_", "transcript": "NM_002530", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.358", "cds_effect": "2338G>A", "depth": "891", "equivocal": "false", "functional_effect": "missense", "gene": "MSH6", "percent_reads": "35.8", "position": "chr2:48027460", "protein_effect": "A780T", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3456", "cds_effect": "370C>T", "depth": "735", "equivocal": "false", "functional_effect": "nonsense", "gene": "NTRK2", "percent_reads": "34.56", "position": "chr9:87322769", "protein_effect": "R124*", "status": "unknown", "strand": "+", "transcript": "NM_006180", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3211", "cds_effect": "1378G>A", "depth": "710", "equivocal": "false", "functional_effect": "missense", "gene": "GATA6", "percent_reads": "32.11", "position": "chr18:19761489", "protein_effect": "E460K", "status": "unknown", "strand": "+", "transcript": "NM_005257", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3793", "cds_effect": "5623G>T", "depth": "754", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "37.93", "position": "chrX:76855977", "protein_effect": "D1875Y", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0823", "cds_effect": "1252G>A", "depth": "1057", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "8.23", "position": "chr12:115112488", "protein_effect": "A418T", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.4891", "cds_effect": "2437C>T", "depth": "1196", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "48.91", "position": "chr13:110435964", "protein_effect": "P813S", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.355", "cds_effect": "2243G>T", "depth": "862", "equivocal": "false", "functional_effect": "missense", "gene": "WHSC1L1", "percent_reads": "35.5", "position": "chr8:38162963", "protein_effect": "G748V", "status": "unknown", "strand": "_", "transcript": "NM_023034", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3612", "cds_effect": "3292G>T", "depth": "645", "equivocal": "false", "functional_effect": "nonsense", "gene": "KDM5A", "percent_reads": "36.12", "position": "chr12:419055", "protein_effect": "E1098*", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3307", "cds_effect": "323G>A", "depth": "756", "equivocal": "false", "functional_effect": "missense", "gene": "DIS3", "percent_reads": "33.07", "position": "chr13:73355047", "protein_effect": "R108H", "status": "unknown", "strand": "_", "transcript": "NM_014953", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3279", "cds_effect": "835C>T", "depth": "1101", "equivocal": "false", "functional_effect": "missense", "gene": "FAS", "percent_reads": "32.79", "position": "chr10:90774034", "protein_effect": "R279C", "status": "unknown", "strand": "+", "transcript": "NM_000043", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2987", "cds_effect": "1988C>A", "depth": "1058", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "29.87", "position": "chrX:129148736", "protein_effect": "S663Y", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3431", "cds_effect": "853A>T", "depth": "816", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "34.31", "position": "chr2:29917815", "protein_effect": "N285Y", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.0516", "cds_effect": "4599A>C", "depth": "717", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "5.16", "position": "chr6:117663633", "protein_effect": "K1533N", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3683", "cds_effect": "2341G>A", "depth": "1029", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "36.83", "position": "chr12:49445125", "protein_effect": "A781T", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3458", "cds_effect": "3634C>T", "depth": "723", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "34.58", "position": "chr6:117680986", "protein_effect": "R1212C", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.2837", "cds_effect": "207A>C", "depth": "571", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "28.37", "position": "chr16:2100469", "protein_effect": "K69N", "status": "unknown", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3555", "cds_effect": "173C>T", "depth": "948", "equivocal": "false", "functional_effect": "missense", "gene": "P2RY8", "percent_reads": "35.55", "position": "chrX:1585279", "protein_effect": "S58L", "status": "unknown", "strand": "_", "transcript": "NM_178129", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.333", "cds_effect": "219G>T", "depth": "898", "equivocal": "false", "functional_effect": "missense", "gene": "PDK1", "percent_reads": "33.3", "position": "chr2:173423458", "protein_effect": "K73N", "status": "unknown", "strand": "+", "transcript": "NM_002610", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3226", "cds_effect": "1067A>G", "depth": "902", "equivocal": "false", "functional_effect": "missense", "gene": "NKX2_1", "percent_reads": "32.26", "position": "chr14:36986532", "protein_effect": "D356G", "status": "unknown", "strand": "_", "transcript": "NM_003317", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3299", "cds_effect": "323T>C", "depth": "788", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "32.99", "position": "chr3:142281921", "protein_effect": "L108P", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3698", "cds_effect": "1479_1480insT", "depth": "849", "equivocal": "false", "functional_effect": "frameshift", "gene": "STAT3", "percent_reads": "36.98", "position": "chr17:40476849", "protein_effect": "T494fs*55", "status": "unknown", "strand": "_", "transcript": "NM_139276", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3663", "cds_effect": "767G>A", "depth": "808", "equivocal": "false", "functional_effect": "missense", "gene": "ESR1", "percent_reads": "36.63", "position": "chr6:152265314", "protein_effect": "R256Q", "status": "known", "strand": "+", "transcript": "NM_000125", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3278", "cds_effect": "3898C>T", "depth": "784", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "32.78", "position": "chr3:142253969", "protein_effect": "R1300C", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3598", "cds_effect": "3595G>A", "depth": "792", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "35.98", "position": "chr13:110434806", "protein_effect": "E1199K", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3317", "cds_effect": "1822G>A", "depth": "841", "equivocal": "false", "functional_effect": "missense", "gene": "BAP1", "percent_reads": "33.17", "position": "chr3:52437222", "protein_effect": "D608N", "status": "unknown", "strand": "_", "transcript": "NM_004656", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3178", "cds_effect": "37C>T", "depth": "837", "equivocal": "false", "functional_effect": "nonsense", "gene": "BTK", "percent_reads": "31.78", "position": "chrX:100630236", "protein_effect": "R13*", "status": "unknown", "strand": "_", "transcript": "NM_000061", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3304", "cds_effect": "3655G>A", "depth": "1244", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "33.04", "position": "chr2:212248612", "protein_effect": "A1219T", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3618", "cds_effect": "1013A>C", "depth": "738", "equivocal": "false", "functional_effect": "missense", "gene": "PPP2R2A", "percent_reads": "36.18", "position": "chr8:26223871", "protein_effect": "E338A", "status": "unknown", "strand": "+", "transcript": "NM_002717", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3375", "cds_effect": "191T>C", "depth": "809", "equivocal": "false", "functional_effect": "missense", "gene": "FANCG", "percent_reads": "33.75", "position": "chr9:35078718", "protein_effect": "V64A", "status": "unknown", "strand": "_", "transcript": "NM_004629", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}, {"allele_fraction": "0.3458", "cds_effect": "1964C>T", "depth": "697", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CB", "percent_reads": "34.58", "position": "chr3:138409914", "protein_effect": "A655V", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1153674.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "371.95", "status": "high", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}